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Abstract
White matter integrity is crucial to healthy executive function, the cognitive domain that
enables functional independence. However, in the ageing brain, white matter is highly
vulnerable. White matter inflammation increases with age and Alzheimer disease (AD),
which disrupts the normal function of white matter. This may contribute to executive
dysfunction, but the relationship between white matter inflammation and executive
function has not been directly evaluated in ageing nor AD. White matter is also particularly
vulnerable to cerebrovascular disease, corresponding with the common presentation of
executive dysfunction in vascular cognitive impairment (VCI). Thus, white matter may be
an important substrate by which vascular injury exacerbates the cognitive impact of
comorbid AD pathology and cerebrovascular pathology. To study the relationship
between age, pathogenic amyloid precursor protein (APP), white matter inflammation,
cerebrovascular disease, and executive dysfunction, the transgenic rat model of AD
(TgAPP21) was evaluated for astrocytosis, microgliosis and cognitive impairment. The
TgAPP21 rat was found to demonstrate spontaneously increased white matter microglia
activation, impaired reversal learning, and a regressive impairment of behavioural
flexibility, a key subdomain of executive function. The TgAPP21 rat also developed a
precocious increase in white matter microglia activation. However, this was not matched
by a continued increase in behavioural inflexibility, suggesting a dynamic and agedependent relationship between white matter inflammation and behavioural flexibility.
Hypertension induced by chronic angiotensin-II infusion impaired both wildtype (Wt) and
TgAPP21 rats’ working memory and behavioural flexibility. However, while Wt rats
demonstrated a linear increase in white matter astrocytosis in response to blood pressure
elevation, normotensive TgAPP21 rats already had an increased baseline level of white
matter astrocytosis and further increase in response to hypertension was not observed.
TgAPP21 rats also demonstrated a greater vulnerability to cerebrovascular disease, as
focal striatal ischemic injury resulted in reduced set shifting efficiency. Thus, the TgAPP21
rat is an important model for studying the complex relationship between age, pathogenic
APP, and cerebrovascular disease and their impact on executive dysfunction. These
[i]

findings support the emerging significance of white matter inflammation and executive
dysfunction in the pathophysiology of ageing, AD, and VCI.

Keywords
White Matter, Inflammation, Microglia, Cognitive Impairment, Executive Function,
Behavioural Flexibility, Alzheimer Disease, Amyloid, Vascular Dementia, Ischemic
Stroke, Hypertension, Animal/Rat Model.
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Chapter 1: Introduction
This chapter outlines the current literature pertaining to white matter integrity,
neuroinflammation, and cognitive impairment in the context of Alzheimer disease (AD)
and vascular cognitive impairment (VCI). AD and vascular pathology frequently occur
together and important intersections of these two conditions are observed in white matter
tissue. Investigating this link between AD and vascular pathology will develop our
understanding of the early pathophysiology of the two leading causes of dementia.

1.1

White Matter and Cognitive Function

Neuroscience and behavioural neurology has traditionally focused on grey matter even
though white matter occupies 40-50% of the adult human brain1. Although Jean-Martin
Charcot described the white matter lesions observed in multiple sclerosis and
amyotrophic lateral sclerosis in the 19th century2, it would not be until 1965 that the notion
of “cerebral disconnection” as a more general mechanism for cognitive impairment would
be introduced by Norman Geschwind1. Today, white matter continues to be understood
generally as tissue that mediates the transfer of information, in contrast to the processing
of information which is attributed to grey matter. This applies to all levels of cognition, but
the striking abundance of white matter in the frontal lobes, the seat of integration and
coordination, underscores the importance of white matter for higher-level domains of
cognition,1 including inhibition, cognitive flexibility, planning, problem solving, reasoning,
abstract thinking, complex social processing, and creativity. Comparative neuroanatomy
identifies our species’ unique proportion of white matter volume, featuring an exceptional
quantity of thick myelinated fibres, as crucial to our ability to excel in higher-level
cognition3.
Conversely, impairments of higher level cognition can be attributed to white matter
disruptions, including lesions that are far subtler than what Jean-Martin Charcot could
detect1. Aided by developments in neuroimaging, the term white matter dementia was
introduced in 1988 to expand the scope of dementia research3. Similarly, recent decades
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saw an increased interest in the role of glial cells in normal and disordered neurological
function4,5. White matter is defined by a preponderance of axons, myelin, and
oligodendrocytes but also includes an abundance of astrocytes, microglia, and blood
vessels3, so the roles of glial cells in disorders of the central nervous system (CNS) would
naturally direct more research to white matter4-7. The following sections will review current
literature on the cognitive correlates of white matter and the general impairments
observed with white matter dysfunction. Thereafter, white matter dysfunction will be
described in the context of AD and VaD.

1.1.1 White Matter Integrity
Healthy white matter function depends on thick and well-organized myelination of axons8.
White matter structure is also experience dependent, with ongoing white matter
reorganization playing an important role in supporting cognitive plasticity9. White matter
degeneration can present clearly in the form of volume loss, measured with neuroimaging
or as gross atrophy on post-mortem studies. More subtle forms of white matter
degeneration

include

microstructural

changes

that

alter

molecular

diffusion

characteristics as measured by diffusion-weighted magnetic resonance imaging (DWMRI), including an early form of this technique, diffusion tensor imaging (DTI)10. In short,
DTI relies on differences in the displacements of water molecules depending on tissue
type11. One of the most commonly metrics used in DTI is fractional anisotropy (FA), which
quantifies how restricted water molecule diffusion is in a given voxel. FA measures range
from 0 to 1, with low values seen in the CSF-filled ventricles where water diffusion is
unrestricted in all directions, and high values in myelinated white matter tracts such as
the corpus callosum, where water movement is greatly restricted to move primarily along
the direction of the axons11,12.
A loss of FA in white matter tissue, where FA is expected to be high, indicates
microstructural changes that are presumed to be predominantly the result of
demyelination or alterations in myelin structure11-13. However, FA also reflects axonal
caliber, injury, and density, as well as uniformity of fibre direction and gliosis; research
continues to identify the histopathological correlates of DTI metrics, including FA, and
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how these radiological-histopathological correlates change in different disease
contexts12. Despite this, and with some controversy10, DTI measures such as FA are
widely inferred as a measure of white matter integrity. The limitations of this interpretation
are well detailed by Jones et al10, but the appeal to inferring deleterious microstructural
changes based on DTI measurements is supported by cognitive correlates12. In normal
aging9,14-21 and many different neurodegenerative conditions22-28, loss of FA in white
matter has been correlated with cognitive impairments, most often with processing speed
and executive function.
The clinical utility of measuring microstructural white matter changes is further
demonstrated by the potentially diagnostic and prognostic value of leukoaraiosis. Also
known as white matter hyperintensities, leukoaraiosis is a radiological phenomenon of
diffuse hypodense (on CT) or hyperintense (on T2 MRI) white matter29-34. Leukoaraiotic
white matter has reduced white matter integrity, as measured by DW-MRI35,36 and
leukoaraiosis is an important risk factor for stroke, dementia, and death37-39. The term
leukoaraiosis, derived from the Greek leuko (white) and araiosis (rarefaction) was coined
intentionally so as not to assume any particular disease etiology;40 still to this day, the
exact processes that causes leukoaraiosis has not been determined. Vascular pathology
is commonly proposed as the underlying mechanism of leukoaraiosis41-44, although
dysregulation of glial cells and inflammation have also been implicated45,46.

1.1.1.1

White Matter Vascular Insufficiency

White matter is particularly sensitive to vascular disruption44,47-52. When mild hypercapnia
was induced in healthy subjects to produce systemic vasodilation, a significant steal
phenomenon was observed that resulted in reduced blood flow to white matter50. The
very regions that had reduced blood flow matched the common neuroanatomical
locations of leukoaraiosis matter, namely periventricular44,50. This was also supported by
a previous study of subjects with leukoaraiosis that had normal blood flow to grey matter
but reduced white matter blood flow52. Reduced blood flow indicates a poorer
cerebrovascular reserve in white matter, and the white matter regions that are relatively

4
more prone to leukoaraiotic changes indeed fall in the “watershed” regions in between
the major arterial zones of the brain50,51,53,54. Moreover, white matter has been shown to
be highly vulnerable to ischemic injury, with increased susceptibility seen with age51. The
greater white matter vulnerability to ischemia is attributed to a relative paucity of
collaterals in deep white matter53 and the high sensitivity of oligodendrocyte precursor
cells to ischemia-induced oxidative stress51. In a rat model maintained on a high saturated
fat, salt, and refined sugar diet, hypertension and cerebral small vessel blockage was
associated with white matter atrophy 55.
Hypertension also correlates with disruptions of white matter structure49,56 and is a key
risk factor for leukoaraiosis47,57. At the same time, the presence of leukoaraiosis is more
common in subjects with orthostatic hypotension58 and increased pulse pressure59,60.
Cerebral small vessel disease (SVD) is an umbrella term for pathologies of perforating
cerebral arterioles, capillaries, and venules42, and is associated with systemic vascular
risk factors such as hypertension, atherosclerosis, diabetes mellitus, and atrial
fibrillation61; cerebral SVD also often manifests as leukoaraiosis41-44. Thus, due to the
organization of the cerebrovasculature50,53, white matter is extremely susceptible to
common systemic cardiovascular conditions. A lot of histopathological heterogeneity has
been observed in leukoaraiosis, so that in general, any vascular conditions that cause
cerebral hypoperfusion, blood brain barrier (BBB) disruption, chronic ischemia,
microinfarcts, venous collagenosis, vessel tortuosity, or vessel wall thickening is also
thought to cause leukoaraiosis43,54,62.

1.1.1.2

White Matter Gliosis and Inflammation

In addition to the large variety of vascular abnormalities observed in leukoaraiotic white
matter, many active and dystrophic glial cells are also observed43. This includes
dysfunctional oligodendrocytes, clasmatodendritic astrocytes (abnormal astrocytes with
swollen soma and short blunt processes), and activated microglia44,62,63. As glial cells
actively maintain white matter integrity and homeostasis, they may be important targets
for therapeutic intervention64,65. Neuroinflammation in neurodegenerative diseases is
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thought to be driven primarily by microglia, which are involved in both cytokine secretion
and phagocytosis4,66,67; microglia-mediated inflammation affects white matter in
particular, both in normal aging and in neurodegenerative disease68. Indeed,
experimental studies have shown that the inhibition of white matter microgliosis improves
white matter integrity after cerebral hypoperfusion69-76, thus microglia play an important
role in the vascular vulnerability of white matter. Although microglia activation does
not capture the entire scope of neuroinflammation, microglial activation is a strong
indicator of a proinflammatory environment67 and will be used as the key measure
of neuroinflammation in this thesis. Astrocytes also interact with microglia in
inflammatory conditions and are an important factor in both white matter maintenance
inflammation5-7,66,77. Despite the importance of both microglia and astrocytes in
maintaining white matter in neurodegenerative disease and in health, there is a paucity
of literature on how dysregulation of these white matter glial cells affect cognition. In two
recent rodent studies, white matter microglial activation was associated with executive
dysfunction78,79, and two recent post-mortem studies of dementia pugilistica and alcoholrelated neuropathology also demonstrated an association between executive dysfunction
with white matter astrocytosis80,81. The prevalence and burden of diseases that can
induce dysregulation of white matter microglia and astrocytes, and consequentially,
impair white matter integrity and executive function, warrants more research.

1.1.2 Executive Function
Executive function refers to a group of inter-dependent cognitive functions that enable
planning, mental manipulation, and control over goal-directed behaviour. The core
subdomains of executive function are inhibitory control, working memory, and cognitive
flexibility82, which all rely on information processing in the prefrontal cortex (PFC) and its
extensive connections with other cortical and subcortical brain regions. Although specific
locations of leukoaraiosis do associate with impairments of specific subdomains28,
leukoaraiosis in any region is also correlated with hypometabolism in the PFC and global
impairments of executive function21,28,83. The substantial convergence of fibre pathways
that connect the PFC1 may explain how pathology in even a small focal white matter
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lesion could affect metabolism in the entire frontal cortex and cause broad impairments
of executive function31.
Of all cognitive domains, executive function is often the most sensitive to both
environmental and physiological stressors82. Accordingly, executive function declines in
late adulthood82,84, which has been linked to disruptions of white matter integrity14-21. Even
in normal aging, white matter volume shows a greater decline than grey matter
volume12,85. For patients diagnosed with dementia or at risk of dementia, one of the most
difficult challenges is the loss of functional independence, which is strongly dependent on
executive function86-88. In a clinical setting, functional independence is most often
evaluated according to an individual’s capacity for activities of daily living (ADLs),
including personal hygiene, mobility, and eating88. More complex ADLs such as the
management of finances and medications, cooking, housekeeping, often referred to as
instrumental ADLs (IADLs), are also evaluated to offer a more sensitive measure of
cognitive impairment in earlier stages of neurodegenerative diseases88. Indeed, the
cognitive domain that best predicts current and future functional independence, as
measured by ADLs and IADLS, is executive function86-88. This emphasizes the
importance of supporting general white matter health for maintaining executive function
as well as functional independence.

1.1.2.1

Inhibitory Control

Inhibitory control of attention, thought, behaviour, and emotions constitutes one of the
core subdomains of executive function82. Inhibitory control of attention can occur
involuntarily, as with the filtering of stimuli at the level of perception such as background
noise at a cocktail party. Inhibitory control of attention can also occur voluntarily, as when
effort is made to ignore stimuli that distract from goal-directed behaviour82. The inhibition
of both mental representations and behaviour can be best appreciated in conditions
where such inhibition is impaired; intrusive memories and thoughts are a core component
of post-traumatic stress disorder89,90, substance addiction91, and the obsessive
component of obsessive-compulsive disorder92, while impairments of behavioural
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inhibition are also seen in substance addiction91 and the compulsions seen in obsessivecompulsive disorder92. Lastly, inhibitory control of emotions is regularly required in social
interaction and maintaining motivation while delaying gratification through arduous tasks,
such as writing a dissertation82.
The PFC is responsible for regulating and inhibitory control over attention, thought,
behaviour, and emotions. The inferior frontal gyrus in the ventrolateral PFC (VLPFC)
plays an important role in inhibition via direct connections to other cerebral cortices, basal
ganglia, the subthalamic nucleus, and cerebellar cortices93,94. In particular, the right
VLPFC has been associated with behavioural inhibition, whereas the bilateral actions of
the VLPFC contribute more to inhibition of attention and thoughts93-95. Inhibition of
emotions appears to be more directly regulated by both the ventromedial PFC (VMPFC),
which have extensive connections with the amygdala, hypothalamus, nucleus
accumbens, and brainstem nuclei93,94. Both the VMPFC and VLPFC are considered to
initiate top-down control of inhibition but other structures downstream are also crucial to
inhibitory control, namely the basal ganglia and supplementary motor areas94. While focal
lesions in any of these structures may cause specific impairments of inhibition, white
matter lesions in any of the circuits that connect these structures will also impair inhibitory
control93.

1.1.2.2

Working Memory

Another core domain of executive function is working memory, defined as the function of
holding and manipulating information that is not perceptually present (mental
representations)82. Working memory is often further distinguished by verbal and nonverbal (visual-spatial) content, and is utilized in all instances of mental math, mental
reorganization or revision of information, and relating different pieces of information such
as verbal translation; working memory is essential for reasoning. Working memory may
often be miscategorized as a type of short-term memory rather than a subdomain of
executive function, but working memory is more closely linked to executive function in
terms of neuroanatomy, childhood development, and function82.
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There is considerable controversy over whether working memory is a dissociable
cognitive domain. Of course, working memory and short-term memory are highly interrelated. This is demonstrated by short-term memory tasks that require a longer
(suprathreshold) number of information items, wherein working memory is automatically
engaged to organize the information. The key distinction between working memory and
short-term memory is that the former involves manipulations of information in addition to
the mental holding of that information. Holding information activates the VLPFC during
tasks that require either working memory or short-term memory, while working memory
dependent tasks involving the manipulation of information are also associated with
activation of the dorsolateral PFC (DLPFC)82. Similarly, working memory and inhibitory
control are often functionally inter-dependent and show high neural co-activation82.
Working memory directs inhibitory control, while inhibitory control regulates the
information that can occupy working memory. This has lead many to view inhibitory
control as derivative, with working memory enhancement of specific goals or thoughts
considered to be sufficient to automatically repress unwanted goals or thoughts, that is,
inhibitory control. Others still maintain that working memory and inhibitory control are
dissociable domains, and that mental suppression requires more than just a relative lack
of mental enhancement. While this debate continues82, most will agree that all
subdomains of executive function are highly interdependent, including the subdomain of
cognitive or behavioural flexibility.

1.1.2.3

Cognitive/Behavioural Flexibility

Cognitive flexibility, often referred to as behavioural flexibility in the context of rodent
studies, builds on both inhibitory control and working memory. Cognitive flexibility
describes the ability to change perspectives or goals, which involves the inhibition of
current thoughts or goal-directed behaviours and the engagement of new ones82.
Representative tasks that require cognitive flexibility include design fluency, verbal
fluency, and category fluency, wherein a subject is asked to, respectively, think of different
uses of a table, different words that begin with a certain letter, or alternate sequentially
between letters and numbers82. Accordingly, cognitive flexibility is considered to be crucial
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for creativity. Lesions of the dorsomedial PFC (DMPFC) produce the most consistent
impairments of different types of fluency96,97.
Another common task that requires cognitive flexibility is task switching. A relatively
simple form of task switching is known as reversal, such as when a rewarding option is
changed from a left switch to a right switch. Lesions of the orbitofrontal cortex (OFC),
located between the VMPFC and VLPFC98, result in reversal impairments99,100. A more
complex form of task switching is known as set shifting, which requires a subject to
redirect their attention between different sets of cues; this is exemplified by the Wisconsin
Card Sorting Task, wherein subjects need to shift between sorting rules that depend on
shape, colour, or number101. In contrast to reversal, set shifting is impaired by lesions of
the DLPFC99,100.
Both reversal and set-shifting tests have also been adapted for rodent studies, wherein
maze-based or operant-based challenges require rodents to reverse behaviour or shift
behaviour according to attentional sets100. Although the functional divisions of the PFC
do not arrange in the same neuroanatomical topography in rodents, reversal and set
shifting impairments are similarly doubly dissociated in rats102. Additional pathways
between the PFC, thalamus, and striatum that also contribute to set shifting behaviour
are also conserved across species102, further supporting the interpretation that
behavioural flexibility in rats is still very informative for the study of cognitive flexibility in
humans98,100. Though there certainly are limitations to the human-rodent homology of
cognitive-behavioural flexibility, other executive functions, and underlying neural
correlates, the experimental possibilities of rodent studies are still crucial to identifying the
neural

substrates

impairments100,103.
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1.2

Alzheimer Disease

Alzheimer disease (AD) is a devastating condition of progressive neurodegeneration and
the most common cause of dementia104. AD is a terminal illness and no current therapies
can stop or reverse disease progression. As with many diseases of advanced age, there
is heterogeneity in disease presentation and progression, and there are many
environmental and lifestyle factors that are considered to modify the risk of incidence104.
Neuropathologically, AD presents with protein-rich plaques, neurofibrillary tangles
(NFTs), and gliosis, but disease etiology remains undetermined. The following sections
will outline the clinical and neuropathological features that currently define AD and explore
emerging research on the role of glia and white matter pathology.

1.2.1 Clinical Profile of Alzheimer Disease
Patients with symptoms of dementia can be evaluated in a clinical setting and if the
pattern of cognitive impairment and biomarkers are characteristic of AD, a diagnosis of
“probable AD” can be made105. As current clinical diagnoses are not sufficiently sensitive
nor specific for AD, diagnosis of AD is not confirmed until post-mortem evaluation106;
currently, there are no cognitive impairments or biomarkers that can provide definitive
clinical diagnosis. However, the most recent criteria put forward by National Institute of
Aging-Alzheimer’s Association (NIA-AA) and the International Working Group for New
Research Criteria for the Diagnosis of AD (IWG2) have endorsed the use of some
biomarkers in aiding clinical diagnosis105,107. Though biomarkers are an active area of
development107-109, recommendations from NIA-AA and the 4th Canadian Consensus
Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) do not recommend
regular use of biomarkers in the diagnosis of AD until more definitive evidence of safety
and benefit is available110. Current treatments offer only modest delays of symptom
progression111,112, but early and accurate diagnosis does improve care planning and
symptom management112.
Memory impairment is considered to be a cardinal symptom of AD and different types of
memory are affected in a typical sequence as the disease progresses113. As
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neurodegeneration typically begins in the structures of the medial temporal lobe including
the hippocampus, episodic memory is often the earliest to be impaired114. Episodic
memory describes memory of autobiographical events. Episodic memory of recent events
tends to be affected prior to impairments of remote memory recall and immediate recall,
which rely more on extra-hippocampal structures114. For example, a patient with mildmoderate AD may have difficulty recalling a family visit from a day prior but could recall
childhood memories or the meal that they just completed. As the disease progresses,
semantic memory becomes impaired as well, which are memories of nonautobiographical facts such as the capital of a country. Procedural memory, which
describes non-declarative memories including motor skills such as playing the piano, is
spared until late in disease progression. More recently, several other cognitive domains
have been recognized as important features of early AD: visuospatial, language, and
executive. Since 2011, the NIA-AA has recommended that symptoms of amnesia are not
required for a diagnosis of probable AD105. This also applies to recent versions of two
other widely used diagnostic criteria: the 5th edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-V)115 and the IWG2107. Executive dysfunction is
observed in the majority of early AD patients, with complex attentional functions as the
most commonly affected: working memory, dual processing, attentional control, and
response selection116.
The global prevalence of AD was estimated to be 35.6 million in 2010; this figure is
projected to nearly double every 20 years, due to the expected growth of the elderly
population117. Early onset AD (EOAD), defined as the onset of dementia before 65 years
of age, is rare but follows strong inheritance patterns118,119. Late onset AD (LOAD;
diagnosed after the age of 65) is also considered to be a genetic disorder but with complex
interactions with environmental factors120. After the age of 65, 17% of women and 9% of
men are predicted to be diagnosed with AD in their lifetime, with risk increasing with
age121. Overall, AD contributes to 60-80% of all dementia cases104. Common genetic
variation of Apolipoprotein E (ApoE), which is involved in cholesterol and lipid transport
throughout the body, is the strongest known genetic risk factor specific to LOAD122. In
particular, an estimated 27% of the general population carries at least one allele for the
ApoE ε4 isoform; carriers of a single ε4 variant have a 2-3 fold increased risk of LOAD,
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while the rare 2% of the public that are ε4/ε4 carriers have a 12-fold increased
risk104,123,124. Though ApoE has been implicated in AD by direct CNS dysregulation, it may
also affect AD pathophysiology indirectly by cerebrovascular dysregulation, as ApoE is
also a major risk factor for cardiovascular morbidity125. However, variations in ApoE only
account for 1/4 of the genetic variance that contributes to LOAD diagnosis, and genetics
overall can only account for 1/2 of the variance in LOAD diagnosis126. Thus, potentially
modifiable environmental factors may play an important role for the majority of the
population.
Mild cognitive impairment (MCI) is a clinical diagnosis that identifies patients with
relatively minor functional challenges due to cognitive impairments. MCI is primarily
distinguished from dementia in that ADLs are not severely impaired, despite impairments
in one or more cognitive domains127. Though MCI is not attributed to any particular
neuropathology and can progress to different forms of dementia128, of which AD is only
one form of dementia, the NIA-AA identifies MCI due to AD as the symptomatic
predementia phase of AD127. As with the use of emerging diagnostic biomarkers, the
CCCDTD4 recommends that MCI due to AD is only diagnosed in specialized clinical
practice and for research purposes. Patients with MCI are at increased risk of developing
dementia129, but this is controversial as the annual conversion rate is highly variable (320%) and the majority of MCI diagnosed patients might not progress to a diagnosis of
dementia even after 10 years of follow up130-134. Ongoing research on MCI is focused on
identifying factors that distinguish MCI from cognitively unimpaired older adults and
factors that predict conversion to the different forms of dementia. A large range of clinical
factors and biomarkers have been found to predict conversion to AD, offering insight into
the early pathophysiology and trajectory of AD:127,128,134 multidomain impairment135-139,
vascular risk factors140, ApoE isoforms139, plasma and CSF biomarkers141, and
neuroimaging biomarkers142,143 including white matter hyperintensities144,145.
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1.2.2 Neuropathology of Alzheimer Disease
The pathophysiology of AD remains undetermined and the disease has considerable
pathological heterogeneity. However, all presentations of AD feature aggregates of
amyloid protein and NFTs, attributed to increased production and/or impaired protein
clearance.
Amyloid precursor protein (APP) is expressed widely throughout the brain and in many
other organs146,147, but its physiological functions have not been fully identified148.
Mutations of APP and key enzymes involved in the amyloidogenic cleavage pathway of
APP (PSEN1/2) have been linked to autosomal dominant forms of EOAD, though not all
mutations are fully penetrant118. Two post-translational cleavage pathways have been
identified for APP, with the amyloidogenic pathway producing an extracellular amyloid-β
(Aβ) fragment. Aβ aggregates into several forms, ranging in size from soluble oligomers
to insoluble fibrils that can form plaques. More recently, soluble Aβ oligomers, also known
as also known as Aβ-derived diffusible ligands (ADDLs), have been considered to be a
key player in the neurotoxic mechanism of AD as Aβ oligomers can bind a range of
synaptic receptors and induce synaptic loss149. Interestingly, Aβ oligomers also elicit proinflammatory responses and impairment of essential glial functions149. Moreover, neurons
are no longer considered to be the sole source of Aβ; reactive astrocytes can also
contribute significantly to Aβ production150.
Tau protein is another important molecular factor in the pathophysiology of AD. Under
physiological conditions, tau protein stabilizes neuronal microtubules. Pathological
stressors induce hyperphosphorylation of tau, which then aggregates to form neurotoxic
NFTs151. In AD, NFTs present after the accumulation of Aβ plaques but are a stronger
neuropathological correlate of cognitive impairment152. NFTs accumulate first in the
entorhinal cortex, and as the disease progresses, NFTs propagate into hippocampal
regions, the lateral temporal cortex, association cortices, and lastly to primary unimodal
cortices153-155. This contrasts the propagation of Aβ plaques which follow a more inward
direction, first accumulating in the neocortical association regions before spreading to
allocortical structures, the limbic regions, diencephalon, and lastly, the brainstem and
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cerebellum155-157. Despite this difference in neuropathological propagation, direct
interactions of Aβ and tau protein are thought to be synergistically deleterious and central
to the development of dementia158-160, with glial cells playing an important role in
mediating the interaction of Aβ and tau dysregulation161,162.

1.2.2.1

Current Diagnostic Criteria

Although post-mortem evaluation continues to be considered the gold-standard for
verifying a clinical diagnosis of AD, many cases of autopsy-identified AD do not have a
clinical history of dementia106. While such cases may indicate pre-symptomatic AD, which
was intended by design163, neuropathological criteria continue to be refined to improve
correlation with clinical history164. Currently, the most widely recognized guidelines were
put forward by the NIA-AA165, which determines the neuropathological stage of AD
according to:
•

Extracellular Aβ deposits, also known as senile plaques, scored according to the
Thal phases156.

•

Intracellular NFTs that feature aggregates of hyperphosphorylated tau protein,
scored by Braak stages154

•

Dense aggregates of Aβ and dystrophic neurites known as neuritic plaques, scored
according to the Consortium to Establish a Registry for Alzheimer Disease
(CERAD) criteria166. These represent a subset of senile plaques and are more
closely associated with neuronal injury.

The scores of these 3 neuropathological features are combined to determine whether
brain tissue has low, intermediate, or high levels of AD neuropathological changes. Senile
plaques in the Thal phases include diffuse Aβ plaques, which are usually not associated
with glial responses or synaptic loss167. Though diffuse Aβ plaques are a sensitive
indicator of AD dementia, they are also common in elderly individuals without dementia.
However, characterizing the distribution and density of all forms of senile plaques
continues to play a role in the NIA-AA guidelines by improving sensitivity for cognitive
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impairment168 and detection of early disease156,164. The Thal phases are also
recommended for correlation with neuroimaging studies165. To offer improved diagnostic
specificity for cognitive impairment, the CERAD criteria excludes diffuse plaques and
emphasizes neuritic plaques, which are more closely associated with cognitive
impairment167. The Braak distribution of NFTs provides even stronger clinicopathological
correlation, as neocortical NFT burden provides the strongest neuropathological correlate
for cognitive impairment152,167. However, NIA-AA guidelines clearly state that Aβ deposits,
NFTs, and neuritic plaques should not be considered the comprehensive molecular profile
of AD neuropathology165. Rather, the guidelines prompt further research into elucidating
the unknown mechanisms by which amyloid and tau proteins are dysregulated and
identifying the specific molecular processes that lead to neurodegeneration. Experimental
animal models continue to be recommended for this line of research165.

1.2.2.2

Role of Glia in Alzheimer Disease

Both neuritic plaques and NFTs are associated with astrocytosis and microgliosis169.
Whereas Aβ load plateaus early after symptom onset169,170, astrocytosis and microgliosis
continue to increase linearly as the disease progresses169. Moreover, astrocytosis and
microgliosis are correlated with NFT burden and loss of cortical thickness169, raising the
question of whether these glial responses are merely reacting to the AD pathology or
playing a central role in the disease mechanism66. As glial cells are fundamental to the
maintenance of CNS homeostasis, including inflammatory processes, glial cells present
a favorable therapeutic target for modifying the course of AD64,65.
Neuroinflammation in AD is thought be driven primarily by microglia, the brain’s resident
myeloid cells, which are involved in both cytokine secretion and phagocytosis66. This is
distinct from the conditions that are traditionally defined as neuroinflammatory diseases,
namely multiple sclerosis and the different forms of encephalitis, which are driven by
peripheral leukocytes that migrate into the CNS from systemic circulation66. The adaptive
immune response, mediated primarily by T- and B-lymphocytes, has not been implicated
in AD neuroinflammation, so mechanisms seen in most autoimmune conditions are
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unlikely to be observed in AD. Furthermore, astrocytes are also directly involved with AD
neuroinflammation66,77. Unlike in MS, traumatic injury, or ischemic stroke, astrocytes in
AD do not typically form glial scars even though they upregulate expression of glial
fibrillary acidic protein (GFAP)66. Instead, reactive astrocytes appear to modulate
microglial function and play an important role in Aβ degradation66,77,171. This is further
complicated by the observation of senescent or dystrophic microglia and astrocytes
associated with prolonged exposures of high Aβ concentrations, which may indicate a
crucial decompensation in the course of AD66,172,173. It remains to be determined which
specific processes in AD neuroinflammation are protective and which are detrimental66.
Both preclinical and clinical studies suggest a critical role of glial-mediated inflammation
in AD. Cognitive and neuropathological profiles of transgenic mouse models of AD have
been improved by a breadth of molecules with anti-inflammatory properties: rapamycin,
minocycline, pioglitazone, thalidomide, etanercept, and celastrol, all of which modulate
tumour necrosis factor-α (TNF-α) signalling and the activation of pro-inflammatory
microglia and astrocytes174-176. TNF-α is a pro-inflammatory cytokine that plays a pivotal
role in inflammation throughout the body, and its expression is increased by both neurons
and glial cells during both acute and chronic brain injury.176 Aβ activates several TNF-α
dependent

pathways,

including

cyclooxygenase

(COX)-mediated

inflammatory

processes177. Non-steroidal anti-inflammatory drugs (NSAIDs) reduce these inflammatory
processes by inhibiting COX in neurons, microglia, and astrocytes178,179, and NSAIDs may
also offer neuroprotection by COX-independent pathways such as the direct promotion
of non-amyloidogenic processing of APP179-181. Cohort studies of have shown promise in
reducing the risk of AD, with the most recent meta-analysis of 236 000 participants from
16 cohort studies citing a 19% relative risk reduction of AD diagnosis179. This supports
the potential of anti-inflammatory drugs as a disease modifying therapy but the optimal
NSAID type, dose, and the duration and timing of treatment have yet to be identified.
Skepticism over this direction of research is raised by several studies that showed an
increased incidence of AD among NSAID cohorts179. The only randomized-controlled trial
of NSAID intervention did find reduced AD incidence if treatment was initiated in
asymptomatic individuals, but increased incidence if treatment was initiated in patients
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with cognitive impairment or dementia182, suggesting that the timing of NSAID intervention
with regard to disease stage is a crucial factor. This consideration is likely to extend to
other anti-inflammatory drug trials, such as the phase-II trial of the anti-TNF-α biologic,
etanercept, which showed favourable but non-significant trends in patients with mild to
moderate AD183.
In AD, glial cell density increases throughout grey matter tissue, but also in white
matter184. Oligodendrocytes provide important tropic supports to neurons, but Aβ is toxic
to oligodendrocytes in vitro185,186. Histological changes of white matter are commonly
observed in AD; while oligodendrocyte density is decreased, post-mortem evaluation has
found astrocyte and microglia numbers to be increased in the white matter of patients
with AD dementia187,188. PET studies have also identified increased white matter
inflammation in AD patients68,189.

1.2.2.3

White Matter Changes in Alzheimer Disease

Much of AD continues to be defined by pathological changes in grey matter but white
matter degeneration is also observed in AD, both on imaging and in histological
samples23,190-193. In AD, white matter degeneration can range from demyelination to
atrophy32,190,194. The specific patterns of white matter atrophy may also be crucial to
differentiating potentially distinct forms of AD191. Whereas LOAD more typically featured
white matter atrophy in the medial temporal regions, EOAD features greater cingulate
atrophy191. Atypical variants of AD include the logopenic variant of primary progressive
aphasia (lv-PPA), which features more left parietal white matter atrophy, and posterior
cortical atrophy (PCA), which features more occipital white matter atrophy. Compared to
LOAD, more white matter atrophy in the lateral temporal cortex, parietal cortex, cingulum,
and corpus callosum were observed in EOAD, lv-PPA, and PCA191. Thus, specific
patterns of white matter atrophy may aid in characterizing specific forms of AD.
This has prompted the possibility that white matter disease may be a core feature of
AD186. However, whether white matter atrophy is due to local degenerative changes or
secondary to remote neuronal injury, i.e., due to Wallerian or anterograde degeneration
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has not been determined190. Currently, there is more evidence in favour of white matter
atrophy as a secondary process, as grey matter and white matter volume loss are usually
correlated190. However, primary local damage and retrograde damage due to AD cannot
be ruled out190. Oligodendrocytes may be sensitive to the increased concentrations of Aβ
seen in the brains of patients with AD, and loss of oligodendrocytes due to increased
concentrations of Aβ could contribute to white matter demyelination and consequent
degeneration185,186. Moreover, the specific patterns of diffusion tensor changes seen in
AD are not indicative of primarily Wallerian degeneration190,195,196. While grey matter and
white matter volume loss may be correlated in AD, white matter damage seen in MCI
showed no relationship with grey matter atrophy190,194. This suggests that especially in
the early stages of disease, white matter may undergo atrophy due to local injury and
retrograde degeneration as well as secondary degeneration due to grey matter injury and
anterograde degeneration190. The growing evidence of glial dysregulation as a common
feature of AD also suggests potential inflammatory mechanisms by which white matter
could be damaged directly68,186,197, independent of grey matter senile plaques and
NFTs167.
Any observed primary local damage could also be attributed to vascular injury, as white
matter is particularly sensitive to vascular disruption49-51 and cerebrovascular disease is
highly comorbid with AD198,199. However, there is considerable overlap in the findings that
are conventionally attributed to purely AD and purely vascular neuropathologies200-204,
with many proposing that vascular disruption may be central to AD as well31,33,34,202,205,206.
The intersection of AD and VaD may be most apparent in leukoaraiosis, the radiological
phenomenon of diffuse hypodense (on CT) or hyperintense (on T2 MRI) white matter2934.

Leukoaraiosis is associated with disruptions of white matter integrity35,36 and vascular

pathology41,45,50,207-211, but leukoaraiosis is also an important risk factor for AD37-39 and
leukoaraiosis volume has also been correlated directly with the severity of cognitive and
functional impairment in AD212-214. Recently, CSF concentrations of Aβ were found to
correlate with leukoaraiosis volume215,216. In the Dominantly Inherited Alzheimer Network
(DIAN) study, which follows a cohort of carriers of genetic mutations known to cause
EOAD (PSEN1/2, APP), leukoaraiosis volume began to increase significantly 6 years
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prior to estimated symptom onset32. Specifically, in the parietal and occipital lobe,
leukoaraiosis was significantly increased as early as 22 years prior to estimated symptom
onset. This offers strong support for leukoaraiosis as a core feature of AD and a potential
biomarker as opposed to an observation that is commonly coincidental due to chance
alone32. However, the pathological basis of leukoaraiosis has yet to be identified. While
many studies suggest a vascular etiology for leukoaraiosis41, dysregulation of astrocytes
in the BBB45 and genetic variation related to inflammation has also been implicated46.
Though dysregulation of astrocytes and aberrant inflammation can certainly be initiated
by vascular pathology, AD-related proteinopathies may also drive the dysregulation of
glial cells and neuroinflammation, as discussed above. While leukoaraiosis may already
be an informative predictor for dementia, further experimentation is needed to identify the
etiology of leukoaraiosis in the context of AD.
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1.3

Vascular Cognitive Impairment

Cerebrovascular disease is highly heterogeneous and the second most prevalent cause
of dementia104,199,217. When cerebrovascular disease causes cognitive and functional
impairment, Vascular dementia (VaD) is diagnosed. However, in many patients,
cerebrovascular disease may result in cognitive impairment but not functional
impairment217, analogous to MCI with cerebrovascular etiology218,219. In recognition of
this, broader diagnostic categories have been proposed: major Canadian and US
associations endorse vascular cognitive impairment (VCI)217,220, the International Society
for Vascular Behavioural and Cognitive Disorders (VASCOG) endorse vascular cognitive
disorder221, and the DSM-V uses the term vascular neurocognitive disorders115. While the
terminology will continue to evolve in research and clinical settings, this thesis will refer
to the term VCI to include both VCI-no dementia (VCIND)218,219 and VaD. VCIND and VaD
exist on a spectrum of cognitive manifestations of cerebrovascular disease, with VaD only
diagnosed when cognitive impairment causes severe functional impairment. In the
Canadian Study of Health and Aging, following a diagnosis of VCIND, 58% died and 46%
developed dementia within 5 years; of patients that progressed to dementia and were
alive at follow-up, 35% had AD, 15% had mixed dementia, 42% had VaD, and 8% had an
unclassified form of dementia222. Since effective prevention and treatment for
cerebrovascular disease exists, there is growing interest in reliably identifying VCI to limit
disease progression217,222.
Unlike AD, there is not a defined set of pathological criteria for the post-mortem diagnosis
of VaD, and clinical diagnostic criterion are applied inconsistently223. Moreover, increased
recognition of the comorbidity of AD and VaD has made it difficult to distinguish the two
diseases, with growing recognition of mixed dementia as the most prevalent form of
dementia199,224. Mixed dementia will refer to the prevalent case in which both AD and
cerebrovascular disease contribute to cognitive impairment199,224, although comorbidity of
other forms of neurodegenerative disease are also common.
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1.3.1 Clinical Profile of Vascular Cognitive Disorders
Generally, VCI can result from overt symptomatic cerebrovascular disease, such as
ischemic or hemorrhagic stroke, or from “covert” cerebrovascular disease, such as
asymptomatic lacunar infarcts or small vessel disease199. Particularly in patients with
covert cerebrovascular disease, thorough physical examination, neuropsychological
assessment, and neuroimaging play an important role in diagnosing VCI. Due to the
vascular nature of VCI, functional and cognitive impairments evolve suddenly, in contrast
to the relatively gradual progression of impairments seen in AD. Any cognitive domain
can be impaired and multidomain impairment is common in VCI. As the frontal lobes and
white matter are particularly susceptible to cerebrovascular disease, executive functions
are the most commonly affected199. Deficits in ADLs only contribute to the diagnosis of
VCI if they are due to cognitive impairments; functional impairments as a result of any
motor or sensory sequalae related to cerebral infarcts are not considered, emphasizing
the cognitive component of VCI220.
The epidemiological estimates of VCI vary greatly but offer important insights into the
complex relationships between cerebrovascular disease and dementia. Risk factors for
VCI are generally the same risk factors identified for stroke and cardiovascular disease:
smoking, atrial fibrillation, hypertension, diabetes, hyperlipidemia, and ApoE ε4, while
regular exercise confers protection220. After the age of 55, lifetime risk of stroke is 21% in
women and 17% in men121, while estimates for the proportion of patients that develop
cognitive impairment after a symptomatic stroke ranges greatly, from 6-41%225,226. With
regard to covert cerebrovascular disease, 67-76% of elderly subjects without a history of
cognitive impairment exhibit cerebrovascular pathology in post-mortem evaluation, with
small vessel disease being the most common198,227. Thus, even in the absence of overt
cognitive symptoms, cerebrovascular disease is highly prevalent. Both overt and covert
cerebrovascular disease contribute to an overall prevalence of VaD in 1.6% of individuals
over the age of 65, with prevalence increasing exponentially with age228. Though there
are no direct studies of the lifetime risk of VaD, lifetime risk of all-cause dementia is 22%
in women and 14% in men over the age of 65121, of which 15-20% is attributed to
VaD225,228-230. Similarly, VaD accounts for 18% of early dementia cases diagnosed prior
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to 65 years of age228. However, cerebrovascular disease is estimated to contribute 33%
of the risk of all-cause dementia199,217; cerebrovascular disease is highly comorbid with
AD, such that mixed dementia is estimated to be more prevalent than either “pure” AD or
VCI199,224.

1.3.2 Neuropathology of Vascular Cognitive Disorders: Cerebrovascular Disease
Cerebrovascular disease, the underlying neuropathology of VCI, is very heterogeneous,
and multiple types of cerebrovascular lesions can be observed in a single brain.
Universally accepted neuropathological criteria for VCI do not exist221,223, and the
correlations between the breadth of cerebrovascular disease and its range of clinical
manifestation is an area of ongoing research226,231,232. However, it is informative to
classify cerebrovascular disease according to major etiological categories199,226:
•

Large vessel disease or atherosclerosis: proliferation of the intima (atheroma) in
medium and large arteries, with accumulation of cholesterol and leukocytes that
can lead to plaque formation and calcification. Plaques can rupture, causing local
thrombosis and a single large brain infarct or produce emboli and multiple infarcts.

•

Small vessel disease: reduced compliance in arterioles and capillaries due to
arteriosclerosis, lipohyalinosis, arteriolosclerosis, and amyloid angiopathy,
resulting in lacunar infarcts, even smaller microinfarcts, small hemorrhages, and
extravasations of blood known as microbleeds.

•

Cardiac: cardioembolic injury, commonly attributed to atrial fibrillation, as well as
any condition that impairs cerebral perfusion such as cardiomyopathy, cardiogenic
shock.

•

Other Systemic: sickle cell disease, autoimmune conditions such as vasculitis,
circulatory shock.

Cerebrovascular lesions can be further categorized according to distribution: focal,
multifocal, or diffuse. Focal lesions can be attributed to any of the etiologies described
above, but focal lesions that result in VCI are usually the result of an infarct in functionally
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important regions. Focal lesions affecting the mesial temporal lobe, anterior cingulate
cortex, caudate, thalamus, angular gyrus of the dominant hemisphere, and key white
matter areas can result in strategic infarct dementia223. Multifocal lesions of large vessel
etiology can result in multiple infarct dementia223. Multifocal or diffuse lesions of small
vessel etiology are particularly heterogeneous and are seen in VCI attributed to multiple
lacunar infarcts, Binswanger disease, hypertensive angiopathy, and cerebral amyloid
angiopathy223. In two hereditary cerebrovascular conditions that can result in VCI,
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)233
and Moya Moya disease234, both small and large vessel disease are seen in a
multifocal/diffuse distribution. The categories of cerebrovascular pathologies outlined
here are far from exhaustive but do capture some of the breadth of factors involved.
Further considerations related to neuropathological staging include lesion severity,
location(s), and sampling strategies are also in ongoing development, and will likely play
an important role in correlating cerebrovascular disease and VCI226,231,232.
The high co-occurrence of AD and cerebrovascular disease199,224 has generated research
on whether the two diseases may have synergistic neuropathological and cognitive
effects235-239. This is supported by the Nun Study, which found that AD pathology was far
more likely to correlate with dementia if cortical infarcts or lacunar strokes were also
present240. This has been replicated, with a recent metanalysis of 2856 from 10 studies
finding that compared to patients with post-mortem evidence of AD, patients with both AD
neuropathology and cerebrovascular disease were three times more likely to have had
dementia241. In a large post-mortem study from the National Alzheimer’s Coordinating
Centre, 80% of patients diagnosed with AD were also found to have cerebrovascular
pathology, significantly greater than the 67% of subjects that had cerebrovascular
pathology but no cognitive impairment198. Furthermore, a recent large cross-sectional
study with participants of the Religious Orders Study and the Rush Memory and Aging
Project found the odds of a clinical diagnosis of AD to be increased in participants that
had cerebral atherosclerosis or cerebral arteriosclerosis, confirmed post-mortem239.
Thus, the prevention and treatment of cerebrovascular disease is likely to play an
important role in reducing the burden of dementia by addressing both AD and VCI241-243.
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1.4

The Neurovascular Hypothesis of Alzheimer disease

In recognition of the high comorbidity between AD and VCI, the Neurovascular
Hypothesis of AD proposes that the interaction of amyloid pathology and cerebrovascular
disease is a core mechanism that leads to neuronal injury and cognitive impairment236.
The Neurovascular Hypothesis directs focus to neurovascular unit (NVU), which is
composed of neurons, astrocytes, endothelial cells, myocytes, pericytes, crucial
extracellular components, and resident immune cells244. A crucial component of the NVU
is the BBB, which segregates the interstitial microenvironment of the CNS and regulates
the clearance of neurotoxic molecules such as Aβ. The NVU also regulates the coupling
of blood flow and local metabolic demands, known as hyperaemia or neurovascular
coupling203,245. Thus, the NVU is crucial to protecting the brain from both AD pathology
and cerebrovascular disease. At the same time, the NVU can be directly disrupted by
both of these diseases as well as systemic vascular conditions203,237,238,246-248.
Experimental studies have generated evidence in support of the Neurovascular
Hypothesis, identifying potential therapeutic targets that may prevent important
neurodegenerative disease mechanisms203,237,246-251.

1.4.1 The Neurovascular Unit and Blood-Brain-Barrier
Autoregulation of large vessels maintains near-constant blood flow to a large vascular
territory, accomplished by intravascular regulation of the luminal diameter to compensate
for fluctuations in systemic blood pressure. In contrast, coupling occurs at the microscopic
level of the vascular bed, accomplished through a complex coordination between NVU
cells responding to fluctuations in the metabolic demands of the local parenchyma244.
Myocytes are the smooth muscle cells that make autoregulation of arteries and arterioles
possible, and myocytes communicate with downstream pericytes via gap junctions252.
Pericytes are also contractile cells that regulate blood flow at the level of capillary beds
and individual capillaries, and pericytes have been found to communicate with both
endothelial cells and astrocytes244. Astrocytes are considered to be the key detector of
abluminal metabolic demands, receiving glutamatergic signals from neurons and
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interneurons244. To relay these signals and affect local blood flow, astrocyte endfeet
release vasoactive substances such as eicosanoids which directly stimulate or inhibit the
contraction of pericytes253. Additionally, astrocyte endfeet release potassium ions into
blood vessels and onto myocytes, inducing vasodilation253. Endothelial cells also
modulate vascular tone, and relay signals of vascular tone to astrocytes244. Importantly,
cells of the NVU are mutually dependent on crucial extracellular trophic factors during
both development, maintenance, and microstructural remodelling244. The NVU directs the
formation, maintenance, and remodelling of the BBB, which regulates the passive and
active diffusion of molecules and ions both into and out of the brain parenchyma. The
physical barrier of the BBB is formed in part by the complex basement membrane that is
maintained by both endothelial cells and astrocytes248. More recently, the primary
inflammatory cells of the brain, microglia, have also been found to respond to ischemia
and contribute to BBB and vascular remodelling by cytokine signalling. Dysregulation of
any of the NVU cells or microglia can contribute to a dysfunctional BBB.

1.4.2 NVU Dysfunction
The NVU maintains neurovascular coupling and the microenvironment of the CNS,
promoting healthy CNS function. However, vascular conditions can lead to dysregulation
of the NVU, disrupting CNS homeostasis. Hypertension, ischemic stroke, and covert or
‘silent’ brain infarcts (SBI) are among the most prevalent vascular etiologies that can
cause NVU dysfunction. The NVU is essentially the site at which small vessel disease
occurs; arteriolosclerosis, lipohyalinosis, microbleeds, and microhemorrhages indicate
profound disruption of the NVU254. Due to the diffuse nature of small vessel disease, NVU
dysregulation is likely to exist well beyond the immediate temporal or anatomical proximity
of detectable cerebrovascular lesions, such as SBI. Impaired coupling results in
oligaemia, hypoxia237, and mitochondrial-mediated oxidative stress237, with further injury
propagated by dysregulated inflammation248,255,256. Meanwhile, a ‘leaky’ BBB can result
in extravasation of circulating molecules and proteins that have toxic and proinflammatory effects in the brain237,254. Interestingly, peripheral sources of circulating Aβ
can enter the CNS, induce Aβ-related pathology, and disrupt neuronal function237,246,257;
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this can be prevented by molecular interventions that target specific molecules in the
NVU246. Thus, NVU dysfunction can exacerbate or result in AD pathology. In turn,
abluminal pathology such as AD can also propagate dysregulation of the NVU and BBB,
creating a self-propagating pathological cycle.

1.4.2.1

Hypertension

Hypertension is a highly prevalent condition, affecting 23% of Canadian adults, of whom
only 68% have controlled blood pressure258. Hypertension is also recognized as a leading
vascular risk factor for stroke and dementia259,260, including AD261-263. Experimental
animal models of comorbid hypertension to exacerbate AD-related pathology251,264-268.
However, while the connection between hypertension and cerebrovascular disease is well
established259,260, it remains inconclusive whether anti-hypertensive therapy reduces AD
incidence269-274. In addition to dysregulating cerebrovascular autoregulation, hypertension
can also disrupt neurovascular coupling203. This was observed in an experimental
hypertensive rodent model that had an attenuated blood low response to whisker
stimulation275, which was further exacerbated by neocortical application of Aβ or by
transgenic expression of pathogenic APP276. Similarly, in a clinical cohort study using
PET imaging, hypertensive subjects demonstrated a reduced hemodynamic change
during a memory task277. Moreover, hypertension has been shown to cause BBB
leakiness and the pro-inflammatory activation of microglia and astrocytes278. Perivascular
macrophages, resident immune cells that are distinct from microglia, have also been
found to release reactive oxygen species in response to hypertension, resulting in
neurovascular and cognitive dysfunction279. These are some of the mechanisms by which
hypertension can disrupt the NVU and CNS function, even in the absence of detectable
cerebrovascular disease203.
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1.4.2.2

Ischemic Stroke and Silent Brain Infarcts

The lifetime risk of ischemic stroke in the Framingham study was found to be 18% for
women and 15% for men at 55 years of age280. in a recent retrospective cohort study in
London, Ontario, cardioembolic etiology accounted for 56% and large artery
atherosclerosis accounted for 26% of ischemic stroke cases

281.

Small vessel disease

can also result in ischemic lesions, including microinfarcts and lacunar infarcts; when
these infarcts do not cause symptoms, they are classified as an SBI. By their nature, SBIs
are found incidentally on neuroimaging or in post-mortem evaluation, most often affecting
subcortical white matter, basal ganglia, thalamus, and the infratentorial region282.
Disturbingly, SBI are found in 10-20% of the general elderly population, increasing with
age and hypertension283,284 to as high as 62% in select elderly populations with other
significant morbidity285. While the chronic impact of SBI on proximal intact NVUs is difficult
to investigate, it is likely to demonstrate similar processes seen in ischemic strokes and
small vessel disease. Following ischemic stroke, autoregulation and coupling are
impaired even in brain regions that appear uninjured203. Similarly, in a transient middle
cerebral artery occlusion model, BBB disruption can be observed 30 days after injury,
even on the contralateral hemisphere286. When striatal lacunar infarcts were modelled in
a transgenic mouse model of AD, increased APP, tau, and inflammatory microglia were
observed in the cortex and hippocampus287. In this same study, anti-inflammatory
treatment reduced the area and density of APP near the injury site. Thus, inflammation
may play an important role in propagating AD-related pathology following NVU injury by
ischemic stroke and SBI.

1.4.2.3

Abluminal Injury: Alzheimer Disease Pathology

Aβ is generally cleared from the brain by enzymatic degradation or by active clearance
across the BBB, mediated by the low-density lipoprotein receptor-related proteins (LRP)
pathway. Endothelial cell LRP1 binds and initiates clearance of abluminal unbound Aβ as
well as ApoE-bound Aβ; interestingly, ApoE ε4 inhibits this active transport of Aβ out of
the brain237. By impairing the clearance of Aβ, reduced expression of LRP1 in blood
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vessels has been associated with AD in both preclinical and clinical studies237. However,
Aβ can impair its own clearance by oxidizing LRP1, which was observed in the
hippocampal tissue of AD patients288. As Aβ is toxic to virtually all cell types in the NVU,
increased concentrations of Aβ, as seen in AD, can directly disrupt the NVU289,290.
Additionally, dysregulated inflammation induced by AD pathology can further disrupt the
NVU, while failure of perivascular macrophages to clear Aβ can contribute to its
accumulation in the brain279,289,291. Thus, the disruption of the NVU may be either a cause
of AD, a consequence of AD, or both. In any case, there is strong indication that the NVU
has a central role in neurodegenerative disease.

1.4.3 White Matter Pathology and the Neurovascular Hypothesis of Alzheimer Disease
The Neurovascular Hypothesis offers a potential understanding of AD that is non-neuroncentric236, as it draws attention to the important role of non-neuronal cells in the NVU.
Similarly, the often-overlooked factor of white matter disease may also play an important
role in the Neurovascular Hypothesis; disruption of NVUs in periventricular white matter,
which is particularly vulnerable to cerebrovascular pathology44,47-52, may contribute to the
accumulation of cerebral Aβ and in turn, AD. Both in preclinical and clinical studies, AD
pathology is associated with impaired coupling235,245. Dramatic pericyte loss is observed
in the white matter of patients that had AD, which is also accompanied with
demyelination292. This was further investigated in transgenic mice lacking cerebral
pericytes, which developed white matter dysfunction, white matter atrophy, hippocampal
and cortical atrophy, and cognitive impairments292. Furthermore, a transgenic mouse
model of AD treated with simvastatin, a cholesterol lowering drug, showed improved
coupling and cognition293.
The role of proinflammatory astrocytes and microglia in NVU injury, white matter integrity,
and cognitive impairment is also strongly supported; 5 recent experimental animal studies
showed that targeted modulation of astrocyte- and microglia-mediated inflammation
protected white matter microstructure, white matter function, and cognition following
chronic hypertension, hypoperfusion, and ischemic injury72-76. These studies did not
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evaluate whether protecting white matter integrity had beneficial effects on executive
function, but this link has been demonstrated in humans. In elderly individuals with
hypertension and/or diabetes mellitus type 2, neurovascular coupling was measured by
changes in blood flow velocity in the middle cerebral artery during a series of cognitive
evaluations; more responsive coupling was correlated with better scores on cognitive
flexibility tasks and higher white matter FA, an indicator of white matter integrity294. In the
same study, consumption of flavanol-cocoa for 30 days improved coupling and
behavioural flexibility scores, which was attributed to the beneficial effects of cocoa
flavanols on systemic and cerebral vascular function294. Altogether, these studies strongly
indicate that white matter inflammation and cerebrovascular disease play an important
role in the pathogenesis of executive dysfunction and AD. However, with regard to
executive function, this has yet to be evaluated in an experimental model of AD.
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1.5

Rationale and Objectives

White matter is highly susceptible to ageing12,85, as both amyloid pathology and
cerebrovascular

disease

can

initiate

white

matter

inflammation

and

dysfunction44,68,186,215,216,292. In recent studies, microglia- and astrocyte-mediated
inflammation of white matter was shown to impair executive function78-81, a major
cognitive domain that is crucial for maintaining functional independence86-88. However,
the relationship between white matter inflammation and executive function in the contexts
of ageing or AD has not been directly evaluated, even though both increased
inflammation and executive dysfunction are common in advanced age and
AD68,84,116,190,191,193. Thus, we hypothesized that ageing and pathogenic APP induce
white matter inflammation, resulting in executive dysfunction. Furthermore, as white
matter is particularly vulnerable to cerebrovascular disease44,47-52, chronic dysfunction of
the NVU can result in reduced clearance of Aβ237 and further exacerbation of white matter
inflammation248,255,256. Thus, vascular injury exacerbates white matter inflammation
and executive dysfunction induced by ageing and pathogenic APP. A transgenic rat
model of AD was studied to test these hypotheses and address the following research
objectives:
1) To determine the effect of pathogenic APP on white matter inflammation and
executive function (Chapter 2 and Chapter 3)
2) To characterize the temporal relationship between age, pathogenic APP
expression, white matter inflammation, and executive function (Chapter 3)
3) To evaluate the impact of comorbid pathogenic APP and cerebrovascular stress
(hypertension; Chapter 4) or injury (ischemia; Chapter 5) on executive function
The attributes of the transgenic model, the TgAPP21 rat, permitted the investigation of
pre-Aβ-plaque dysfunction295-298, modelling the early stages of AD-related pathology.
Evaluation of inflammation was focused on microglia and astrocytes, as these cells are
central to the neuroinflammatory processes observed in neurodegenerative disease66.
Testing paradigms for rat behavioural flexibility have been well established100,299,300, and
behavioural flexibility is considered to be the most integrated cognitive subdomain of
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executive function82. Thus, evaluation of executive function in the TgAPP21 rat was
focused on behavioural flexibility.
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Chapter 2: The Cognitive and Neuroinflammatory Profile of
the TgAPP21 Rat
This study set out to determine the effect of pathogenic APP on white matter inflammation
and executive function (Objective 1) and is currently under review for Scientific Reports.

2.1

Abstract

Executive dysfunction and white matter pathology continue to be relatively understudied
in Alzheimer’s disease (AD). The TgAPP21 rat model of AD expresses hAPP with swe/ind
mutations but does not spontaneously develop plaques; however, previous studies of this
model suggest a spontaneous impairment of behavioural flexibility, an important
subdomain of executive function. In this study, 7 – 8-month-old male TgAPP21 rats were
tested for behavioural flexibility, learning, and memory using an operant conditioning
chamber and the Morris Water Maze (MWM). TgAPP21 rats demonstrated a regressive
behavioral inflexibility during set shifting in an operant conditioning chamber, and
regressive behaviour was also demonstrated in the MWM probe test; this behavioural
phenotype has not been previously described in the MWM. Clinical research of prodromal
AD suggests that white matter pathology may underlie impairment of executive functions
such as behavioural flexibility. Diffuse microglia activation was increased in the white
matter of TgAPP21, which was found to correlate with the number of reversal errors in
the operant conditioning chamber. TgAPP21 rats are therefore an instrumental model of
behavioural inflexibility and plaque-independent extrahippocampal changes of early ADrelated amyloidopathy.
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2.2

Introduction

Patients with mild cognitive impairment that exhibit executive dysfunction are more likely
to progress to Alzheimer’s disease (AD)1-7. Executive dysfunction can also be detected
early in AD, even prior to diagnosis8-11. Particular subdomains of executive function that
are important predictors of progressive cognitive decline include cognitive flexibility and
working memory1-5. Despite this, behavioural characterization of rodent models of AD has
largely focused on hippocampal dependent cognition such as memory and spatial
processing12-14. To advance our understanding of the early mechanisms underlying AD
and other dementias, further characterization of executive functions in rodent models is
needed15.
The TgAPP21 transgenic Fischer 344 rat (hAPP with Swedish and Indiana mutations) is
ideal for modelling the prodromal phase of AD. TgAPP21 rats do not spontaneously
develop plaques16,17, but while amyloid aggregates are absent in naïve TgAPP21 rats,
aggregates can be induced by cerebral stressors16-19. No behavioural changes have been
found in previous studies of naïve TgAPP21 rats, which have only evaluated hippocampal
dependent spatial learning and memory17. In contrast, TgAPP21 rats with ischemic injury
of the dorsal striatum demonstrated significantly more behavioural inflexibility than injured
wildtype (control) rats and uninjured TgAPP21 rats, characterized by a specific increase
of regressive errors on an extradimensional set shifting task20. While the interaction of
ischemic striatal injury and transgene expression produced a synergistic increase of
behavioural inflexibility, the transgene alone had an overall effect of increased regressive
behaviour. This warrants closer investigation of spontaneous regressive behaviour in
TgAPP21 rats. Mild cortical pathology has only been observed in naïve TgAPP21 rats
that were aged to 18 – 19 months of age and was absent in younger rats and would
therefore be unlikely to underlie spontaneous behavioural inflexibility in younger rats.
However, significant dysregulation of membrane lipids has been found in TgAPP21 white
matter by 12 months of age21. Recent clinical research on the early stages of dementia
have found white matter pathology to be linked to executive dysfunction, including
behavioural inflexibility22-32. As features of both white matter pathology and executive
dysfunction have been observed independently in the TgAPP21 rat, this model may
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present an important opportunity to study the link between white matter changes and
executive function.
To better characterize spontaneous behavioural changes in TgAPP21 rats, a complement
of behavioural tests was performed in the present study. We found that TgAPP21 rat
demonstrated

behavioural

inflexibility

in

an

operant-chamber-based

test

of

extradimensional set shifting33. This manifested as increased regressive behaviour and
reversal impairments in an operant conditioning chamber. To corroborate previous
findings of normal hippocampal-dependent function in TgAPP21 rats, the Morris Water
Maze (MWM) was used to evaluate spatial learning, memory, and working memory34-38.
MWM tests confirmed that TgAPP21 rats had unimpaired spatial learning and memory,
but we were surprised to also observe a previously undescribed regressive-like behaviour
during the MWM probe test. These observations demonstrate how tests of behavioural
inflexibility can inform tests of hippocampal function, such as learning and memory.
Lastly, as white matter inflammation has been linked to executive dysfunction, we
analyzed brain tissue for activation of microglia and astrocytes in the plaque-free
TgAPP21 rat. While astrocyte activation was not increased in TgAPP21 rat, widespread
activation of white matter microglia was significantly increased. Microglia activation in the
supraventricular corpus callosum (SVCC) was also significantly correlated with reversal
impairment. Our findings identify the TgAPP21 rat as having the behavioural and
neuropathological profile that reflects some of the earliest observable neurological
changes that precede diagnosis of dementia.
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2.3

Methods

2.3.1 Animals
Animal ethics and procedures were approved by the Animal Care Committee at Western
University (protocol 2014-016) and are in compliance with Canadian and National Institute
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23).
All rats used in this study were housed in facilities maintained by Western University
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. Homozygous
transgenic Fischer 344-APP21 rats (TgAPP21) were studied to model the effect of
increased brain concentrations of amyloid protein. Developed by lentiviral infection of
zygotes, TgAPP21 rats overexpress a pathogenic human APP sequence with Swedish
and Indiana mutations, and produce high levels of beta-amyloid (both 1-40 and 1-42), but
do not deposit beta-amyloid plaques16. TgAPP21 rats were bred and aged in house,
alongside wildtype Fischer 344. TgAPP21 homozygosity was validated using tissue
samples from pups. 10 male TgAPP21 rats and 10 male wildtype Fischer 344 (Wt) rats
with body masses ranging from 300-430 g were aged to an average of 6.7 months (SD =
0.3) before behavioural studies began; rats were euthanized at 7.5 months of age (SD =
0.3). This age range was selected to allow for some age-dependent pathology of hAPP
expression and to minimize other health variables expected in more advanced age.

2.3.2 Set Shift & Reversal
Behavioral flexibility was assessed using an operant conditioning based set-shifting task
as developed by Floresco et al39. As described in our recent publication40, the set-shifting
task required rats to perform an extradimensional strategy shift, in which they had to
transition from a learned visual cue-dependent strategy to a newly-rewarding egocentric
spatial strategy (Figure 2-1). The overall experimental series included acclimation and
training, initial set formation (visual cue discrimination task) and finally, set-shifting
(response discrimination task). Throughout these experimental steps, animals were
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tested during their dark cycle at regular individual times, completing all training and testing
in the same apparatus.

2.3.2.1

Apparatus

Two operant conditioning chambers (Med Associates; St. Albans, VT) were fitted in
separate sound attenuating boxes. The operant conditioning chambers were equipped
with two retractable response levers which were located on either side of a central food
pellet receptacle. A bright stimulus light was located above each lever (Figure 2-1), and
there was a house light at the back of the apparatus at roof level. All operant conditioning
chamber inputs and outputs were handled using MED-PC software (Med Associates; St.
Albans, VT) with customized programs that automated control of the chamber and data
recording. Immediately following a correct lever press, a 45 mg sucrose pellet (Dustless
precision pellets, Bio-Serv; Burlington, ON) was dispensed into the central pellet
receptacle as a positive reinforcement.

2.3.2.2

Food Restriction & Initial Operant Conditioning

To ensure motivation for food reinforcement, food restriction was initiated 6 days before
lever-press training and continued throughout testing. Feed quantity was adjusted
individually to maintain rat body mass at 85% of initial free-feed mass. Rats were weighed
regularly during food restriction, and there was no difference in loss of body mass
between groups. Water was provided freely during food restriction.
Three days prior to training, pellets were placed daily in the rat’s cage to allow for
acclimation to the future reinforcement used in testing. Rats were habituated to the
operant conditioning chamber for 20 min, followed by daily training of lever pressing; lever
presses were reinforced with a pellet using a fixed-ratio 1 (FR1) schedule. Rats were
trained under manual control of lever extension & retraction using operant conditioning
strategies until they could consecutively alternate between 15 left and 15 right lever
presses. They were then trained daily on an automated 90-trial program that pseudo-
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randomly alternated lever presentation; each trial allowed the rat 10 s to press an
extended lever, followed by a 20 s inter-trial period. The training program was repeated
daily until the rat completed 90 trials with 5 or fewer omissions.

2.3.2.3

Side Bias Determination

The side bias determination program was run immediately after training was complete.
Both levers were presented on all trials, and rats were granted a 10 s response period
with a 20 s inter-trial period. Initially, either lever was rewarded with a pellet, but the
following reward would only be given when the opposite lever was pressed. This was
repeated until the rat completed 7 pairs of lever alternations (a pair could be initiated on
either side). A side bias was identified if one lever was pressed twice as many times as
the other lever, otherwise the lever-side that initiated 4 or more of 7 alternation pairs was
classified as the biased side. Each rat’s side bias was used for the response
discrimination task, where the lever opposite the rat’s side bias was always considered
the correct lever.

2.3.2.4

Visual Cue Discrimination

One day after completion of side bias determination, rats began the visual cue
discrimination (VCD) task (Figure 2-1). On each trial, illumination of one stimulus light
preceded the extension of both levers by 3 s and remained illuminated when both levers
were extended. The rat then had 10 s to press the lever associated with the illuminated
stimulus to receive a pellet. If no lever was pressed (omission), then no pellet was
granted, levers were retracted, and lights were turned off. The location of the stimulus
light was counterbalanced and presented equally over both levers during the test. All
animals were presented with 100 trials on a testing day, with 20 s inter-trial periods. 8
correct consecutive responses were needed to achieve test criterion, and if this was not
met within the allotted trial limit, the animal was placed in its home cage and retested the
next day. Omissions were not considered to disrupt a streak of correct responses.
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2.3.2.5

Set-shifting: Response Discrimination

On the day after the VCD task performance criterion was achieved, rats were given 20
VCD trials to test for retention of the learned rule (i.e., “follow the light”). On the 21st trial,
the paradigm was switched to a response discrimination (RD) task in which only the lever
opposite the rat’s side bias was always considered correct despite the location of the
stimulus light. The RD task continued for 120 trials, with a performance criterion set at 8
correct consecutive responses.
It is important to note that half of the RD task trials could be considered as ‘congruent’
and the other half were ‘incongruent’, occurring in a counterbalanced and pseudorandom
sequence. ‘Congruent trials’ occurred when the visual cue distractor was illuminated
above the correct lever, so that a rat would be rewarded whether it was responding in
accordance with the previously-correct VCD strategy or the new RD strategy (Figure 2-1).
Hence, success on a congruent trial was not informative of the rat’s behavioural strategy.
In contrast, ‘incongruent trials’ occurred when the visual cue distractor was illuminated
above the incorrect lever, so that a rat would only receive a pellet if it responded in
accordance with the new RD strategy (Figure 2-1). Thus, success on an incongruent trial
was informative of the rat’s behavioural strategy. In this study, we also included a 24 h
delayed 20 trial retrieval test for response discrimination.

2.3.2.6

Set-shifting Behavioural Measures

Traditional measures for assessing set-shifting behaviour during the RD task included the
number of trials to criterion, number of errors to criterion, and error profiling, namely by
perseverative, never-reinforced, or regressive error types (Figure 2-1)39,40. Errors made
on incongruent trials were deemed either perseverative or regressive. ‘Perseverative’
errors were scored earlier in the RD task when rats continued to adhere to the original
VCD strategy (i.e., “follow the light”), so long as 6 or more incorrect lever responses were
observed in a block of 8 incongruent trials (which randomly occurred over a block of 16
trials that also included 8 interspersed congruent trials). Later in the RD task, rats
successfully disengaged from the previously-correct VCD strategy. Once 5 or fewer
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incorrect lever responses were observed in a block of 8 incongruent trials, all incorrect
responses to incongruent trials in that block and on all subsequent blocks were scored
as ‘regressive’ errors. Thus, perseverative errors were an indicator of the rat’s failure to
inhibit the previously-learned strategy, whereas regressive errors indicated the rat’s
failure to engage or maintain a new strategy39. Incorrect responses made on congruent
trials, when the rat’s response did not follow either the VCD or RD strategies, were scored
as ‘never-reinforced’ errors (Figure 2-1). Never-reinforced errors reflected the rat’s
exploration of new operant strategies and provided an index of a rat’s ability to filter out
non-rewarding options39.

2.3.2.7

Reversal

Immediately after the Response Discrimination Retrieval test, a 120-trial session of spatial
reversal was initiated, wherein the opposite lever became the only rewarding lever; the
cue light continued to pseudorandomly alternate during the reversal trials to ensure
sufficient cognitive challenge.
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Figure 2-1: Testing behavioral flexibility in an operant based set-shifting task
During the final day of testing, rats were first exposed to 20 visual cue discrimination
(VCD) trials that required them to retrieve the strategy learned the day earlier, i.e.,
pressing the lever under the randomly illuminated light for a pellet. On the 21st trial, rats
were then challenged to shift from the original, no-longer rewarding strategy (VCD)
towards a new strategy (lever position; response discrimination). In this shift, errors on
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congruent trials were characterized as never-reinforced, while errors on incongruent trials
were either perseverative or regressive. Perseverative errors occurred early in the shift,
when rats persisted with the old strategy on 75% or more of incongruent trials, failing to
disengage from the no-longer rewarding strategy. Regressive errors occurred later in the
shift, when rats had already disengaged from the old strategy and followed it on less than
75% of incongruent trials but regressed back to the old strategy, failing to fully engage
and/or maintain the new strategy.
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2.3.3 Morris Water Maze
Following set shifting and recovery of normal body weight, rats were tested in the MWM.
In a dimly lit room, a water tank (144 cm diameter) was filled with room temperature water,
dyed with black non-toxic acrylic paint, and a target platform (12 cm diameter) was
submerged below 3 cm of water. To allow for multiple tolerances of navigational error, the
‘target quadrant’ and a 7.5 cm vicinity to the platform designated as the ‘platform region’
were both evaluated in swim path analysis (Figure 2-4A). Rats were placed in a fixed start
location and had to locate the hidden platform to be removed from the water tank. The
rats were given six 90 s learning trials (with 1 h inter-trial rest intervals) to learn the
location of the submerged platform; this learning schedule was adapted from Roof et al41.
Twenty-four hours after the last learning trial, the rats’ swim behaviour was again
recorded during the probe test, wherein the platform was removed.
In addition to tracking the rat’s location over time, swim strategies were analyzed
according to swim time in key regions. Swim time in the annulus (Figure 2-4A), a 27cm
wide ring corresponding to the location and diameter of the platform region, approximated
the use of an egocentric strategy based on distance from the wall, also known as
‘chaining’38. Swim time in a subset of the annulus outside of the target quadrant (Figure
2-4A) was also analyzed to determine if egocentric navigation to a platform generalized
to the rest of the maze. The thigmotactic region designated a 10 cm proximity to the tank
walls; swim time in this region indicated thigmotactic behaviour. The ‘goal directed
corridor’ was a subjective interpretation of the rats’ intended swim path, based on video
recordings of swim behaviour and heading as judged by a blinded rater. When the corridor
was directed at the platform location, the rater scored the amount of time that the rat
demonstrated ‘allocentric navigation’ (Figure 2-4A)38. Working spatial memory is another
crucial component of navigation, and can be dissociated by testing trial-dependent
learning as in match-sample testing35,37. Three days after the probe test, 5 consecutive
days of delayed match-sample testing assessed spatial working memory. Each day,
during the ‘sample trial’, a new start location and a new platform location was used. 6 h
later, the rats were tested on these new spatial parameters during the ‘match trial’ and
were assessed for improvement in their latency to locate the platform (schematic location
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of platforms can be found in Figure 4-5B). The 6 h delay was used to create a greater
working memory challenge37.
After MWM testing was complete, potentially confounding differences in visual perception
or swim speed were evaluated on 4 cued trials (2 different start locations for 2 different
platform locations) wherein the location of the platform was visibly marked. All swim paths
were tracked using ANYmaze tracking software, version 4.70 (Stoelting Company; Wood
Dale, IL), with a top-view webcam (C525, Logitech, Newark, CA). The experimenter was
not visible to the rats during testing.

2.3.4 Open Field
The day after MWM testing was complete, rat behaviour in the open field was evaluated.
Rats were placed in a square 45 cm open field with 40 cm black walls and a black floor
and permitted to explore freely for 20 mins. A top-view webcam was used for behavioural
tracking with ANYmaze software, version 4.70. Active time was measured as the sum of
time spent on both locomotor and non-locomotor movement. The experimenter was not
visible to the rats during testing.

2.3.5 Immunohistochemistry & Image Processing
After all behavioural testing was complete, rats were euthanized with intraperitoneal
injection of pentobaribital (Euthanyl, Bimeda MTC Animal Health Inc; Cambridge, ON)
and after transcardiac perfusion with 200 ml of 0.01 PBS followed by 200 ml of freshly
depolymerized and buffered 4% paraformaldehyde solution (PFA), brain tissue was
collected and stored in 4% PFA for 24 h before transfer to 30% sucrose solution (n = 10
for both groups). 30 µm coronal sections were prepared using a cryostat (CryoStar NX50,
Thermo Fischer Scientific; Ottawa, ON) and stored in cryoprotectant until all tissue was
available for IHC. Standard protocols were followed for DAB-mediated IHC of free floating
sections, using an ABC-HRP kit (Thermo Fischer Scientific #32020; Ottawa, ON), a
1:1000 concentration of OX6 primary antibody to identify activated microglia (BD
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Pharmingen #554926; Mississauga)42, and a 1:2000 concentration of GFAP primary
antibody to identify reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON)43. Stained
brain sections were mounted onto slides (VWR #16004-368; Mississauga, ON), air-dried,
dehydrated in baths of progressive concentrations of ethanol and Xylene, and coverslipped with DePex mounting medium (BDH Chemicals; Mississauga, ON).
Stitched micrographs of slides were prepared using a 10x objective lens on an upright
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging;
Mississauga, ON); light source intensity, exposure, aperture, and diaphragm parameters
were fixed for all imaging. Prior to each scan, white balance was automated using an offtissue reference point and a focus plane was programmed for the micrograph. Anatomical
regions of interest (Figure 2-7A; forceps minor, cingulum, corpus callosum, internal
capsule, hippocampus) were captured at coronal sections: Bregma +3.00mm, +2.00mm,
+0.00mm, -3.00mm, and -5.50mm44. The subset of the corpus callosum, the
supraventricular corpus callosum (SVCC), was of particular interest and outlined on the
anterior two coronal planes of the corpus callosum, excluding the portion of the corpus
callosum that was medial to the lateral ventricles. Micrographs were processed and
analyzed using ImageJ, version 1.50b; after regions of interest were outlined using the
polygon tool, images were converted to 8-bit, processed using the subtract background
command, and then thresholded with a fixed grayscale cut-off value of 237. Area
coverage (%) was recorded for each region of interest. For anatomical regions that
spanned multiple coronal sections (corpus callosum, cingulum, hippocampus), an
average area coverage was calculated, weighted by cross-sectional area at each coronal
plane.

2.3.6 Data Analyses
Graphpad Prism 7.0 software was used to generate figures and for statistical
comparisons of group means; equal variances were not assumed for group comparisons
(Welch’s t-test), which were corrected for multiplicity using the Holm-Sidak method.
Bonferroni correction was used for one-sample t-tests. Where dependent measures were
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repeated over time, 2-way repeated measures ANOVA was performed, followed by
Sidak’s post hoc tests. IBM SPSS, version 23, was used for regression and partial
correlation analysis. Group statistics were summarized in figures as means with error
bars = SEM; all errors noted in text indicate SEM. Significance was determined with α =
0.05. The datasets generated and analysed for the current study are available from the
corresponding author on reasonable request.
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2.4

Results

2.4.1 Set Shift & Reversal
Attentional set shifting, an important component of behavioural flexibility, was tested in
an operant conditioning chamber using appetitive conditioning with sucrose pellet
reinforcement. Wt and TgAPP21 rats were first food restricted until they respectively lost
13.5 +/- 0.7% and 13.8 +/- 0.3% of ad libitum weight. On the visual cue discrimination
task, rats were first trained to press the lever that was associated with a cue light. This
cue light would be activated on every trial above one of two levers, alternating sides in
pseudorandom fashion (Figure 2-2A). The number of trials needed to achieve a learning
criterion of 8 correct consecutive lever presses was not significantly different between
groups (Figure 2-2B), indicating no differences in learning. 24 h after the learning criterion
was achieved, a 20-trial test was run for retrieval of visual cue discrimination. Again, no
group differences were observed on this visual cue retrieval test (Figure 2-2C),
suggesting that visual cue memory was unimpaired in the TgAPP21 rats. No group
differences in the number of omissions were observed throughout discrimination trials,
indicating no group differences in motivation to lever press.
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Figure 2-2: TgAPP21 rats demonstrate unimpaired learning and memory of visual
cue discrimination
(A) When a rat pressed the lever associated with the cue light, which pseudorandomly
alternated sides, they were rewarded with a sucrose pellet.
(B) The number of learning trials needed to achieve a criterion of 8 correct consecutive
responses and (C) the number of correct lever presses (out of 20 trials) after a 24 h delay
were not significantly different between Wt and TgAPP21 rats.
n = 10 for both groups, error bars = SEM.
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Immediately after the 20 trials of the visual cue retrieval test, attentional set shifting was
evaluated over 120 response discrimination trials wherein sucrose pellet reinforcement
was now determined by a spatial strategy. This extradimensional shift challenged rats to
ignore the cue light, which continued to pseudorandomly alternate sides, and learn that
only one of the levers would yield a food pellet. No group differences were observed in
the number of trials needed to achieve the learning criterion of 8 correct consecutive
responses during response discrimination (Figure 2-3A). We then evaluated the types of
errors committed, which can be categorized as never reinforced, perseverative, or
regressive21. Never reinforced errors occur when a lever press follows neither the
previously learned rewarding visual cue strategy (i.e., “follow the light”) nor the new spatial
strategy (e.g., “always press the left lever”). Never reinforced errors tend to occur in the
early-middle trials of response discrimination and reflect a failure to filter out nonrewarding operant behaviour. Perseverative errors occur early during response
discrimination, when rats persist in following the no-longer rewarding visual cue strategy.
Once rats disengage from the visual cue strategy, that is, when <75% of responses follow
the old strategy, subsequent errors following the old strategy are considered regressive.
TgAPP21 rats demonstrated a nonsignificant trend for fewer perseverative errors, which
were negatively correlated with regressive errors (r = -0.81, p = 0.005, F(1,8) = 15.11; no
correlation seen in Wt rats). This shift in the error profile of TgAPP21 rats reflected a
significant increase in the number regressive errors (Figure 2-3B; p = 0.046, t = 2.256, df
= 10.9). Furthermore, TgAPP21 rats committed significantly more errors even after
achieving the response discrimination learning criterion of 8 correct consecutive trials
(Figure 2-3C; p = 0.01, t = 2.793, df = 15.66). Errors after reaching criterion are uncommon
and suggest a very aberrant regressive behavioural phenotype.
To test for retrieval of response discrimination, a retrieval test of 20 trials was run after a
24 h delay; no group differences were observed in the proportion of correct lever presses
(Figure 2-3D). Immediately after the response discrimination retrieval test, 120 trials of a
spatial reversal task were run, wherein the rewarding lever was now on the side opposite
to the previously rewarding lever. As the cue light continued to alternate pseudorandomly
during this task, profiling the errors types was not possible. However, TgAPP21 rats
performed significantly more total errors on this task (Figure 2-3E; p = 0.02, t = 2.538, df
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= 15.25). No group differences in the number of omissions were observed throughout
response discrimination and reversal trials, indicating no group differences in motivation
to lever press.
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Figure 2-3: TgAPP21 rats demonstrate increased regressive behaviour during
extradimensional set shifting and impaired spatial reversal
Immediately after visual cue retrieval, rats were challenged to ignore the cue light, which
continued to pseudorandomly alternate sides, and learn that only one of the levers would
always yield a food pellet.
(A) The number of trials required to achieve 8 correct consecutive responses under the
new spatial strategy was not different between Wt and TgAPP21 rats.
(B) However, the types of errors committed over the 120 trials allotted for the set shift
differed. Never reinforced errors were committed when a rat’s response was not in
accordance with the visual cue strategy or the new correct spatial strategy and reflect a
failure to filter out non-rewarding operant behaviour. Perseverative errors were committed
when a rat continued to follow the no-longer rewarding visual cue strategy. Once a rat
had begun to disengage from the visual cue strategy (<75% of responses following the
old strategy), subsequent responses following the visual cue strategy were considered
regressive errors; TgAPP21 rats committed significantly more regressive errors.
(C) This paralleled a significant increase in the subset of regressive errors that were
committed after criterion for response discrimination was met (8 correct consecutive
responses), further suggesting a highly regressive behavioural phenotype.
(D) After a 24 h delay, there was no difference in the retrieval of response discrimination,
as inferred by the correct number of responses out of 20 trials.
(E) When the rewarding strategy was again changed, so that only the opposite lever
would now yield a sucrose pellet on all trials (reversal), TgAPP21 rats committed more
errors.
n = 10 for both groups, error bars = SEM.
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2.4.2 Morris Water Maze
To test for spatial learning capacity, rats were trained on a modified MWM protocol41. Six
90 s learning trials with 1 h intervals allowed both Wt and TgAPP21 rats to learn the
location of the submerged platform (Figure 2-4B). No differences in MWM learning
efficiency was observed; navigational strategies were similar except TgAPP21
demonstrated a greater reliance on egocentric navigation during trials 4-6 (Figure 2-5D;
p = 0.049, F(1,18) = 4.421).
The probe test identified clearer distinctions in navigational behaviour. 24 h after the last
learning trial, the platform was removed, and the rats’ memory of the platform location
during a 90 s probe test was inferred by latency to enter the platform region and
preference for the target quadrant in which the platform was previously located (Figure
2-4C). No significant differences were observed in the latency to enter the platform region,
suggesting that TgAPP21 rats have no spatial memory impairments; 1 outlier Wt rat is
not represented in Figure 2-4C (ROUT method, Q = 0.1%), but was still included in all
statistical analyses. Both groups showed a significant preference for the target quadrant
(Wt: p = 0.04, t = 2.758, df = 9; Tg: p = 0.01, t = 4.27, df = 9; compared to a chance value
of 25% of swim time), indicating that both groups formed a true allocentric map of the
MWM38. However, when the probe test was parsed into 30 s segments, TgAPP21 rats
demonstrated a significantly increased preference for the target quadrant during the last
30 s segment of the probe test (Figure 2-4D; see supplementary online files for
representative video recordings; Appendix B). This behaviour was unusual in that a
preference for the target quadrant should normally remain level or extinguish over the
course of the probe test.
During the probe test, TgAPP21 rats also demonstrated abnormal search strategies that
further indicate impairments of behavioural flexibility. No group differences were observed
in thigmotaxis during the learning trials (Figure 2-5A), but while Wt rats showed an
increase of thigmotaxis during the probe test, TgAPP21 rats did not (Figure 2-4E, Figure
2-5E; p = 0.004, t = 3.597, df = 18). Furthermore, TgAPP21 rats spent significantly more
time in both egocentric search for the platform (time spent in the annulus) and allocentric
platform-directed swim (Figure 2-4E). Only in the final 30 s segment of the probe test,
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TgAPP21 rats normalized the proportion of time in egocentric navigation, though they
continued to favour allocentric search for the platform (p = 0.001, t = 3.773, df = 54). The
group differences in egocentric and allocentric navigation help characterize the group
differences in thigmotactic response; TgAPP21 rats continued to navigate according to
the allocentric and egocentric cues associated with the learned platform location, while
Wt rats employed a broader search strategy which involved more swim time in the
thigmotactic region.
Comparing across behavioural testing paradigms, the TgAPP21 rats’ impairment on
spatial reversal (Figure 2-3E) and greater adherence to search strategies favouring the
last known platform location despite platform removal (Figure 2-4E) indicate impairments
of behavioural flexibility. More specifically, the TgAPP21 rats’ regressive behaviour on
response discrimination (Figure 2-3BC) and increased target quadrant preference late in
the probe test (Figure 2-4D) identifies a primarily regressive inflexibility.
No significant group differences were observed in average swim time improvement on
match-sample testing (Figure 2-5F), so working memory is unlikely to have played a role
in behavioural differences seen in MWM navigational behaviour. After MWM tests were
completed, potentially confounding differences in visual perception or swim speed were
evaluated on 4 cued trials wherein the location of the platform was visibly marked. No
differences were observed in swim time to the platform, and no differences in swim speed
were observed
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Figure 2-4: TgAPP21 rats demonstrate regressive inflexibility during the Morris
Water Maze probe test
(A) Apparatus schematic of start location, region designations, and platform location; the
platform (grey) was submerged below 3 cm of water. The schematic is not to scale.
(B) Wt and TgAPP21 showed no significant differences in learning to locate the platform.
(C) During the 24 h delayed probe test, the platform was removed before observation of
swim behaviour. Recall of the learned platform location, as inferred by latency to enter
the platform region, was not significantly different between Wt and TgAPP21 rats.
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(D) TgAPP21 rats spent more swim time in the target quadrant during the last 30 s
segment of the probe test. * The TgAPP21 rats’ increased preference in this final segment
of the test was significant in comparison to the first two segments (p < 0.02) and in
comparison with the Wt rats (p = 0.03). The dotted horizontal line indicates the time in the
target quadrant that would be expected by chance.
(E) TgAPP21 rats demonstrated atypical swim strategies following the removal of the
platform during the delayed probe test: TgAPP21 rats did not increase swim time in the
thigmotaxis region; TgAPP21 rats spent more time in egocentric navigation to the platform
region, as demonstrated by the greater preference for both the annulus and the annulus
outside of the target quadrant; TgAPP21 rats spent more time in allocentric navigation to
the learned platform location.
The increased preference for the target quadrant (D) and swim strategies favouring the
platform’s last known location (E) indicate a regressive inflexibility in the TgAPP21 rats.
n = 10 for both groups, error bars = SEM.
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Figure 2-5: Supplementary MWM behavioural analysis
(A) During MWM learning trials, repeat exposure had a significant effect on thigmotactic
behaviour, progressively reducing thigmotaxis in both groups (p < .0001, F(5,90) = 56.73).
Wt and TgAPP21 showed no significant differences in (B) allocentric navigation or (C-D)
egocentric navigation during learning. However, TgAPP21 rats did tend to spend more
time in the annulus outside of the target quadrant; while this trend was not statistically
significant across all learning trials (p = 0.053), it was significant when only trials 4 – 6
were analyzed (p = 0.049, F(3,36) = 4.421). This suggests that TgAPP21 have an
increased reliance on egocentric spatial navigation as this measure captures a search
strategy that relies on swimming a fixed distance from the maze wall, even when outside
of the target quadrant.
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(E) Thigmotaxis over the full 90 s of the probe test was significantly affected by genotype
(p = 0.002, F(1,18) = 12.8). Over the course of the probe test, all rats demonstrated
increasing thigmotaxis (p = 0.04, F(2,36) = 3.63).
(F) On delayed match-sample testing for working memory, no group differences were
observed.
n = 10 for both groups, error bars = SEM.
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2.4.3 Open Field
Potentially confounding behavioural variables such as exploratory behaviour and anxiety
were evaluated in the open field. The day after MWM testing was complete, rat behaviour
in the open field was evaluated; the first 5 min of the 20 min test are considered to be
relatively more anxiogenic for the rats. TgAPP21 demonstrated reduced exploration in
the open field with significantly less travel distance over the full 20 min duration of the test
(p < 0.0001, t = 6.981, df = 36), and reduced active time during both the first 5 min (p =
0.003, t = 3.421, df = 36) and full 20 min duration of the test (p = .002, t = 3.691, df =36;
Figure 2-6AB). A generalized reduction in exploratory behaviour may be a relevant factor
in the TgAPP21 rats’ MWM target quadrant preference during the probe test, but distance
travelled in the target quadrant during the MWM probe had no correlation with distance
travelled in the open field. Moreover, reduced exploration would not explain the increased
goal-oriented return to the target quadrant and no rat was immobile at any time in MWM
testing.
Group differences in anxiety are unlikely to have affected operant conditioning chamber
or MWM behaviour, as no differences in anxiety were observed in the open field (Figure
2-6C). TgAPP21 rats showed a nonsignificant trend (p = 0.06) for reduced time in the
open field centre during the full 20 min test period; this is more likely to be due to the
TgAPP21 rats’ reduced locomotion than an increased level of anxiety, as time in the
centre of the field correlated with total distance travelled (r = 0.69, p = 0.0008; F(1,18) =
16.26). The absence of group differences in open field centre avoidance disputes the
possibility that Wt rats exhibited more thigmotaxis during the MWM probe (Figure 2-4E)
test suggesting increased levels of anxiety; time spent in the centre of the open field did
not correlate with thigmotactic swim time.
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Figure 2-6: TgAPP21 rats exhibited less exploratory behaviour in the open field
(A) TgAPP21 rats demonstrated reduced locomotion over the full 20 min test and (B)
reduced active time during both the first 5 min and the full 20 min test, indicating reduced
exploratory behaviour.
(C) The relatively exposed centre of the open field is considered to be anxiogenic,
particularly during initial exploration of the open field. No significant group differences
were observed for the avoidance of the centre, suggesting no differences of anxiety in
response to novel environments.
n = 10 for both groups, error bars = SEM.
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2.4.4 Activated Microglia in White Matter
Qualitative observations of increased concentrations of activated OX6-positive
microglia42 informed which anatomical regions of interest to analyze quantitatively (Figure
2-7AB): the forceps minor, corpus callosum, cingulum, internal capsule, and
hippocampus. A subset of the corpus callosum, the supraventricular corpus callosum
(SVCC; immediately superior and anterior to the lateral ventricles) was also analyzed
separately, as it was observed to have particularly increased concentrations of OX6positive microglia in TgAPP21 rats. Interestingly, this same region has also been found
to have some of the greatest age-dependent dysregulation of membrane lipids21.
Significantly more area coverage by OX6-positive microglia was observed in the white
matter tracts of TgAPP21 rats (Figure 2-7D): corpus callosum, SVCC, cingulum, and
internal capsule. Nonsignificant trends for increased OX6-positive microglia area
coverage was also observed for the forceps minor (p = 0.08, t = 2.26, df = 18) and
hippocampus (p = 0.08, t = 2.025, df = 18). Within individual brains, increased microglia
activation was highly correlated across anatomical regions, even when controlling for
genotype (Table 2-1). This suggests a pro-inflammatory cue that is diffuse, consistent
with broad over-expression of pathogenic hAPP. To avoid collinearity in modelling
relationships between white matter microglia activation and behavioural findings,
stepwise regression was used to identify the most informative predictors. Only reversal
errors in the operant conditioning chamber were found to be significantly related to white
matter area coverage by OX6-positive microglia, for which the SVCC was identified as
the most informative predictor (Figure 2-7C; R2 = 0.42, p = 0.002, F(1,18) = 12.794).
Independently, both genotype and SVCC microglia activation were significant predictors
of reversal errors (β = 0.513, p = 0.02, t = 2.538, df =18, ; β = 0.645, p = 0.002, t = 3.577,
df = 18). When genotype and SVCC microglia activation were both included in a linear
regression model, SVCC microglia activation was still a significant predictor of reversal
errors (β = 0.544, p = 0.04, t = 2.212, df = 17) while genotype was not, suggesting that
the relationship between genotype and reversal errors was primarily mediated by white
matter microglia activation (p = 0.005, Sobel statistic = 2.600). No group differences in
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morphology or area coverage by reactive GFAP-positive astrocytes43 were observed
(Figure 2-7E).
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Table 2-1: Global activation of microglia across anatomical regions
Forceps Corpus
Internal
SVCC
Cingulum
Hippocampus
Minor
Callosum
Capsule
Forceps
Minor
Corpus
Callosum
SVCC
Cingulum
Internal
Capsule
Hippocampus

-

0.62

0.55

0.56

0.61

0.47

0.005

0.014

0.014

0.005

0.044

0.95

0.85

0.73

0.56

<0.0001

<0.0001

<0.0001

0.013

0.78

0.63

0.48

<0.0001

0.004

0.0383

0.70

0.70

0.001

0.001

-

-

-

-

0.61
0.006
-

Strong positive partial correlations indicate that microglia activation increased globally
within individual rats’ brains; values shown indicate Pearson’s r and corresponding p
values for correlations of OX6+ microglia activation (% Area) between anatomical regions
of interest. These correlations were controlled for genotype, so increases in microglia
activation were seen globally for both Wt and TgAPP21 rats. n = 20. SVCC =
Supraventricular Corpus Callosum
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Figure 2-7: Increased microglia activation in TgAPP21 white matter correlates with
reversal impairments
(A) Representative coronal sections developed with DAB-immunohistochemistry and an
OX6 primary antibody, with anatomical regions of interest outlined on the left hemisphere
and digitally processed images overlaid on the right hemisphere; FM = forceps minor, CC
= corpus callosum, Cing = cingulum, IC = internal capsule, HCP = hippocampus. The
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supraventricular corpus callosum (SVCC) was a subsection of the corpus callosum that
was directly superior and anterior to the lateral ventricles. Scale bar = 2 mm.
(B) Representative DAB-immunohistochemistry image of corpus callosum tissue with
1.3% area coverage by OX6-positive microglia. Scale bar = 50 µm. (C) A significant linear
relationship was found between OX6-positive microglia area coverage in the SVCC and
the number of spatial reversal errors in the operant conditioning chamber (R2 = 0.42, p =
0.002). Microglia activation throughout the brain was highly correlated (Table 2-1) and
using stepwise linear regression, OX6+ microglia area coverage in the SVCC was
identified as the most informative predictor of reversal errors.
(D) Microglia activation was significantly increased in the white matter tracts of TgAPP21
rats; cross-sectional area coverage by OX6+ microglia was increased in the corpus
callosum, SVCC, cingulum, and internal capsule.
(E) No group differences were observed for cross-sectional area occupied by GFAPpositive astrocytes.
n = 10 for both groups, error bars = SEM.
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2.5

Discussion

Our findings replicate the absence of learning and memory deficits in naïve TgAPP21 rats
but capture a spontaneous increase of regressive behavioural inflexibility, reversal
impairments, a reduction of exploratory locomotor behaviour. Although TgAPP21 rats do
not develop amyloid plaques16-20, we have found a spontaneous increase of white matter
activation of microglia. Microglia activation in the supraventricular corpus callosum was
also a significant mediator of reversal impairment, even when accounting for genotype.
The globally increased activation of white matter microglia suggests that TgAPP21 rats
spontaneously develop an inflammatory response to the widespread overexpression of
pathogenic hAPP, which may have precipitated the cognitive impairments and
amyloidopathy seen in previous studies when TgAPP21 rats were exposed to cerebral
stressors18-20. The initiation of pathology at the axon is consistent with previous findings
of neurofibrillary tangles appearing spontaneously in 18 – 19-month-old TgAPP21 rats17.
Microglia activation in the white matter of TgAPP21 is also consistent with clinical studies
that have found increased white matter pathology in early stages of AD30,31, which likely
involves inflammatory processes23,29,31,32.
The TgAPP21 rats’ increased reversion to the learned target quadrant during the final
third of the MWM probe test paralleled our observations of regressive behaviour during
response discrimination. To our knowledge, this behaviour in the MWM probe test has
not been previously reported, perhaps because of previous recommendations to perform
probe tests for only 30 – 60 s to avoid extinction34,45. One possible interpretation is
informed by our finding that TgAPP21 rats exhibited reduced exploration in the open field,
so it is possible that TgAPP21 rats were less motivated to explore the water maze during
the probe test. However, TgAPP21 rats were never immobile during the probe test and a
reduced exploratory drive would not explain the increased goal-oriented return to the
target quadrant during the last third of the probe test. Another interpretation is that
TgAPP21 rats had a more accurate spatial recall of the platform location. This is unlikely
as there were no group differences in the time required to swim to the platform region and
both groups demonstrated a significant preference for the target quadrant. Moreover, this
would not account for the TgAPP21 rats’ significantly increased preference for the target
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quadrant in only the last third of the probe test. It is the timing of the TgAPP21 rats’
preference for the target quadrant that is particularly indicative of a regressive behavioural
inflexibility, whereas a persistently greater preference could be expected with
perseverative behavioural inflexibility. The increase in thigmotaxis in Wt rats was more
likely a consequence of a swim strategy that involved more ‘random search’ and
‘scanning’, as evidenced by reduced ‘direct swim’ and ‘chaining’ patterns of swim.
Random search and scanning patterns of swim result in more crossing into the
thigmotactic region, but are still generally successful strategies for finding new platform
locations46. In contrast, TgAPP21 demonstrated less navigational flexibility following the
removal of the platform. Our MWM probe results highlight how behavioural inflexibility in
rodents could lead to misinterpretation of increased target quadrant preference as an
indication of better memory. Tests for behavioural flexibility can inform performance on
memory tests38, and our findings reaffirm the need to develop a better understanding of
how executive dysfunction can confound measures of memory.
We demonstrate in this study that the TgAPP21 rat is a highly relevant model as it
demonstrates both executive dysfunction and white matter pathology, which have been
linked in the early stages of neurodegenerative diseases22-32. While cerebral amyloid
deposits are not observed spontaneously in TgAPP21 rats across their lifespan18, we
have shown that TgAPP21 rats have increased microglia activation in white matter and
impairments of behavioural flexibility by the age of 7 – 8 months. Therefore, the TgAPP21
rat is useful to the study of these early disease processes that precede the canonical
features of AD.
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Chapter 3: Behavioural Inflexibility and White Matter
Inflammation Across the TgAPP21 Lifespan
This chapter expands the experiments described in Chapter 2 to an additional 3 age
points, characterizing the temporal relationship between age, pathogenic APP
expression, white matter inflammation, and executive function (Objective 1 & 2). Data
from the 8-month-old rats in Chapter 2 was included in this study. While delayed matching
to sample testing in the MWM was performed in this study, it could not be completed in
the oldest cohort and no informative results were observed in the younger cohorts, thus
delayed matching to sample test results are not presented in this chapter. The manuscript
of this study is under review for publication in the Journal of Neuroscience.

3.1

Abstract

Neuroinflammation and behavioural inflexibility are common in late adulthood but far more
profound in Alzheimer disease (AD). To investigate the relationship between
neuroinflammation, behavioural flexibility, ageing, and AD, male wildtype Fischer 344 and
the TgAPP21 rats were aged to 4, 8, 13, and 22 months and evaluated for
neuroinflammation and cognitive impairment. TgAPP21 rats overexpress a pathogenic
variant of the human amyloid precursor protein (Swedish and Indiana mutations) but do
not spontaneously develop overt pathology related to AD. In both genotypes, learning
and memory were similarly impaired in older rats. However, at 8 months of age, TgAPP21
rats demonstrated behavioural inflexibility in set shifting, reversal, and the Morris Water
Maze, while wildtype rats showed inflexibility at 13 and 22 months of age. This early
inflexibility in TgAPP21 rats was accompanied by a precocious increase in activated
microglia within the corpus callosum; 8- and 13-month-old TgAPP21 rats had similar
levels of microglia activation as 13- and 22-month-old wildtype rats, respectively.
However, while neuroinflammation within the white matter continued to progress with age,
behavioural inflexibility peaked in 8-month old TgAPP21 rats. These findings suggest that
prior to the onset of learning and memory impairments, age-dependent white matter
inflammation has an important but dynamic effect on behavioural inflexibility.
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3.2

Introduction

Executive functions are necessary for maintaining functional independence1. Inhibition,
working memory, and behavioural flexibility are core subdomains of executive function,
but these cognitive subdomains decline with age2,3. This has been linked to disruptions
of white matter integrity, which are observed even in “healthy” elderly individuals4-7, as
white matter tract integrity is important for executive function6,8. White matter volume also
shows a greater age-dependent decline than grey matter volume9, emphasizing the
importance of white matter changes in ageing. Therefore, developing a better
understanding of the processes that affect white matter integrity will be crucial to
supporting healthier aging.
Experimental studies have found that white matter microgliosis is associated with
disruption of white matter integrity, resulting in cognitive impairments10-17. Age-associated
dysregulation of microglia leads to a pro-inflammatory environment in the brain18, and this
process appears to be particularly pronounced in white matter19. While this association
has been well established, the specific processes that incite dysregulation of microglia
remains unclear. Since amyloid pathology is highly prevalent and also progresses with
age20, amyloid has been widely considered a common culprit in age-associated microglial
dysregulation18,21,22. This may account for the observations of neuroinflammation19,23,
white matter disruption24,25, and executive dysfunction26-29 in the early stages of Alzheimer
disease (AD). To determine the temporal sequence and molecular links between
dysregulation of amyloid and microglia, longitudinal preclinical studies are needed.
Previous studies of microglia-mediated disruption of white matter integrity were limited in
investigating impairments of executive function, such as behavioural flexibility. Although
experimental animal studies have demonstrated a strong association between white
matter microgliosis, disruption of white matter integrity, and cognitive impairments, the
combined role of age and pathogenic human amyloid precursor protein (hAPP) in white
matter microgliosis is not clear. The transgenic APP21 (TgAPP21) rat was developed
from the Fischer 344 strain and overexpresses a pathogenic variant of hAPP30. TgAPP21
rats do not spontaneously develop AD-associated pathology but are more vulnerable to
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acute cerebral stressors, which can induce amyloid aggregation and a regressive form of
behavioural inflexibility31-33.
In this study, male wildtype Fischer 344 (Wt) and TgAPP21 rats were aged to 4, 8, 13,
and 22 months of age and evaluated for cognitive impairments and white matter microglia
activation.

As

amyloid

can

trigger

the

activation

of

microglia

and

chronic

neuroinflammation localizes to white matter in the aging brain19, we predicted an earlier
increase in the activation of microglia in the white matter of TgAPP21 rats. Accordingly,
microglia-mediated disruption of white matter integrity would cause impairments of
behavioural flexibility in TgAPP21 rats at a younger age. Indeed, we found a precocious
age-dependent increase of microglia activation in the corpus callosum of TgAPP21 rats,
and in an operant-conditioning chamber, regressive forms of behavioural inflexibility
during set shifting and reversal impairments peaked in TgAPP21 rats at 8 months of age.
Regressive target quadrant preference in the MWM also peaked in 8-month-old TgAPP21
rats. These findings suggest that pathogenic hAPP expression can accelerate white
matter microgliosis and affect behavioural flexibility, a core component of executive
function.
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3.3

Methods

3.3.1 Animals
Animal ethics and procedures were approved by the Animal Care Committee at Western
University (protocol 2014-016) and are in compliance with Canadian and National Institute
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23).
All rats used in this study were housed in facilities maintained by Western University
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. Homozygous
transgenic Fischer 344-APP21 (TgAPP21) rats were studied to model the effect of
increased brain concentrations of amyloid protein. Developed by lentiviral infection of
zygotes, TgAPP21 rats overexpress a pathogenic hAPP with Swedish and Indiana
mutations and produce high levels of beta-amyloid (both 1-40 and 1-42) but do not
spontaneously develop β-amyloid plaques30. hAPP homozygosity was validated using
tissue samples from pups.
Male TgAPP21 and wildtype (Wt) Fischer 344 rats were bred and aged to form four
different age cohorts (n = 10 – 13 for each genotype at each age cohort; see

Table 3-1 for sample size details). From herein, the four age points will be referred to as
4M, 8M, 13M, and 22M, corresponding to the mean age in months at which the cohorts
were euthanized. Ages were well matched between genotypes, with no significant
differences in the age at which behavioural testing was initiated or the age at which rats
were euthanized and brain tissue was collected (

Table 3-1). Rats that failed training, visual cue discrimination (VCD), or did not achieve at
least 75% correct lever presses on VCD retrieval trials would be excluded from all set
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shifting analyses, as these rats’ motivation to lever press and for food could not be
ensured. Additionally, 22M rats that were not resilient to the stress of food restriction and
behavioural testing were excluded from subsequent behavioural testing.
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Table 3-1: Experimental group characteristics
Cohort

4M

8M

13M

22M

Wt

Tg

Wt

Tg

Wt

Tg

Wt

Tg

12

12

11

12

13

13

9

10

Age at set shifting

3.2
(0.3)

3.0
(0.3)

6.6
(0.4)

7.0
(0.1)

12.6
(0.3)

12.5
(0.3)

21.3
(0.3)

21.5
(0.2)

Age at perfusion

3.8
(0.3)

3.7
(0.3)

7.4
(0.4)

7.7
(0.1)

13.4
(0.3)

13.3
(0.3)

21.9
(0.8)

22.2
(0.6)

Included in
VCD analysis

11

12

11

10

13

13

8

9

Included in
RD analysis

11

12

11

10

13

12

8

8

Included in
Reversal results

8

11

5

7

10

8

4

6

Included in
MWM analysis

12

12

11

12

13

13

5

9

Included in
OF analysis

12

12

11

12

13

13

6

10

N

Values in parenthesis indicate SD.

93
3.3.2 Set Shift & Reversal
The set shifting protocol, which includes side bias determination, is detailed in 2.3.2 Set
Shift & Reversal on page 53. Briefly, rats were food restricted and maintained at 85-87%
of free-feed mass to ensure motivation for 45 mg sucrose pellets (Dustless precision
pellets, Bio-Serv; Burlington ON) during behavioural reinforcement in a sound-attenuated
operant-conditioning chamber (Med Associates; St. Albans, VT). During all training and
testing, each correct lever press was reinforced with a single sucrose pellet (fixed-ratio 1
schedule). Habituation to the operant-conditioning chamber was followed by initial leverpress training; rats were required to lever press on at least 85 of 90 trials of lever
presentations, pseudorandomly alternating sides, before progressing to VCD.
Twenty-four h after initial training, rats were given 100 trials to learn the VCD task. In each
trial, both levers were extended but only the lever paired with the cue light, which
pseudorandomly alternated sides, would yield a sucrose pellet reward when pressed. The
passing criterion for visual discrimination was 8 correct consecutive responses, based on
methods used by Floresco et al34. Twenty-four h after meeting criterion, a VCD retrieval
session of 20 trials was run to evaluate retention. Immediately after the VCD retrieval
session, 120 trials of response discrimination (RD) were initiated: only one lever would
yield a sucrose pellet on all trials, even though the cue light continued to alternate sides.
For each rat, the lever opposite a previously determined side bias was selected to be
rewarding during RD (as described previously)33. This challenged the rats to ignore the
previously learned VCD strategy and to acquire a spatial strategy, constituting an extradimensional set shift. As described previously33, RD trials were binned into 16 trials of 8
congruent and 8 incongruent trials. Perseverative errors were scored when rats reverted
to the VCD strategy on incongruent trials; once rats demonstrated disengagement from
VCD (5 or fewer errors in a block of 8 incongruent trials), subsequent reversions to the
VCD strategy on incongruent trials was scored as regressive errors. Incorrect lever
presses on congruent trials were scored as never-reinforced errors. The passing criterion
for RD was 8 correct consecutive responses. We departed from common approaches to
operant-conditioning chamber based set shifting35 in that we allowed rats to complete all
120 trials of RD instead of removing them from the chamber once they achieved criterion.
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This allowed us to quantify the number of errors committed after criterion, offering a more
complete measure of regressive behaviour. We also conducted a 24 h delayed 20 trial
RD retrieval test. This was immediately followed by a 120-trial session of spatial reversal,
wherein the opposite lever became the only rewarding lever; the cue light continued to
pseudorandomly alternate during the reversal trials to ensure sufficient cognitive
challenge.
During all discrimination tests (VCD, RD, reversal), rats were granted a 10 s response
period during which the chamber was illuminated. If the correct lever was pressed, the
chamber remained illuminated for another 4 s so that rats could retrieve the sucrose pellet
reward. This was followed by a dark inter-trial period so that trials lasted a total of 30 s.
Cue lights were presented 3 s before lever extension and extinguished upon lever press
or the end of the 10 s response period. Omissions (no lever press) were not treated as
errors and did not reset a count of correct consecutive lever presses.
In this chapter, rats that failed to achieve a correct lever press rate of at least 75% on the
visual cue discrimination (VCD) retrieval test were excluded from all set-shifting results,
whereas results in Chapter 2 focused only on rats that could achieve the higher threshold
of at least 80%. This parameter was modified to maintain sufficient sample size in the
oldest cohort; 5/17 22MO rats achieved only 75%. Similarly, only rats that achieved at
least 75% correct lever press on the response discrimination (RD) retrieval trials were
evaluated in reversal. Exclusions are detailed in 3.4.1.5 Exclusions & Outliers on page
108 and Table 3-2.

3.3.3 Morris Water Maze
Following set shift & reversal, rats’ body weights were restored to ad libitum feed levels
(5 – 7 days), before proceeding to MWM testing. In a dimly lit room, a water tank (144 cm
diameter) was filled with room temperature water, dyed with black non-toxic acrylic paint,
and a target platform (12 cm diameter) was submerged below 3 cm of water. Rats were
placed in a fixed start location and had to locate the hidden platform to be removed from
the water tank. The rats were given six 90 s learning trials (with 1 h inter-trial rest intervals)
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to learn the location of the submerged platform; this learning schedule was adapted from
Roof et al36. Twenty-four hours after the last learning trial, the rats’ swim behaviour was
again recorded during the probe test, wherein the platform was removed. To allow for
multiple tolerances of navigational error, the ‘target quadrant’ and a 7.5 cm vicinity to the
platform location designated as the ‘platform region’ were both evaluated in swim path
analysis.
After MWM testing was complete, potentially confounding differences in visual perception
or swim speed were evaluated on 4 cued trials (2 different start locations for 2 different
platform locations) wherein the location of the platform was visibly marked. All swim paths
were tracked using ANYmaze tracking software, version 4.70 (Stoelting Company; Wood
Dale, IL), with a top-view webcam (C525, Logitech; Newark, CA). The experimenter was
not visible to the rats during testing. Several 22M rats were not fit for MWM testing (failure
to restore ad libitum body weight after food restriction for set shifting or failure to swim
safely) and were excluded from analysis (4 Wt rats and 1 TgAPP21 rat), leaving a reduced
sample size of n = 5 Wt and n = 9 TgAPP21 rats from the 22M cohort.

3.3.4 Open Field
The day after MWM testing was complete, rat behaviour in the open field was evaluated.
Rats were placed in a square 45 cm open field with 40 cm black walls and a black floor
and permitted to explore freely for 20 mins. A top-view webcam was used for behavioural
tracking with ANYmaze software, version 4.70 (Stoelting Company). Active time was
measured as the sum of time spent on both locomotor and non-locomotor movement.
The experimenter was not visible to the rats during testing.

3.3.5 Immunohistochemistry & Image Processing
After all behavioural testing was complete, rats were euthanized with intraperitoneal
injection of pentobaribital (Euthanyl, Bimeda MTC Animal Health Inc; Cambridge, ON)
and after transcardiac perfusion with 200 ml of 0.01 PBS followed by 200 ml of freshly
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depolymerized and buffered 4% paraformaldehyde solution (PFA), brain tissue was
collected and stored in 4% PFA for 24 h before transfer to 30% sucrose solution (n = 5
for all 8 groups). 30 µm coronal sections were prepared using a cryostat (CryoStar NX50,
Thermo Fischer Scientific; Ottawa, ON) and stored in cryoprotectant until all tissue was
available for IHC. Standard protocols were followed for DAB-mediated IHC of free floating
sections, using an ABC-HRP kit (Thermo Fischer Scientific #32020; Ottawa, ON), a
1:1000 concentration of OX6 primary antibody for MHC II to identify activated microglia
(BD Biosciences #554926; Mississauga, ON37), and a 1:2000 concentration of GFAP
primary antibody to identify reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON38).
Stained brain sections were mounted onto slides (VWR #16004-368; Mississauga, ON),
air-dried, dehydrated in baths of progressive concentrations of ethanol and Xylene, and
cover-slipped with DePex mounting medium (BDH Chemicals; Mississauga, ON).
Stitched micrographs of slides were prepared using a 10x objective lens on an upright
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging;
Mississauga, ON); light source intensity, exposure, aperture, and diaphragm parameters
were fixed for all imaging. Prior to each scan, white balance was automated using an offtissue reference point and a focus plane was programmed for the micrograph. Anatomical
regions of interest (forceps minor, cingulum, corpus callosum, internal capsule,
hippocampus) were captured at coronal sections: Bregma +3.00, +2.00, +0.00, -3.00, and
-5.50 mm39. The subset of the corpus callosum, the supraventricular corpus callosum
(SVCC), was of particular interest40 and outlined on the anterior two coronal planes of the
corpus callosum, excluding the portion of the corpus callosum that was medial to the
lateral ventricles. Micrographs were processed and analyzed using ImageJ, version
1.50b; after regions of interest were outlined using the polygon tool, images were
converted to 8-bit, processed using the subtract background command, and then
thresholded with a fixed grayscale cut-off value of 237. Percentage of area coverage was
recorded for each region of interest. For anatomical regions that spanned multiple coronal
sections, an average area coverage was calculated, weighted by cross-sectional area at
each coronal plane; the corpus callosum and cingulum were analyzed across 3 coronal
planes (Bregma +2.00, +0.00, and -3.00 mm) and the hippocampus was analyzed across
2 coronal planes (Bregma -3.00 and -5.50 mm).
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3.3.6 Data Analysis
Two-way ANOVA were used to test the effects of age and genotype on outcome
measures using GraphPad Prism 7.0 software (La Jolla, CA). The conservative Dunnett’s
post-hoc analysis was used to compare outcome measures across age cohorts within
either genotype. When comparing genotype groups at a given age, Sidak’s post-hoc
analysis was used. Microglia activation in separate brain regions were also analyzed with
two-way MANOVA models using IBM SPSS version 23 (Armonk, NY). Partial correlations
between outcome measures, controlling for age and genotype, were also calculated in
SPSS; outcome measures were evaluated for normality to determine whether Spearman
or Pearson correlations were more appropriate. Binary outcome measures such as
exclusions and meeting test criteria were analyzed in SPSS using logistic regression with
age and genotype as independent variables. Any exclusion of outliers from figures or
analyses is noted; statistical outliers on any outcome measures were identified using the
robust regression and outlier method (ROUT)41. All errors bars shown in figures indicate
standard error of the mean (SEM); probability values of statistical tests were only reported
for significant comparisons.
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3.4

Results

3.4.1 Set Shift
3.4.1.1

Visual Cue Discrimination

Learning and memory were analyzed in an operant-conditioning chamber. On VCD, food
reward would be given when rats pressed the lever associated with a visual cue, which
would pseudorandomly present over the left or the right lever. VCD learning was impaired
only in 22M rats (Figure 3-1A); genotype did not affect VCD performance, but age was a
significant factor (p = 0.0001, F(3,79) = 7.9; 2-Way ANOVA). The age-dependent
impairment of VCD learning was significant in TgAPP21 rats, as 22M TgAPP21 rats
required significantly more trials to reach VCD criterion than 4M TgAPP21 (p = 0.002, q
= 3.454, df = 78), 8M TgAPP21 (p = 0.003, q = 3.371, df = 78), and 13M TgAPP21 rats
(p = 0.0001, q = 4.394, df = 78; Dunnett’s post-hoc test). A similar trend was observed for
22M Wt rats but was not significant. The exclusion of a single statistical outlier within the
8M Wt group (identified as an outlier using the ROUT method with Q = 0.5%) this did not
alter the interpretation of any statistical comparisons.
Similarly, on the 24 h delayed VCD retrieval trials, only 22M rats demonstrated an
impairment of memory (Figure 3-1B). Again, only age was a significant factor (p < 0.0001,
F(3,79) = 10.22; 2-Way ANOVA). The age-dependent impairment on VCD retrieval was
significant in both 22M Wt rats (compared to 4M Wt: p = 0.05, q = 2.398, df = 79; and
13M Wt rats: p = 0.004, q = 3.288, df = 79) and in 22M TgAPP21 rats (compared to 4M
TgAPP21: p = 0. 0005, q = 3.963, df = 79; and 13M TgAPP21 rats: p = 0.0009, q = 3.973,
df = 79; Dunnett’s post-hoc test). Although this indicates a memory impairment in 22M
rats, all rats included in these results were still able to press the correct lever on at least
75% of the 20 trials. The exclusion of rats that failed to meet the 75% criterion (Table 3-2)
did not alter findings of statistical significance in either VCD learning or retrieval, but these
rats were still excluded from all set shifting and reversal results as their motivation to lever
press was uncertain; exclusion was not associated with age (Wald’s χ2(3) = 1.082; logistic
regression). Thus, although 22M rats performed significantly worse on the VCD retrieval
trials, they could still access learned memory that enabled VCD.
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Figure 3-1: Impaired visual cue discrimination learning & memory in aged rats.
(A) Learning performance on VCD was scored by the number of trials needed to reach a
criterion of 8 correct consecutive lever presses. Only age had an effect on learning
performance (p = 0.0001). ** 22M TgAPP21 rats required more trials to criterion than all
younger TgAPP21 rats (p < 0.01); a similar but non-significant trend was observed for
22M Wt rats.
(B) Memory of VCD was evaluated after a 24 h delay on a 20-trial test, scoring the
proportion of correct lever presses. Again, only age had a significant effect on the 24 h
delayed retrieval test (p < 0.0001). * 22M Wt rats performed worse than the 4M and 13M
Wt rats (p < 0.05); *** and 22M TgAPP21 rats also performed worse than 4M and 13M
TgAPP21 rats (p < 0.001). This indicated a memory impairment in 22M rats but not a
complete absence of memory for VCD as all rats included in these results pressed the
correct lever on at least 75% of the 20 trials.
Rats that did not press the correct lever on at least 75% of VCD retrieval (n = 4/91) were
excluded from all analyses of set shifting and reversal behaviour. Error bars indicate SEM;
n = 8 – 13.
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3.4.1.2

Response Discrimination

Immediately after VCD retrieval, rats were challenged to ignore the visual cue and learn
that only one of the levers would yield a food reward on all trials (RD); the rats’ ability to
demonstrate RD depended on their ability to shift between attentional sets. Wt and
TgAPP21 performed similarly in RD, as the number of trials needed to achieve the
criterion of 8 correct consecutive responses did not differ between Wt and TgAPP21 rats
(Figure 3-2A). However, age was a significant factor in the number of trials to reach
criterion (p = 0.03, F(3,77) = 3.096, 2-Way ANOVA). Unexpectedly, 22M TgAPP21 rats
required significantly fewer trials to reach criterion than 4M (p = 0.04, q = 2.534, df = 77)
and 13M TgAPP21 rats (p = 0.02, q = 2.690, df = 77; Dunnett’s post-hoc test). This was
not observed in Wt rats. Age was also the only significant factor in the total number of
errors committed over the entire 120-trial RD session (Figure 3-2B; p = 0.01, F(3,77) =
3.782; 2-Way ANOVA). Again, 22M TgAPP21 rats unexpectedly committed a fewer total
amount of errors than 4M (p = 0.004, q = 3.286, df = 77) and 13M TgAPP21 rats (p =
0.02, q = 2.708, df = 77; Dunnett’s post-hoc test). The reduced number of trials and errors
to RD criterion was attributed to the 22M rats’ partially impaired memory for VCD, which
therefore presented less interference in engaging the spatially-determined reward
strategy.
Despite age-dependent differences in RD performance, no significant differences were
observed in performance on the 24 h delayed RD retrieval task (Figure 3-2C). While 22M
rats demonstrated partial memory impairments in VCD retrieval, they did not demonstrate
any impairment in RD retrieval. This may indicate a dissociable impairment for distinct
forms of memory (visual cue association vs spatial association) or may reflect the reduced
level of locomotor effort required with a spatially-fixed rewarding lever. A total of 26 rats
failed to press the correct lever on at least 75% of RD retrieval trials (Table 3-2). As RD
is more challenging than VCD, and the focus of RD testing is on set shifting, these rats
were still included in the analyses of RD results and were excluded only from subsequent
reversal results & analyses.
Though genotype did not have an overall effect on the number of RD errors committed,
genotype did play a role in the types of errors committed. Early in RD, persistence in
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following the visual cue constitutes a perseverative error; once a rat has already begun
to disengage from VCD, subsequent errors are deemed regressive. Thus, errors
committed after criterion, which should indicate complete disengagement from VCD, are
a particularly aberrant form of regressive error. Never-reinforced errors occur when rats
follow neither the visual nor spatial strategy, indicating a failure to filter out non-rewarding
options. Age had no overall effect on the different types of errors committed during
response discrimination (Figure 3-3). However, genotype was a significant factor in the
number of errors after criterion (p = 0.05, F(3,77) = 4.013; 2-Way ANOVA; Figure 3-3D).
Unexpectedly, the number of regressive errors peaked in 8M TgAPP21 rats and then
decreased in older TgAPP21 cohorts (compared to 22M TgAPP21: p = 0.03, q = 2.66,
df=77; Dunnett’s test). Though the number of regressive errors was not increased in all
TgAPP21 age cohorts, the persistently greater number of errors committed after criterion
still indicates a generally regressive phenotype in TgAPP21 rats.
The number of perseverative errors and regressive errors were negatively correlated,
even when controlling for age and genotype (p < 0.0001, Spearman’s ρ= -0.447, df = 81).
This suggests that there is a generalizable trade-off between errors committed early and
late in RD; a rat that initially appears to shift away from the VCD strategy more quickly (a
decrease in perseverative errors) is likely to require more time to fully acquire response
discrimination (an increase in regressive errors).
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Figure 3-2: Set shifting in aged transgenic rats facilitated by impaired memory of
visual cue discrimination.
Rats’ set shifting performance during response discrimination was measured by (A) the
number of trials needed before 8 correct consecutive responses and (B) the total number
of errors committed across all 120 trials. Age was a significant factor in both the number
of trials needed to achieve criterion and the total number of errors (p < 0.05). * 22M
TgAPP21 rats required fewer trials to achieve criterion than 4M and 13M rats (p < 0.05),
and * 22M TgAPP21 rats committed fewer errors than 4M and 13M rats (p < 0.05).
(C) Neither genotype nor age were significant factors in the number of correct lever
presses during the 24 h delayed RD retrieval session.
Error bars indicate SEM; n = 8 – 13.
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Figure 3-3: Regressive inflexibility in transgenic rats peaked at 8 months of age
Errors made during RD can be categorized as (A) perseverative, (B) never reinforced,
or (C) Regressive. * 8M TgAPP21 rats committed more regressive errors than 22M
TgAPP21 rats (p < 0.05).
(D) Regressive inflexibility is also quantified by the number of errors committed after
achieving RD criterion (8 consecutive correct responses). Genotype was a significant
factor in the number of errors committed after criterion (p = 0.05).
n= 8 – 13; error bars = SEM

104
3.4.1.3

Reversal

Neither age nor genotype were had significant overall effect on the number of errors
committed during reversal. However, 8M TgAPP21 committed significantly more reversal
errors than 4M (p = 0.02, q = 2.729, df = 51) and 22M TgAPP21 rats (p = 0.05, q = 2.432,
df = 51; Dunnett’s post-hoc test; Figure 3-4A). In contrast, Wt rats committed more
reversal errors with age, demonstrating a significant linear trend (R2 = 0.16, p = 0.04,
F(1,23) = 4.599; post-hoc test for linear trend). Due to the high rate of omission trials
during reversal (Figure 3-5), especially in Wt rats, the error rate on reversal as a
proportion of non-omission trials was also evaluated (Figure 3-4B). This yielded similar
results, but with a more robust effect of age in Wt rats (R2 = 0.32, p = 0.003) and an error
rate significantly increased in 22M Wt compared to 4M Wt rats (p = 0.03, q = 2.477, df =
51; Dunnett’s post-hoc test). Only age was a significant predictor for meeting the criterion
of 8 correct consecutive lever presses on the reversal task (Figure 3-4C; p = 0.004, Wald’s
χ2(3) = 13.223; Logistic Regression). Reversal results & analyses included only the rats
that pressed the correct lever on at least 75% of RD retrieval trials. The peak reversal
impairment in 8M TgAPP21 rats, with a concurrent peak in regressive errors, further
suggests that TgAPP21 rats’ behavioural inflexibility was greatest at 8 months of age.
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Figure 3-4: Reversal impairment in transgenic rats peaked at 8 months of age,
increased with age in wildtype rats
(A) While Wt rats demonstrated a linear trend for a greater number of errors with age (R2
= 0.16, p = 0.04), * reversal impairment peaked in 8M TgAPP21 rats, committing
significantly more reversal errors than 4M and 22M TgAPP21 rats (p < 0.05).
(B) To correct for a high frequency of omission trials, error rates were calculated as the
proportion of lever presses that were incorrect, excluding omission trials. With this
correction, the age-dependent linear trend for Wt rats became more robust (R2 = 0.32, p
= 0.003) and * 22M Wt rats showed a significantly greater error rate than 4M Wt rats (p <
0.05). * Reversal impairment in TgAPP21 rats still peaked in the 8M group, which had a
greater error rate than 4M TgAPP21 rats (p < 0.05).
(C) Age, but not genotype, was a significant factor in meeting the reversal criterion of 8
correct consecutive lever presses (p = 0.008).
Error bars indicate SEM; n = 4 – 11.
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3.4.1.4

Omission Trials

To verify whether motivation might have played a role in set shifting, especially in aged
rats, rates of omission trials were analyzed. When rats did not press either lever on a
given trial, the trial was scored as an omission; omission trials can indicate indecision,
stress, anxiety, or a lack of motivation to lever press or for food reward. Omissions were
more common towards the end of a testing session, such as the combined 140 trials of
VCD retrieval followed by RD learning. No groups omitted significantly more trials at any
specific stage of set shifting (Figure 3-5). Individual corrections for omissions did not alter
any findings of significant differences in VCD nor RD but did reveal a clear age-dependent
trend in reversal (Figure 3-4B). Overall, motivation as measured by omission trials did not
confound the effects of age nor genotype.
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Figure 3-5: Neither genotype nor age affected frequency of omission trials.
When rats did not press either lever on a given trial, the trial was scored as an omission;
omission trials can indicate either a lack of motivation, indecision, stress, or anxiety.
Neither age nor genotype had a significant effect on the frequency of omission trials.
Error bars indicate SEM; n = 4 – 13.
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3.4.1.5

Exclusions & Outliers

As failing any of the set shifting criteria would impact performance on subsequent stages,
once a rat was excluded from a given stage, it was also excluded from subsequent stages
(Table 3-2). Rats did not advance to VCD learning if they could not complete initial lever
press training. All rats that began VCD learning were able to achieve VCD criterion. A
single statistical outlier in the 8M Wt group that required 308 trials to criterion on VCD
learning (identified as an outlier using the ROUT method with Q = 0.5%) was excluded
from analyses of VCD learning only; this did not alter the interpretation of any statistical
comparisons but clarified behavioural trends. A single 13M TgAPP21 rat that did not meet
RD criterion and 1 22M TgAPP21 rat that was not active during RD (88 omission trials
out of 120 RD trials) were excluded from all RD and reversal results & analyses. Twentysix rats failed to press the correct lever on at least 75% of RD retrieval trials but these
were only excluded from reversal results & analyses. The rates of exclusion did not
significantly associate with either genotype or any of the age cohorts for any of the set
shifting stages or overall.
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Table 3-2: Stage of Exclusion from Set Shifting Results
4M

Cohort

Wt

8M
Tg

Wt

Initial Training
VCD*

13M
Tg

Wt

Tg

Wt

Tg

1
1

1

1

1

RD Learning
Reversal
(Failed RD
Retrieval)

22M

1
3

1

6

3

3

4

1
1

4

2

Once a rat was excluded, it was also excluded in the analyses of subsequent stages.
* Rats that did not press the correct lever on at least 75% of the 20 trials of VCD retrieval,
a relatively simple task, were excluded from all set shifting and reversal results & analyses
including VCD learning, as these rats’ motivation to lever press was uncertain.
Tg = TgAPP21
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3.4.2 Morris Water Maze
3.4.2.1

Navigational Learning

Learning performance was measured by the rats’ latencies to find the hidden platform
across trials 2-6 only, as the first trial reflected the rats’ chance discovery of the platform
location. Age was the only significant factor in MWM learning (Figure 3-6; p < 0.0001,
F(3,79) = 25.162; 2-Way RM-ANOVA). Compared to 4M rats, both 13M (Wt p = 0.0003,
q = 4.103, df = 79; TgAPP21 p = 0.001, q = 3.722, df = 79) and 22M rats (Wt p < 0.0001,
q = 5.171, df = 79; TgAPP21 p < 0.0001, q = 5.970, df =79; Dunnett’s post-hoc test)
required more time to reach the platform when averaging swim time on trials 2-6.
However, only 22M rats failed to show any improvement even by trial 6; 13M Wt still
reduced swim time by trial 5 (p = 0.002, q = 3.586, df = 395) and 13M TgAPP21 by trial 3
(p = 0.0006, q = 3.906, df = 395; Dunnett’s post-hoc test). Thus, while age impaired MWM
learning performance, all but 22M rats demonstrated significant improvement in swim
time.

3.4.2.1

Navigational Memory

While no genotype differences were observed in MWM learning, genotype differences on
the 24 h delayed probe test were observed. During the probe test, the platform was
removed, and rat swim behaviour was observed during a 90 s probe. Latency to swim to
the platform region, a 7.5 cm vicinity to the learned platform location, was analyzed to
evaluate spatial memory. With age, both Wt and TgAPP21 rats required more time to
locate the platform (Figure 3-7A; p < 0.0001, F(3,79)=8.761; 2-Way ANOVA). Genotype
was not a significant factor, but the age-dependent trend for increasing latency to the
platform region was more robust in TgAPP21 rats (R2 = 0.30, p < 0.0001) than Wt rats
(R2 = 0.17, p = 0.009; post-hoc test for linear trend). Only 22M TgAPP21 rats
demonstrated a significant latency increase over 4M TgAPP21 rats (p < 0.0001, q = 4.875,
df = 79; Dunnett’s post-hoc test).
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Memory was also evaluated by analyzing the proportion of time spent in the target
quadrant, that is, the quadrant of the MWM in which the platform was previously located.
Both age (p = 0.03, F(3,79) = 3.187) and genotype (p = 0.05, F(1,79) = 4.140; 2-Way
ANOVA) had a significant effect on the proportion of time spent in the target quadrant
(Figure 3-7B), with TgAPP21 rats demonstrating a greater preference for the target
quadrant in the 4M, 8M, and 13M groups. 13 MO Wt, 22M Wt, and 22M TgAPP21 rats
did not spend more than 25% of swim time in the target quadrant (one-sample t-tests),
the expected proportion of swim time in the absence of a target preference. 22M
TgAPP21 rats showed a significant decrease in target quadrant preference in comparison
to 4M TgAPP21 (p = 0.02, q = 2.774, df = 79) and 8M TgAPP21 rats (p = 0.003, q = 2.137,
df = 79; Dunnett’s post-hoc test). However, none of the groups demonstrated a significant
increase in the time needed to locate the platform region (Figure 3-7A) in comparison to
the time needed to locate the platform on the last MWM learning trial (Figure 3-6). This
makes it less likely that any of the groups failed to recall a learned platform location.
Rather, the 22M rats’ failure to learn the platform location precluded any preference for
the platform region or target quadrant. When only 4M, 8M, and 13M rats were compared
on the probe test, genotype was still a significant factor with TgAPP21 rats spending more
time in the target quadrant (p = 0.002, F(1,67) = 10.900; 2-Way ANOVA). Thus, so long
as TgAPP21 rats were able to learn and recall the platform location, they would
demonstrate a greater target quadrant preference. The traditional interpretation of target
preference would suggest that TgAPP21 rats demonstrated a better recall of the platform
location.

3.4.2.3

Regressive Platform Search

Just as in the previous study that focused on 8M rats only, it was observed again that
some rats would demonstrate an increased preference for the target quadrant in the late
segment of the probe test. This was unexpected, as preference for the target quadrant
should extinguish, not strengthen, during the course of the probe test. To evaluate the
role of regressive behavioural inflexibility in target quadrant preference, the proportion of
swim time in the target quadrant in the last 30 s segment of the probe test was analyzed
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(Figure 3-7C). Age was a significant factor in this late preference (p = 0.02, F(3,79) =
3.404; 2-Way ANOVA), driven by the difference between 8M and 22M TgAPP21 rats (p
= 0.002, q = 3.474, df = 79; Dunnett’s post-hoc test). Since the 22M rats never
demonstrated that they learned the platform location, a sub-analysis that excluded 22M
rats was also performed. When only 4M, 8M, and 13M rats were compared, only genotype
was a significant factor with TgAPP21 rats demonstrating a greater late preference for
the target quadrant (p = 0.02, F(1,67) = 5.177; 2-Way ANOVA). Thus, across the ages at
which the rats could learn the platform location, TgAPP21 demonstrated a greater
preference for the target quadrant in the last 30 s segment of the probe test. For TgAPP21
rats, the late preference for the target quadrant peaked at 8M of age just as the number
of regressive errors and errors after criterion in RD peaked in 8M TgAPP21 rats.
To more accurately capture the regressive nature of a late target quadrant preference, it
was important to analyze how this compared to target quadrant preferences
demonstrated earlier in the probe test. To do this, the Regressive Index was calculated
for each rat as the difference between the proportion of time in the target quadrant during
the last 30 s and the first 60 s of the probe test. Although genotype nor age had significant
overall effects on the Regressive Index, 8M TgAPP21 (p = 0.02, t = 3.796, df = 11) and
13M Wt rats (p=0.002, t = 5.258, df = 12) both demonstrated a significant non-zero
Regressive Index (one sample-test with Bonferroni correction; Figure 3-7D). This
regressive behaviour in the MWM peaked in both genotypes prior to the development of
navigational learning impairments, just as TgAPP21 regressive behaviour in RD peaked
at 8 months of age prior to the onset of learning and memory impairments in the operantconditioning chamber.
For both genotypes, the age-dependent trends for the regressive index (Figure 3-7D)
replicated the regressive error trends observed in response discrimination (Figure 3-3C).
To test whether the regressive-like behaviour in the MWM probe test was related to
regressive behaviour in response discrimination, the relationships between regressive
error frequency and late target quadrant preference & regressive index scores were
analyzed (Figure 3-8). Regressive error frequency was strongly correlated with both late
target quadrant preference (p = 0.009, R2 = 0.71, F(1,6) = 14.76) and the regressive index
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(p = 0.03, R2 = 0.55, F(1,6) = 7.481). This reaffirms the interpretation of late target
quadrant preference as a regressive behaviour. Altogether, the increased target quadrant
preference demonstrated by TgAPP21 rats in the probe is more indicative of a regressive
inflexibility than an improved memory. In TgAPP21 rats, regressive inflexibility in the
probe test peaked at 8 months of age, paralleling observations in set shifting and reversal,
and in Wt rats, regressive inflexibility was observed at 13 months of age.

3.4.2.4

Cued Trials & Swim Speed

Distal visual cues enabled the rats to navigate the MWM, assuming that the rats’ vision
was not a confounding variable. To test this assumption, cued trials were performed at
the conclusion of MWM testing, wherein a visible marker was placed on a new platform
location with the platform slightly elevated above the water level. Neither age nor
genotype were significant factors in the latency or swim distance to the platform, even
when correcting for swim speed as a covariate. Thus, vision was unlikely to be a
confounding factor in MWM observations. Similarly, neither age nor genotype were
significant factors in swim speeds, averaged across all MWM trials.
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Figure 3-6: Age impaired Morris Water Maze learning
Learning performance was evaluated across trials 2-6. Age had a significant effect on
swimming time to platform (p < 0.0001).
Compared to 4M Wt rats, *** 13M Wt (p < 0.001) and **** 22M Wt rats (p < 0.0001)
required more time to locate the platform.
Compared to 4M TgAPP21 rats, ** 13M TgAPP21 (p < 0.01) and **** 22M TgAPP21 (p <
0.0001) rats also required more time to locate the platform.
Only 22M rats failed to show any improvement even by trial 6; 13M Wt still reduced swim
time by trial 5 (p = 0.002) and 13M TgAPP21 by trial 3 (p = 0.0006).
Error bars indicate SEM; n = 5 – 13.
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Figure 3-7: Age-dependent memory impairment in the Morris Water Maze probe
was preceded by a regressive-like inflexibility
24 h after MWM learning, the platform was removed, and rat swim behaviour was
observed during a 90 s probe trial.
(A) Latency to swim to the platform region, a 7.5 cm vicinity to the learned platform
location, was analyzed to evaluate spatial memory. With age, both Wt and TgAPP21 rats
required more time to locate the platform (p < 0.0001). However, **** only 22M TgAPP21
rats showed a significant increase compared to 4M TgAPP21 rats (p<0.0001).
(B) Time in the target quadrant is another commonly used metric to evaluate spatial
memory; the dotted line marks the 25% proportion of swim time that would be expected
if rats had no bias for the target quadrant. Both age (p = 0.03) and genotype (p = 0.05)
were significant factors in the proportion of time spent in the target quadrant. * 22M
TgAPP21 rats spent less time in the target quadrant than 4M and 8M TgAPP21 rats (p <
0.05). Traditional interpretation of target preference would suggest that 4M, 8M, and 13M
TgAPP21 rats demonstrated a stronger memory for the platform location than agematched Wt rats.
(C) Age was a significant factor in target quadrant preference during the last 30 s segment
of the probe test (p = 0.02). This was driven by a ** significantly greater preference in 8M
TgAPP21 rats (p = 0.002, compared to 22M TgAPP21 rats).
(D) To score the relative increase of a regressive-like preference for the target quadrant,
the Regressive Index measures the difference between the proportion of time spent in
the target quadrant during the last 30 s segment and the first 60 s segment of the probe
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test. * 8M TgAPP21 (p < 0.05) and ** 13M Wt rats (p < 0.01) both demonstrated a
regressive-like preference for the target quadrant.
Error bars indicate SEM; n = 5 – 13.
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Figure 3-8: Regressive behaviour consistent across response discrimination and
Morris Water Maze probe
The group-wise number of regressive errors were significantly correlated with two
different measures of regressive like-behaviour in the Morris Water Maze probe: (A) the
proportion of time spent in the target quadrant last 30 s segment of the probe (p = 0.009,
Pearson’s R2 = 0.71), and (B) the regressive index, which is calculated by the difference
between the proportion of time spent in the target quadrant during the last 30 s segment
compared to the first 60 s of the probe test (p = 0.03, Pearson’s R2 = 0.55).
Error bars indicate SEM; dotted lines indicate 95% confidence interval of linear
regression.
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3.4.3 Open Field
The open field evaluates rats’ locomotor exploration and avoidance of the anxiogenic field
centre. Older and transgenic rats demonstrated less locomotor exploration, with both age
and genotype having a significant effect on the total distance travelled during both the
first 5 min (Figure 3-9A; Age: p < 0.0001, F(3,81) = 14.12; Genotype: p < 0.0001, F(1,81)
= 54.48; 2-Way ANOVA) and the full 20 min duration of the open field (Figure 3-9A; Age:
p < 0.0001, F(3,81) = 24.73; Genotype: p < 0.0001, F(1,81) = 71.48; 2-Way ANOVA).
There was also a significant interaction between age and genotype (p = 0.003, F(3,81) =
5.2; 2-Way ANOVA), with Wt rats showing a greater age-dependent decline in total
distance travelled. Overall, TgAPP21 rats demonstrated a profound reduction in
locomotor exploration. Avoidance of the centre of the open field is an indicator of anxiety.
Neither age nor genotype were significant factors in this measure of anxiety (Figure 3-9B),
thus anxiety is unlikely to have confounded behavioural tests.
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Figure 3-9: Decreased open field exploration in aged and transgenic Rats
(A) Total distance travelled in the open field is a measure of locomotor exploration. Age
and genotype were both significant factors in the total distances travelled during both the
first 5 min (p < 0.0001) and the full 20 min duration of the open field (p < 0.0001); older
and transgenic rats demonstrated less locomotor exploration. There was also a significant
interaction between age and genotype (p = 0.003), with Wt rats showing a greater agedependent decline in total distance travelled. For both the first 5 min and the full 20 min
duration of the test, TgAPP21 rats demonstrated significantly less locomotor exploration
at the 4M, 8M, and 13M age points (p < 0.004), but not at 22 months of age.
(B) Avoidance of the centre of the open field is an indicator of anxiety. Neither age nor
genotype were significant factors in this measure of anxiety.
Error bars indicate SEM; n = 6-13.
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3.4.4 Activated Microglia
The activation of microglia indicates a pro-inflammatory environment. The OX6 antibody
for MHC II was used to identify activated microglia. Major white matter tracts, such as the
corpus callosum (Figure 3-10A), and the hippocampus were found to be common sites
for microglial activation. Though OX6 positive microglia were also observed in the cortex,
thalamus, and striatum, their presence was highly sporadic and qualitative observation
did not indicate any association with genotype. Thus, only major white matter tracts and
the hippocampus were evaluated quantitively. Older rats demonstrated a significant
increase in the cross-sectional area coverage by OX6 positive microglia in the forceps
minor, corpus callosum, cingulum, and internal capsule (Figure 3-10B-G; p < 0.0001,
Wilk’s Λ = 0.057, F(24,73.109) = 5.112; 2-way MANOVA). TgAPP21 rats demonstrated
greater activated microgliosis (p < 0.0001, Wilk’s Λ = 0.285, F(8,25) = 7.847), and there
was a significant interaction between age and genotype (p = 0.01, Wilk’s Λ = 0.223,
F(24,73.109) = 2.067; 2-Way MANOVA). This interaction was most apparent in the corpus
callosum (Figure 3-10D; p = 0.004, F(3,32) = 5.518) and the supraventricular sub-region
of the corpus callosum (Figure 3-10C; p = 0.002, F(3,32) = 6.130; 2-Way ANOVA). Within
these two regions, the age-dependent increase activated microglia was precocious in
TgAPP21 rats, so that 8M TgAPP21 rats had as much microglia activation as 13M Wt
rats, and 13M TgAPP21 rats had as much microglia activation as 22M Wt rats (Figure
3-10CD). This precocious white matter inflammation was not observed in the forceps
minor, cingulum, or internal capsule, but 22M TgAPP21 rats did demonstrate significantly
greater activated microglia area coverage than 22M Wt rats in all white matter regions (p
< 0.01; Sidak’s post-hoc test).
In the hippocampus, only age was a significant factor in microglia activation (Figure
3-10G; p = 0.02, Wilk’s Λ = 0.543, F(9,73.163) = 2.319; 2-Way MANOVA). While 22M
TgAPP21 rats demonstrated more neuroinflammation throughout the hippocampus than
4M rats and 22M Wt did not, there was no significant difference between the 22M
TgAPP21 and 22M Wt rats. However, in the pooled results for the posterior dorsal and
ventral sub-regions of the hippocampus, genotype was a significant factor (p = 0.005,
F(1,32) = 8.989) and interacted significantly with age (p = 0.0009, F(3,32) = 6.997; 2-Way
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ANOVA), such that 22M TgAPP21 rats demonstrated greater neuroinflammation than
22M Wt rats in the posterior hippocampus (p < 0.0001, t = 5.384, df = 32; Sidak’s posthoc test).
Wt rats demonstrated a greater increase of microglia activation in the anterior corpus
callosum than the posterior corpus callosum (p = 0.04, F(1,32) = 4.84; 2-Way ANOVA).
In TgAPP21 rats, microglia activation was more widely and diffusely increased, so that
there was not a significant anterior-posterior gradient of inflammation in the corpus
callosum. This replicates patterns of white matter disruptions observed in healthy elderly
control subjects and patients with AD42.
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Figure 3-10: Precocious corpus callosum inflammation in transgenic rats
IHC for the OX6 primary antibody for MHC II identified activated pro-inflammatory
microglia; white matter areas and the hippocampus were identified as regions with high
microglia activation.
(A) The schematic shows one of the coronal planes on which the corpus callosum was
analyzed (Bregma +2.0 mm). Representative images of 30 µm thick sections were taken
from the dotted outline; 200 µm scale bar.
(B-G) Cross-sectional area coverage by activated microglia was quantified in major white
matter tracts and the hippocampus. (B-F) Age and genotype were significant factors for
microglia activation in white matter (p < 0.0001). The interaction between age and
genotype was also significant (p = 0.01); this interaction was especially apparent in the
supraventricular corpus callosum and the corpus callosum (p < 0.004). In these regions,
the age-dependent increase of white matter inflammation was precocious in TgAPP21
rats, so that 8M and 13M TgAPP21 rats had as much microglia activation as 13M and
22M Wt rats, respectively.
(G) Only age was a significant factor in the activation of microglia in the hippocampus (p
= 0.02); this also applied to the three subregions of the hippocampus analyzed: anterior
dorsal, posterior dorsal, and ventral (p < 0.007). ** p < 0.01, *** p < 0.001, **** p < 0.0001:
significant increases compared to 4M rats of the same genotype.
Error bars indicate SEM, n = 5.
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3.4.5 Reactive Astrocytes
To evaluate whether there was an increase of reactive astrocyte in regions with increased
microglia activation, cross-sectional area coverage by GFAP-positive astrocytes was
evaluated in the same regions (Figure 3-11). Age was a significant factor in astrocyte
reactivity in the forceps minor (Figure 3-11B); p = 0.01, F(1,32) = 4.478), which was also
the only region in which genotype was a significant factor (p = 0.05, F(1,32) = 4.346; 2way ANOVA). In the forceps minor, 22M TgAPP21 demonstrated a significant decrease
in cross sectional area coverage by GFAP-positive astrocytes compared to 8M TgAPP21
(p = 0.004, q = 3.491, df = 32; Dunnett’s post-hoc test; Figure 3-11B). This pattern of
group differences was significantly correlated with the number of regressive errors
committed during response discrimination (group-wise correlation; p = 0.03, Pearson’s R2
= 0.57, F(1,6) = 8.036; Figure 3-12). This relationship was particularly strong in TgAPP21
rats (p = 0.03, Pearson’s R2 = 0.93, F(1,2) = 27.33). Thus, increased astrocyte reactivity
in the forceps minor may have played an important role in the 8M TgAPP21 rats’
regressive inflexibility.
Age was a significant factor in hippocampal astrocytosis (Figure 3-11G; p < 0.0001, Wilk’s
Λ = 0.330, F(9,73.163) = 4.695; 2-Way MANOVA), but without a clear trend and no
differences between the genotypes. This was also observed in the posterior dorsal
hippocampus (p = 0.003, F(3,32) = 5.816) and ventral hippocampus (p < 0.0001, F(3,32)
= 10.439; 2-Way ANOVA), but not the anterior dorsal hippocampus.
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Figure 3-11: Reduced forceps minor astrocyte reactivity in aged TgAPP21
DAB mediated IHC with a primary antibody for GFAP identified reactive astrocytes.
(A) The schematic shows the coronal planes on which the forceps minor was analyzed
(Bregma +3.0 mm). Representative images of 30 µm thick sections were taken from the
dotted outline; 200 µm scale bar.
(B-G) Cross-sectional area coverage by reactive astrocytes was quantified in regions with
increased microglia activation. (B-F) Neither age nor genotype were significant factors in
astrocyte reactivity across most white matter regions except for the forceps minor, in
which both age (p = 0.01) and genotype (p = 0.05) were significant factors in reactive
astrocyte area coverage. ** In the forceps minor, 22M TgAPP21 rats had a decreased
area coverage by reactive astrocytes compared to 8M TgAPP21 rats (p < 0.01).
(G) Age was a significant factor in reactive astrocyte area coverage in the hippocampus
(p < 0.0001).
Error bars indicate SEM, n = 5.
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Figure 3-12: Significant positive correlation between regressive errors and
astrocyte reactivity in the forceps minor.
The group-wise relationship between the number of regressive errors committed during
response discrimination and GFAP-positive reactive astrocyte area coverage in the
forceps minor was significant (p = 0.03, Pearson’s R2 = 0.57).
Error bars indicate SEM; dotted lines indicate 95% confidence interval of linear
regression.

128

3.5

Discussion

The profound acceleration of age-dependent white matter microglia activation builds on
previous observations of increased inflammation in the TgAPP21 rats’ white matter (2.4.4
Activated Microglia in White Matter on page 77). Concurrently, the TgAPP21
demonstrated a regressive behavioural phenotype, committing a greater number of errors
after criterion during set shifting. This was further evidenced by a greater regressive-like
preference for the MWM target quadrant. However, TgAPP21 rats did not show a
persistent or progressive increase in regressive behavioural inflexibility across all
measures. Instead, behavioural inflexibility peaked in 8M TgAPP21 rats, as measured by
the number of regressive errors on set shifting, reversal errors, and the MWM Probe
Regressive Index score. Though learning and memory impairments in 22M rats may
account for an apparent decrease in inflexibility in 22M TgAPP21 rats, the relative
reduction of inflexibility in 13 M TgAPP21 would still be unexpected. Previous studies
have observed that environmental enrichment promotes a relatively greater increase of
neurogenesis in older than younger rodents43, and that environmental enrichment can
promote functional compensation in rodent models of neurodegeneration44. This raises
the question of whether older TgAPP21 rats may have developed compensatory
pathways, which has been described in AD patients with increased paradoxical neural
activation45; this would need to be investigated with positron emission tomography or
functional magnetic resonance imaging.
The TgAPP21 rats’ regressive inflexibility could not be attributed directly to their
precocious white matter inflammation. However, the amount of astrocytosis in the forceps
minor did strongly correlate with the number of regressive errors observed during
response discrimination. This complements recent findings that correlated performance
on the Stroop color-naming task with white matter integrity in the forceps minor, as
measured by fractional anisotropy46. In healthy human subjects, fractional anisotropy is
negatively correlated with age, particularly in the frontal lobe, and is associated with
poorer cognitive performance on an attention-switching task5. Our results suggest that
pathogenic amyloid and astrocytes may also play important roles in frontal white matter
integrity and its behavioural correlates.
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Reduced locomotor exploration, as demonstrated by TgAPP21 rats, has been reported
in other rodent models of Alzheimer disease47. This reduced exploratory behaviour was
observed in all age cohorts, and 4M TgAPP21 rats explored the field as little as 22M Wt
rats did. Interestingly, in a study on bilateral carotid artery stenosis and white matter injury
in aged mice, myelin degradation and microglia activation were associated with reduced
social exploration14. Another study found that mice with white matter injury after bilateral
carotid artery stenosis recovered normal exploratory behaviour of a novel object when
microglia were inactivated by minocycline and TRPM2 knock-out17. These studies
support the interpretation that white matter inflammation in TgAPP21 rats may have
mediated reduced exploratory behaviour.
Several behavioural testing design parameters were crucial to characterizing the
TgAPP21 rat, although they are not standard in rodent studies. Allowing rats to continue
lever pressing in the operant-conditioning chamber even after achieving criterion allowed
us to measure the number of errors committed after criterion during RD. Our MWM test
was 90 s long, allowing us to capture a regressive-like target quadrant preference in 8M
TgAPP21 and 13M Wt rats. Both the Regressive Index and the time spent in the target
quadrant during the last third of the probe test correlated significantly with the number of
regressive errors committed during response discrimination learning. This reiterates the
potentially confounding role that behavioural flexibility can have on memory testing in the
MWM probe. The inherent challenge of maintaining animal wellness in aged rats presents
an important limitation in our results; 22M behaviour and neuroinflammation may have
been confounded by insidious health factors. Future work should focus on identifying the
specific microglia populations that are activated in vivo in response to hAPP expression
and the specific molecular pathways that link the expression of pathogenic hAPP and
microglia activation. Targeted anti-inflammatory intervention or pro-inflammatory
challenges will be important for confirming potentially causal links.
The observation of precocious microglia activation in the corpus callosum of TgAPP21
rats reinforces the central role of neuroinflammation in early AD. Increased activation of
white matter microglia presented independently of amyloid plaque formation, as amyloid
deposits do not develop spontaneously in the TgAPP21 rat31,32,48. Moreover, the onset of
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behavioural inflexibility preceded impairments of hippocampal-dependent behaviour,
such as spatial and memory impairments. This presents important considerations for
future experimental and clinical studies of behavioural inflexibility related to ageing and
dementia. In particular, these findings warrant closer investigation of white matter
inflammation and regressive forms of inflexibility in the earliest stages of cognitive
impairment associated with amyloid pathology.
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Chapter 4: The Role of Hypertension in Executive Function
and White Matter Astrocytosis
This study set out to evaluate the impact of comorbid pathogenic APP and
cerebrovascular stress on executive function (Objective 3). The experiments in this study
were conducted prior to our development of set-shifting methodology, thus evaluation of
behavioural flexibility was limited to delayed match-sample testing in the MWM, which
evaluates both working memory and behavioural flexibility. A manuscript of this study is
under review for publication in Hypertension.

4.1

Abstract

Hypertension is recognized as a risk factor for Alzheimer disease (AD), but the causal
link remains undetermined. Although astrocytes and microglia play an important role in
maintaining the neurovascular unit, astrocytes and microglia have been understudied in
comorbid models of hypertension and AD. In this study, male transgenic Fischer 344 rats
(TgAPP21) overexpressing a pathogenic human amyloid precursor protein received 8
weeks of chronic Angiotensin II (AngII) infusion to increase blood pressure, and the rats
were evaluated for astrocytosis, microgliosis, and cognitive function. A linear relationship
between astrocytosis and blood pressure was observed in the corpus callosum and
cingulum of wildtype rats, with hypertensive wildtype rats matching the elevated baseline
astrocytosis seen in normotensive transgenic rats. In contrast, hypertensive transgenic
rats did not demonstrate a further increase of astrocytosis, indicating a deficient response.
AngII infusion did not affect activation of microglia, which were elevated in the white
matter and hippocampus of transgenic rats. AngII infusion did impair both wildtype and
transgenic rats’ executive functions in the Morris Water Maze. These results present
important implications for the interaction between hypertension and pathogenic human
amyloid precursor protein expression, as AngII infusion produced cognitive impairments
in both genotypes, but transgenic rats were additionally impaired in developing a normal
astrocytic response to elevated blood pressure.

135

4.2

Introduction

Cerebrovascular pathology is commonly observed in all types of dementia. In addition to
vascular dementia, this is also apparent in Alzheimer disease (AD), with 80% of cases
showing coincident cerebrovascular pathology on autopsy1. Hypertension is recognized
as a leading vascular risk factor for AD2-4, but the causal link between hypertension and
AD has not been identified. Moreover, it remains inconclusive whether anti-hypertensive
therapy can offer cognitive protection5-10. Observed interactions between AD and vascular
pathology has given rise to the Neurovascular Hypothesis of AD11-13. The Neurovascular
Hypothesis proposes that cerebrovascular dysregulation, such as systemic hypertension,
disrupts amyloid and tau protein homeostasis, leading to neuronal injury and cognitive
impairment. At the same time, amyloid- and tau-mediated injury can disrupt
neurovascular coupling. Central to this bi-directional pathology is the neurovascular unit,
maintained in part by astrocytes and microglia, which are responsive to hypertension1416.

The importance of hypertension as a risk factor for AD is further supported by the close
link

between

hypertension

and

leukoaraiosis,

also

known

as

white

matter

hyperintensities17. Leukoaraiosis is associated with disruptions of white matter
integrity18,19 and is an important predictor for dementias including AD20. These white
matter disruptions can cause impairments of executive functions such as working memory
and behavioural flexibility18, which is also seen in patients with hypertension21-23.
Hypertension disrupts astrocytic polarity and the blood-brain barrier24-27, which may be
an initiating factor in the development of leukoaraiosis28. Thus, white matter pathology
plays an important role in the cognitive effects of hypertension.
Previous animal models of comorbid hypertension and AD have demonstrated that
hypertension does exacerbate amyloidopathies and cognitive impairment29-34, but these
studies did not present data on white matter disruption, executive function, astrocytes, or
microglia. In the present study, we investigated the impact of hypertension on the
transgenic Fischer 344 rat (TgAPP21) which overexpresses a pathogenic variant of the
human amyloid precursor protein (hAPP)35, focusing on astrocytes, microglia, and
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executive function. Cerebral amyloid pathology does not occur spontaneously in
TgAPP21 but can be induced35-37, thus TgAPP21 are ideal for modelling the roles of
hypertension and glial cells in the early pre-plaque stages of AD. For 8 weeks, 8 – 10month-old male wildtype and transgenic rats were chronically infused with either normal
saline (Wt & Tg rats) or Angiotensin II (AngII; Wt-AngII & Tg-AngII rats) to elevate blood
pressure and model the effects of hypertension38-40. We expected increased astrocytosis
particularly in the white matter regions of Wt-AngII and Tg-AngII, accompanied by
executive dysfunction, as both white matter and executive function are particularly
vulnerable to hypertension21-23. As both hypertension and high levels of amyloid activate
astrocytes and microglia12,14-16,41-43, we expected the greatest amount of glial activity in
the comorbid Tg-AngII rats.
Indeed, after 8 weeks of blood pressure elevation, we found greater astrocyte reactivity
in the corpus callosum and cingulum of Wt-AngII rats. The level of white matter
astrocytosis in Wt-AngII rats was similar to Tg rats, which appeared to have an elevated
baseline level of reactive astrocytes. However, Tg-AngII rats did not demonstrate a further
increase of astrocytosis. AngII infusion did impair both Wt-AngII and Tg-AngII rats in the
Morris Water Maze (MWM) adaptation of a delayed match-sample test, a spatial task that
also tests working memory and behavioural flexibility. These results present important
implications for the interactive effects of hypertension and genetic risk factors for AD, as
AngII infusion produced cognitive impairments in both genotypes, but Tg-AngII were
additionally impaired in developing a normal astrocytic response to elevated blood
pressure.
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4.3

Methods

4.3.1 Animals
Animal ethics and procedures were approved by the Animal Care Committee at Western
University (protocol 2014-016) and are in compliance with Canadian and National Institute
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23).
Homozygous TgAPP21 rats were studied to model the effect of increased brain
concentrations of pathogenic hAPP35. 26 male wildtype Fischer 344 rats and 29 male
TgAPP21 rats were aged to 7.25 months (SD = 0.55 months), weighing an average of
367 g (SD = 38 g), before osmotic pumps were implanted to deliver saline or AngII for 8
weeks. Behavioural testing was performed during the last 2 weeks of saline or AngII
infusion.

4.3.2 Blood Pressure Elevation & Measurement
With random allocation, 13 wildtype and 14 TgAPP21 rats were infused with normal saline
(Wt, Tg); 13 Wt and 15 TgAPP21 rats were infused with AngII to elevate blood pressure
(Wt-AngII, Tg-AngII)38-40. Osmotic pumps (Alzet, model 2004; Cupertino, CA) were filled
with a saline-angiotensin II solution (Sigma Aldrich, A9525; Oakville, Ontario) or with
normal saline. The angiotensin II solutions were diluted according to lot-specific osmotic
pump flow rates and individual rat weight to deliver 10 000 ng/kg/h. The pumps were
implanted subcutaneously on the medial dorsum at the level of the scapulae. The pump
reservoir allowed for drug or saline delivery for only 4 weeks, so pumps were replaced
once to allow delivery for a total of 8 weeks. Volume pressure reading tail cuffs were used
to measure arterial tail blood pressure (Kent Scientific, CODA High Throughput)44,45. In
between pump implantation and behavioural tests, blood pressure was measured weekly,
so that there were 6 measurements during the 8-week period of angiotensin II or normal
saline infusion.
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4.3.3 Morris Water Maze
On the 7th week of osmotic pump infusion of either normal saline or AngII, rats began
behavioural testing. In a dimly lit room, a water tank (144 cm diameter) was filled with
room temperature water, dyed with black non-toxic acrylic paint, and a target platform (12
cm diameter) was submerged below 3 cm of water. Rats were placed in a fixed start
location and had to locate the hidden platform to be removed from the water tank (Figure
5A). The rats were given six 90 s learning trials (with 1 h inter-trial rest intervals) to learn
the location of the submerged platform, aided by large distal visual cues; this learning
schedule was adapted from Roof et al46. Twenty-four hours after the last learning trial,
the rats’ memory for the platform location was evaluated on a test trial. Rats were also
evaluated on a 5-day series of delayed match-sample testing, to test for performance in
more challenging spatial shifts (Figure 5B)47,48. Each day, during the ‘sample trial’, a new
start location and a new platform location was used. The rats are tested on these new
spatial parameters 6 h later during the ‘match trial’ and were assessed for improvement
in their latency to find the platform. The 6 h delay was used to create a greater working
memory challenge48. This was repeated with new start and platform locations each day
over 5 days.
After MWM testing was complete, potentially confounding differences in visual perception
or swim speed were evaluated on cued trials, wherein the location of the platform was
visibly marked. All swim paths were tracked using ANYmaze tracking software, version
4.70 (Stoelting Company; Wood Dale, IL), with a top-view webcam (C525, Logitech;
Newark, CA). The experimenter was not visible to the rats during testing.

4.3.4 Open field
The day after MWM testing was completed, rat exploratory behaviour and anxiety was
evaluated in the open field. Rats were placed in a square 45 cm open field with 40 cm
black walls and a black floor and permitted to explore freely for 20 mins. A top-view
webcam was used for behavioural tracking with ANYmaze software, version 4.70
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(Stoelting Company; Wood Dale, IL). The experimenter was not visible to the rats during
testing.

4.3.5 Immunohistochemistry & Image Processing
Immediately after all behavioural testing was complete, before pump reservoirs were
depleted, rats were euthanized, perfused with 200 ml of 0.01 PBS followed by 200 ml of
freshly depolymerized and buffered 4% paraformaldehyde solution (PFA), and brain
tissue was collected and stored in 4% PFA for 24 h before transfer to 30% sucrose
solution. 30 µm thick coronal sections were prepared from a subset of brains from each
group (n = 8 – 10) using a cryostat (CryoStar NX50, Thermo Fischer Scientific; Ottawa,
ON). DAB-mediated IHC of free floating sections was performed with an ABC-HRP kit
(Thermo Fischer Scientific #32020; Ottawa, ON), a 1:1000 concentration of OX6 primary
antibody for MHC II to identify activated microglia (BD Biosciences #554926;
Mississauga, ON)49, and a 1:2000 concentration of GFAP primary antibody to identify
reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON)50.
Stitched micrographs of slides were prepared using a 10x objective lens on an upright
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging;
Mississauga, ON). Anatomical regions of interest (cingulum, corpus callosum, internal
capsule, hippocampus) were captured at coronal sections: Bregma +2.00, +0.00, and 3.00 mm51. Micrographs were processed and analyzed using ImageJ, version 1.50b; after
regions of interest were outlined using the polygon tool, images were converted to 8-bit,
processed using the subtract background command, and then thresholded with a fixed
grayscale cut-off value of 237. Percentage of area coverage by DAB-positive cells was
recorded for each region of interest. The corpus callosum and cingulum were analyzed
across 3 coronal planes and an average area coverage was calculated, weighted by
cross-sectional area at each plane.
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4.3.6 Data Analysis
Two-Way ANOVA and linear regressions were used to evaluate the effects of genotype
and AngII infusion using GraphPad Prism 7.0 software (La Jolla, CA). ANCOVA models
were used to evaluate the effect of blood pressure as a continuous predictor variable with
IBM SPSS version 23 (Armonk, NY). The conservative Sidak’s post-hoc analysis was
used to compare outcome measures within genotype and infusate factors.
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4.4

Results

4.4.1 Blood Pressure Elevation and Measurement
Average MAP was significantly elevated during the 8 weeks of AngII infusion (Figure 4-1;
p < 0.0001, F(1,51) = 31.52; 2-Way ANOVA). There were no genotype differences in
response to AngII infusion and its effects on MAP, DBP, and SBP. Post-hoc comparisons
found a significant MAP increase of 17 +/- 5 mmHg and 22 +/- 6 mmHg in Wt-AngII and
Tg-AngII rats, respectively (+/- SE of difference; Wt-AngII: p = 0.004, t = 3.307, df=51,
Tg-AngII: p < 0.0001, t = 4.673, df = 51; Sidak’s test). DBP and SBP demonstrated the
same pattern of significant changes; DBP respectively increased by 12 +/- 5 mmHg and
21 +/- 5 mmHg in Wt-AngII and Tg-AngII rats (Wt-AngII: p = 0.04, t = 2.446, df = 51; TgAngII: t= 4.547, df = 51), while SBP respectively increased by 19 +/-5 mmHg and 21 +/5 mmHg Wt-AngII and Tg-AngII rats (Wt-AngII: p = 0.004, t = 4.039, df = 51; Tg-AngII: p
<0.0001, t= 4.604, df = 51; Sidak’s test). There were no group differences in baseline
blood pressures, measured prior to pump implantation.
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Figure 4-1: Mean Arterial Pressure during 8 weeks of normal saline or AngII
infusion.
AngII infusion had a significant effect on mean arterial pressure (p < 0.0001). There were
no differences in the genotypes’ response to AngII.
n = 13 – 15; error bars indicate SEM.
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4.4.2 Reactive Astrocytes
Reactive astrocytes were found throughout white matter, cortical, subcortical, and
hippocampal regions. However, qualitative observations identified more variable degrees
of astrocytosis in major white matter tracts (corpus callosum, cingulum, internal capsule)
and the hippocampus, so these regions were selected for closer investigation (Figure
4-2). AngII infusion was found to have a significant effect on astrocyte activity in the
corpus callosum and cingulum (Figure 4-2B; corpus callosum: p=0.05, F(1,34) = 4.265;
cingulum: p=0.03, F(1,34) = 4.973; 2-Way ANOVA). This was driven by significant
differences between Wt and Wt-AngII rats (corpus callosum: p=0.03, t= 2.537, df = 34;
cingulum: p=0.04, t = 2.426, df = 34; Sidak’s test). While area coverage by reactive
astrocytes increased in the corpus callosum and cingulum of Wt-AngII rats, Tg rats also
had elevated astrocytosis that did not increase further in Tg-AngII rats. Astrocytosis in the
corpus callosum and cingulum was linearly correlated with MAP in wildtype rats (Figure
4-2C; R2 = 0.52, p=0.0007, df = 18), but not in transgenic rats. Regardless of whether the
corpus callosum and cingulum were pooled or analyzed separately, similar significant
relationships were identified and the slopes of the regressions between astrocytosis and
MAP were significantly different between wildtype and transgenic rats. Moreover,
genotype, MAP, and their interaction were found to have significant effects on
astrocytosis in the corpus callosum and cingulum in an ANCOVA model that substituted
infusate allocation with MAP as a continuous predictor (genotype: p = 0.009, F(1,34) =
7.568; MAP: p = 0.03, F(1,34) = 4.893; genotype*MAP: p = 0.02, F(1,34) = 6.407;
ANCOVA). The same findings of significance were observed when the corpus callosum
and cingulum were analyzed separately. Absolute MAP was found to be more informative
than individual increases of MAP (as compared to baseline measurements prior to pump
implantation), as relative changes in MAP was not a significant predictor of astrocytosis.
In Wt rats, blood pressure elevation increased white matter astrocyte reactivity to levels
matching Tg and Tg-AngII rats. These findings suggest that white matter astrocyte
reactivity was already saturated in Tg rats and could not increase further in response to
elevated blood pressure.
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In Wt-AngII rats, reactive astrocytes had extensive processes wrapping around blood
vessels (Figure 4-2A). In contrast, Tg-AngII rats showed some increase of reactive
astrocyte processes wrapping around blood vessels, but not as consistently as Wt-AngII.
In comparison to Wt-AngII, astrocytic processes were qualitatively observed to be
reduced in Tg-AngII across blood vessels ranging from 4 – 50 µm in diameter. This further
supports the interpretation that astrocytes in Tg rats were already reactive at maximum
capacity and could not respond to elevated blood pressure in Tg-AngII rats.
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Figure 4-2: Increased white matter reactive astrocytosis in transgenic rats is
unresponsive to blood pressure elevation.
Reactive astrocytes were identified using DAB-mediated IHC with a primary antibody for
GFAP.
(A) The schematic shows one of the coronal planes on which the corpus callosum was
analyzed (Bregma +2.0 mm). Representative images of 30 µm thick sections were taken
from the dotted outline; 200 µm scale bar. Black triangles identify representative blood
vessels with extensive astrocyte wrapping, as commonly observed in Wt-AngII rats; in
comparison, white triangles identify representative blood vessels with relatively
incomplete astrocyte wrapping, as observed in Tg-AngII rats.
(B) AngII infusion was found to have a significant effect on astrocyte activity in the corpus
callosum and cingulum (p < 0.05). This was driven by significant differences between Wt
and Wt-AngII rats only.
(C) Elevated mean arterial pressure linearly increased reactive astrocytosis in wildtype
rats (R2 = 0.52, p=0.0007), but not transgenic rats. n = 9 – 10; error bars indicate SEM.
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4.3.3 Activated Microglia
Activated microglia were found infrequently in Wt and Wt-AngII rats but they did appear
consistently in major white matter tracts and the hippocampus of Tg and Tg-AngII rats
(Figure 4-3A). Both Tg and Tg-AngII rats demonstrated a significant increase of microglia
activation in the corpus callosum, cingulum, internal capsule, and hippocampus (Figure
4-3B; corpus callosum: p < 0.0001, F(1,33) = 22.02; cingulum: p = 0.006, F(1,33) = 14.26;
internal capsule: p = 0.0005, F(1,33) = 15.33; hippocampus: p = 0.03, F(1,33) = 5.248).
Neither AngII infusion nor MAP had any significant relationship with microglia activation
in these regions.
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Figure 4-3: Increased white matter and hippocampal microglia activation in
transgenic rats.
(A) Representative images show activated pro-inflammatory microglia in the corpus
callosum and cingulum, identified using DAB mediated IHC with the OX6 primary antibody
for MHC II. 30 µm thick coronal sections; 200 µm scale bar.
(B) Genotype was a significant factor in microglial activation in all regions analyzed.
n = 8 – 10; error bars indicate SEM.
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4.3.4 Open Field
Exploratory behaviour was evaluated by measuring the total distance travelled in the open
field test; a subanalysis also evaluated the first 5 min period of the 20 min test, during
which relatively more exploration occurs (Figure 4-4A). Genotype was a significant factor,
with Tg and Tg-AngII rats having demonstrated less exploration (first 5 min: p = 0.006,
F(1,51) = 8.342; full 20 min: p < 0.0001, F(1,51) = 22.39; 2-Way ANOVA). AngII infusion
did not have an effect on exploratory behaviour. The centre of the field is considered to
be anxiogenic, but there were no significant group differences in the proportion of time in
the centre during either the first 5 min period or the full 20 min test duration (Figure 4-4B).
Thus, anxiety is unlikely to have confounded behavioural measures.
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Figure 4-4: Reduced exploratory behaviour in transgenic rats.
(A) Tg and Tg-AngII travelled significantly less during both the first 5 min period of the
test and during the full 20 min test, while AngII had no significant effect on distance
travelled.
(B) No significant group differences were observed in avoidance of the anxiogenic centre
of the open field.
n = 13 – 15; error bars indicate SEM.
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4.3.5 Morris Water Maze
No group differences were observed in spatial learning and memory (Figure 4-5A).
However, AngII infusion appeared to impair performance on delayed match-sample
testing (Figure 4-5B). On the ‘sample’ trial, rats were challenged to find a new platform
location every day from a new platform location for 5 days. Swim time improvement was
then evaluated on a 6 h delayed ‘match’ trial. Trial-unique information of changing spatial
parameters every day places demands on spatial reference memory, working memory,
and behavioural flexibility47,48. Both Wt and Tg rats demonstrated significant non-zero
swim time improvements on the match trial (Wt: p = 0.003, t = 4.482, df = 12; Tg: p = 0.03,
t = 3.082, df = 13; one-sample t-test with Bonferonni correction). In contrast, AngII infusion
impaired rats of both genotypes, so that Wt-AngII and Tg-AngII did not demonstrate a
significant swim time improvement. The frequently changing spatial parameters of
delayed match-sample testing placed greater demands on spatial reference memory,
working memory, and behavioural flexibility47,48. However, no group differences were
observed in spatial reference memory (Figure 4-5A), so AngII infusion is more likely to
have impaired working memory and/or behavioural flexibility. During cued trials, no
differences were observed in swim time to platform nor swim speed, so visual acuity nor
mobility were unlikely to have had any confounding effect.
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Figure 4-5: AngII infusion impaired behavioural flexibility.
(A) With a fixed start location, rats were given 6 trials to learn the platform location; 24 h
later, a test trial evaluated spatial memory. No significant group differences were
observed on the learning or test trials.
(B) Every day for 5 days, rats were challenged to learn a new platform location from a
new start location. The randomized start and platform locations are indicated by
corresponding number pairs. After the first exposure to a new platform location on a
‘sample’ trial, swim time improvement was measured on a 6 h delayed ‘match’ trial. * Wt
and Tg rats demonstrated a significant swim time improvement on the match trial (p <
0.03) but Wt-AngII and Tg-AngII rats did not, suggesting that AngII infusion impaired
working memory and/or behavioural flexibility.
n = 13 – 15; error bars indicate SEM.
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4.5

Discussion

Normotensive Tg rats had an elevated baseline of reactive astrocytes in the corpus
callosum and cingulum, while Tg-AngII rats did not show a further increase of
astrocytosis. The increase of reactive astrocytes in Wt-AngII rats was accompanied with
extensive astrocytic processes around blood vessels, which was less consistent and
relatively incomplete in Tg-AngII. This suggested that astrocytes in transgenic rats did not
develop a normal response to elevated blood pressure; the role of transgenic hAPP in
this insufficient response is supported by previous findings of amyloid overwhelming
astrocytes and inducing senescence in astrocytes52,53. AngII infusion impaired both WtAngII and Tg-AngII rats in the MWM adaptation of a delayed match-sample test, a spatial
task that tests working memory and behavioural flexibility, consistent with the clinical
studies on the cognitive effects of hypertension21-23. While AngII infusion did not affect
activation of microglia in either genotype, Tg and Tg-AngII rats demonstrated significantly
more pro-inflammatory activation of microglia in the corpus callosum, cingulum, internal
capsule, and hippocampus. This further indicates dysregulation in the cerebral tissue of
TgAPP21 rats and implicates pro-inflammatory microglia as an important factor in the
early pre-plaque stages of AD42,43. White matter microgliosis has also been identified as
an important early factor of neurodegeneration in recent animal and human studies54,55.
Previous studies have found detrimental histological and cognitive effects of AngII
infusion or AngII blockade to be independent of blood pressure, which has been attributed
to the central effects of AngII56-59. However, these studies did not present data on white
matter pathology in particular. In contrast, we observed a linear astrocytic response to
blood pressure elevation in the corpus callosum and cingulum of wildtype rats. While
pathogenic amyloid may have obscured a linear relationship between blood pressure and
white matter astrocytosis in the TgAPP21 rats, as it might in clinical studies, our finding
suggests that the neurological benefit of AngII blockade may still be dependent on
adequate blood pressure reduction when it comes to white matter integrity. This is
particularly important for the ongoing research on therapeutic targets in the management
of high blood pressure.
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Perspectives
White matter and executive function are particularly vulnerable to hypertension, which is
reinforced by the findings of the present study. Future preclinical research on the cerebral
and cognitive effects of hypertension should evaluate more specific metabolic parameters
of white matter function and the specific cognitive subdomains of executive function. The
comorbidity of hypertension and pathogenic amyloid may also have an overwhelming
effect on astrocytes, which are central to the maintenance of the neurovascular unit. Thus,
identifying specific molecular targets in the astrocyte, such as cell signalling factors, may
prove to be crucial to managing the intersection of cerebrovascular and AD-related
pathology. Characterizing these dysregulations induced by hypertension and amyloid will
be crucial to refining ongoing research on the neuroprotective effects of antihypertensive
treatment.

154

4.6

References

1.

Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed
neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain.
2013;136(Pt 9):2697-2706.

2.

Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia:
the canadian study of health and aging. Arch Neurol. 2010;67(2):187-192.

3.

Iadecola C. Hypertension and dementia. Hypertension. 2014;64(1):3-5.

4.

Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet.
2017;390(10113):2673-2734.

5.

Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE);
outcomes in patients not receiving add-on therapy after randomization. J Hypertens.
2004;22(8):1605-1612.

6.

Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the
Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a doubleblind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689.

7.

McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior
cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database
Syst Rev. 2009(4):CD004034-CD004034.

8.

Sörös P, Whitehead S, Spence JD, et al. Antihypertensive treatment can prevent stroke and
cognitive decline. Nat Rev Neurol. 2013;9(3):174-178.

9.

Perrotta M, Lembo G, Carnevale D. Hypertension and Dementia: Epidemiological and
Experimental Evidence Revealing a Detrimental Relationship. Int J Mol Sci. 2016;17(3):347.

10.

Walker V, Davies N, Kehoe P, Martin R. Can treatments for hypertension be repurposed for the
treatment of dementia? Revue d'Épidémiologie et de Santé Publique. 2018;66:S262-S262.

11.

Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci.
2005;28(4):202-208.

12.

Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other
disorders. Nat Rev Neurosci. 2011;12(12):723-738.

13.

Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular
dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419-434.

14.

Tomassoni D, Avola R, Di Tullio MA, Sabbatini M, Vitaioli L, Amenta F. Increased expression of
glial fibrillary acidic protein in the brain of spontaneously hypertensive rats. Clin Exp Hypertens.
2004;26(4):335-350.

15.

Dunn KM, Nelson MT. Neurovascular signaling in the brain and the pathological consequences of
hypertension. Am J Physiol Heart Circ Physiol. 2014;306(1):H1-14.

16.

Shen XZ, Li Y, Li L, et al. Microglia participate in neurogenic regulation of hypertension.
Hypertension. 2015;66(2):309-316.

155
17.

van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension,
and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension.
2004;44(5):625-630.

18.

O'Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS. Diffusion tensor MRI
correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg
Psychiatry. 2004;75(3):441-447.

19.

Altamura C, Scrascia F, Quattrocchi CC, et al. Regional MRI Diffusion, White-Matter
Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular Dementia. J Clin
Neurol. 2016;12(2):201-208.

20.

Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic
resonance imaging: systematic review and meta-analysis. BMJ. 2010;341(jul26 1):c3666.

21.

Raz N, Rodrigue KM, Acker JD. Hypertension and the brain: vulnerability of the prefrontal regions
and executive functions. Behav Neurosci. 2003;117(6):1169-1180.

22.

Vicario A, Martinez CD, Baretto D, Diaz Casale A, Nicolosi L. Hypertension and cognitive decline:
impact on executive function. J Clin Hypertens (Greenwich). 2005;7(10):598-604.

23.

Li X, Ma C, Sun X, et al. Disrupted white matter structure underlies cognitive deficit in hypertensive
patients. Eur Radiol. 2016;26(9):2899-2907.

24.

Tagami M, Nara Y, Kubota A, Fujino H, Yamori Y. Ultrastructural changes in cerebral pericytes and
astrocytes of stroke-prone spontaneously hypertensive rats. Stroke. 1990;21(7):1064-1071.

25.

Yamagata K, Tagami M, Nara Y, et al. Faulty induction of blood-brain barrier functions by astrocytes
isolated from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol.
1997;24(9-10):686-691.

26.

Tomassoni D, Bramanti V, Amenta F. Expression of aquaporins 1 and 4 in the brain of
spontaneously hypertensive rats. Brain Res. 2010;1325:155-163.

27.

Wang Y, Zhang R, Tao C, et al. Blood-Brain Barrier Disruption and Perivascular Beta-Amyloid
Accumulation in the Brain of Aged Rats with Spontaneous Hypertension: Evaluation with Dynamic
Contrast-Enhanced Magnetic Resonance Imaging. Korean J Radiol. 2018;19(3):498-507.

28.

Huang J, Li J, Feng C, et al. Blood-Brain Barrier Damage as the Starting Point of Leukoaraiosis
Caused by Cerebral Chronic Hypoperfusion and Its Involved Mechanisms: Effect of Agrin and
Aquaporin-4. Biomed Res Int. 2018;2018:2321797.

29.

Diaz-Ruiz C, Wang J, Ksiezak-Reding H, et al. Role of Hypertension in Aggravating Abeta
Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovasc Psychiatry Neurol.
2009;2009:107286.

30.

Gentile MT, Poulet R, Di Pardo A, et al. Beta-amyloid deposition in brain is enhanced in mouse
models of arterial hypertension. Neurobiol Aging. 2009;30(2):222-228.

31.

Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain beta-amyloid accumulation,
cognitive impairment, and memory deterioration through activation of receptor for advanced
glycation end products in brain vasculature. Hypertension. 2012;60(1):188-197.

156
32.

Csiszar A, Tucsek Z, Toth P, et al. Synergistic effects of hypertension and aging on cognitive
function and hippocampal expression of genes involved in beta-amyloid generation and
Alzheimer's disease. Am J Physiol Heart Circ Physiol. 2013;305(8):H1120-1130.

33.

Cifuentes D, Poittevin M, Dere E, et al. Hypertension accelerates the progression of Alzheimer-like
pathology in a mouse model of the disease. Hypertension. 2015;65(1):218-224.

34.

Carnevale D, Perrotta M, Lembo G, Trimarco B. Pathophysiological Links Among Hypertension
and Alzheimer's Disease. High Blood Press Cardiovasc Prev. 2016;23(1):3-7.

35.

Agca C, Fritz JJ, Walker LC, et al. Development of transgenic rats producing human beta-amyloid
precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are
regulated tissue-specifically. BMC Neurosci. 2008;9:28.

36.

Rosen RF, Fritz JJ, Dooyema J, et al. Exogenous seeding of cerebral beta-amyloid deposition in
betaAPP-transgenic rats. J Neurochem. 2012;120(5):660-666.

37.

Silverberg GD, Miller MC, Pascale CL, et al. Kaolin-induced chronic hydrocephalus accelerates
amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP.
Fluids Barriers CNS. 2015;12(1):2.

38.

Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac
hypertrophy through its receptors in the kidney. 2006. 0605545103.

39.

Osborn JW, Fink GD, Kuroki MT. Neural mechanisms of angiotensin II-salt hypertension:
implications for therapies targeting neural control of the splanchnic circulation. Curr Hypertens Rep.
2011;13(3):221-228.

40.

Lohmeier TE. Angiotensin II infusion model of hypertension: is there an important sympathetic
component? Hypertension. 2012;59(3):539-541.

41.

von Bernhardi R, Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and
proinflammatory factors. Brain Res. 2004;1025(1-2):186-193.

42.

von Bernhardi R, Eugenin-von Bernhardi L, Eugenin J. Microglial cell dysregulation in brain aging
and neurodegeneration. Front Aging Neurosci. 2015;7:124.

43.

Prokop S, Miller KR, Heppner FL. Microglia actions in Alzheimer’s disease. Acta neuropathologica.
2013;126(4):461-477.

44.

Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure
recording tail-cuff blood pressure measurements. Am J Hypertens. 2008;21(12):1288-1291.

45.

Kurtz TW, Griffin KA, Bidani AK, et al. Recommendations for blood pressure measurement in
humans and experimental animals. Part 2: Blood pressure measurement in experimental animals:
a statement for professionals from the subcommittee of professional and public education of the
American Heart Association council on high blood pressure research. Hypertension.
2005;45(2):299-310.

46.

Roof RL, Schielke GP, Ren X, Hall ED. A comparison of long-term functional outcome after 2 middle
cerebral artery occlusion models in rats. Stroke. 2001;32(11):2648-2657.

47.

Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms
of learning and memory. Nat Protoc. 2006;1(2):848-858.

157
48.

Bizon JL, LaSarge CL, Montgomery KS, McDermott AN, Setlow B, Griffith WH. Spatial reference
and working memory across the lifespan of male Fischer 344 rats. Neurobiol Aging.
2009;30(4):646-655.

49.

Wong WT. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front Cell
Neurosci. 2013;7:22.

50.

Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):735.

51.

Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. Amsterdam ; Boston ;:
Academic Press/Elsevier; 2007.

52.

Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer's disease.
PLoS One. 2012;7(9):e45069.

53.

Sollvander S, Nikitidou E, Brolin R, et al. Accumulation of amyloid-beta by astrocytes result in
enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol Neurodegener.
2016;11(1):38.

54.

Raj D, Yin Z, Breur M, et al. Increased White Matter Inflammation in Aging- and Alzheimer's
Disease Brain. Front Mol Neurosci. 2017;10(June):206.

55.

Hase Y, Horsburgh K, Ihara M, Kalaria RN. White matter degeneration in vascular and other
ageing-related dementias. J Neurochem. 2018;144(5):617-633.

56.

Tedesco MA, Ratti G, Di Salvo G, Natale F. Does the Angiotensin II Receptor Antagonist Losartan
Improve Cognitive Function? Drugs & Aging. 2002;19(10):723-732.

57.

Takeda S, Sato N, Takeuchi D, et al. Angiotensin receptor blocker prevented beta-amyloid-induced
cognitive impairment associated with recovery of neurovascular coupling. Hypertension.
2009;54(6):1345-1352.

58.

Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin receptor blockers on Alzheimer disease
neuropathology in a large brain autopsy series. Arch Neurol. 2012;69(12):1632-1638.

59.

Takane K, Hasegawa Y, Lin B, et al. Detrimental Effects of Centrally Administered Angiotensin II
are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure. J Am
Heart Assoc. 2017;6(4).

158

Chapter 5: Striatal Ischemic Injury Exacerbates Behavioural
Inflexibility
This study set out to evaluate the impact of comorbid pathogenic APP and
cerebrovascular injury on executive function (Objective 3) and was conducted in close
collaboration with Aaron M Regis, Vineeth Bhoadi, and Dr Seung-Hun Oh. The findings
presented here reflect my contribution which focused on behavioural evaluation, namely
set shifting. This study was published in Behavioural Brain Research.

5.1

Abstract

Alzheimer disease (AD) and stroke coexist and interact; yet how they interact is not
sufficiently understood. Both AD and basal ganglia stroke can impair behavioural
flexibility, which can be reliably modeled in rats using an established operant based setshifting test. Transgenic Fischer 344-APP21 rats (TgAPP21) overexpress pathogenic
human amyloid precursor protein (hAPP) but do not spontaneously develop overt
pathology, hence TgAPP21 rats can be used to model the effect of vascular injury in the
prodromal stages of Alzheimer disease. We demonstrate that the injection of endothelin1 (ET1) into the dorsal striatum of TgAPP21 rats (Tg-ET1) produced an exacerbation of
behavioural inflexibility with a behavioural phenotype that was distinct from saline-injected
wildtype & TgAPP21 rats as well as ET1-injected wildtype rats (Wt-ET1). In addition to
profiling the types of errors made, interpolative modeling using logistic exposureresponse regression provided an informative analysis of the timing and efficiency of
behavioural flexibility. During set-shifting, Tg-ET1 committed fewer perseverative errors
than Wt-ET1. However, Tg-ET1 committed significantly more regressive errors and had
a less efficient strategy change than all other groups. Thus, behavioural flexibility was
more vulnerable to striatal ischemic injury in TgAPP21.
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5.2

Introduction

It is well established that Alzheimer disease (AD) and stroke are frequently coincident
and interact mechanistically1-9. Stroke is not only a significant risk factor for AD2-5, but the
progression of AD is exacerbated in patients who had previously experienced a stroke6,9.
In addition to verbal and episodic memory deficits, AD is associated with impairments in
the cognitive processes underlying executive function, such as attention, working memory
and behavioral flexibility10-17. Separately, executive dysfunction can also occur in
association with vascular dementia induced by stroke18,19, including covert or ‘silent’
strokes in the basal ganglia19-22. In cases of comorbid stroke in AD patients, it is known
that lacunar infarcts, which affect the basal ganglia, thalamus, or deep white matter,
increase the odds of dementia at lower Braak stages1,23. At present, however, it is unclear
whether behavioural flexibility, an important component of executive function, is affected
by subcortical cerebrovascular injury coupled with AD-related pathology.
Over the past decade, a variety of preclinical rodent models have been developed to
investigate the comorbidity of AD and stroke, with focus on characterizing the behavioral
deficits associated with learning and memory-based tasks24-27. Conversely, behavioural
testing of executive function has not been comprehensively investigated in these models
even though, clinically, executive dysfunction plays a key role in the cognitive impairment
of both AD and stroke. Using operant conditioning-based paradigms, it is possible to
screen rodents for executive dysfunction, such as impairments in behavioral flexibility,
using tasks requiring set-shifting. Consistent with patients performing the Wisconsin Card
Sorting Test (WCST), a neuropsychological assessment of behavioral flexibility, these
set-shifting tasks challenge rodents to update their goal-directed strategies when the rules
governing what constitutes a correct behavioral response are suddenly changed28. Within
this context, it is reasonable to predict that a comorbid rodent model of AD and striatal
stroke would lead to significant deficits in behavioral flexibility because AD patients have
been found to perform worse on the WCST than age-matched control subjects29-33, and
patients with clinical features of stroke in their basal ganglia show an inability to shift
strategies during the WCST34,35. Consequently, establishing a preclinical model of
executive dysfunction in a comorbid rodent model of AD and stroke will facilitate future
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investigations into the underlying mechanisms and offer a platform for evaluating potential
therapeutic strategies.
In the present study, we endeavored to characterize behavioral flexibility following focal
striatal ischemic injury in aged Fischer 344 rats expressing pathogenic human amyloid
precursor protein (hAPP); the transgenic Fischer 344-APP21 rat (TgAPP21)
overexpresses hAPP with Swedish and Indiana mutations36. TgAPP21 rats do not
develop amyloid plaques spontaneously, but do develop amyloid deposits under
physiological cerebral stress 37,38, making this an ideal model to investigate the prodromal
phases of AD pathogenesis. An operant conditioned lever-pressing task 39,40 was used to
assess the set-shifting ability of 16-month old TgAPP21 rats 3 months after unilateral
striatal ischemia was induced with endothelin-1 (ET1) injection. The striatum was selected
for ischemic injury due to the clinical link between subcortical lacunar infarcts and poststroke cognitive impairment in the presence of amyloid pathology [1,9]. To characterize
behavioral flexibility, the overall performance and associated error profile of ET1-injected
TgAPP21 rats was compared to that of TgAPP21 rats without striatal ET1 injection, as
well as age-matched wildtype rats with and without ET1 injection.
Consistent with clinical studies of AD patients, we predicted that the TgAPP21 rats would
commit an increased number of errors and show increased perseverance (i.e., a failure
to suppress their actions associated with the previously-correct strategy) compared to
wildtype controls, and that these deficits in behavioural flexibility would be exacerbated
by a unilateral striatal ischemic injury. However, in contrast to our prediction, the ET1injected TgAPP21 rats committed more regressive errors. We further characterized this
unexpected yet robust behavioral phenotype with a logistic exposure-response curve to
interpolate group-wise error rates, providing an additional estimate for the efficiency and
timing of strategy change. Ultimately, we demonstrated that the combined stress of focal
striatal ischemic injury and mutant hAPP overexpression caused an exacerbation of
behavioral inflexibility in our comorbid rat model.
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5.3

Methods

5.3.1 Animals
Animal ethics and procedures were approved by the Animal Care Committee at Western
University (protocol 2014-016) and are in compliance with Canadian and National Institute
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23).
All rats used in this study were housed in facilities maintained by Western University
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. To model
increased brain concentrations of amyloid protein, we used homozygous transgenic
Fischer 344-APP21 rats (TgAPP21). Developed by lentiviral infection of zygotes,
TgAPP21 rats overexpress a pathogenic human APP sequence with Swedish and
Indiana mutations, and produce high levels of beta-amyloid (both 1-40 and 1-42)36.
TgAPP21 rats were bred and aged in house, alongside wildtype Fischer 344. TgAPP21
homozygosity was validated using tissue samples from pups. In total, 22 transgenic male
(Tg) and 18 male wildtype (Wt) rats with body mass ranging from 340-450g, aged 13
months, were used in this study.

5.3.2 Endothelin-1 Focal Ischemic Injury
Focal striatal ischemia was modelled using a unilateral injection of ET1, a potent
vasoconstrictor, into the dorsal striatum of the right hemisphere41. Wildtype (Wt) and
transgenic (Tg) rats were randomly selected for ET1 or saline injection: n = 8 Wt; n = 10
Wt-ET1; n = 9 Tg; and n = 13 Tg-ET1. Surgery was performed with isoflurane anaesthetic
(Baxter Corporation, Missisauga, Canada; 4% with 2.0 L/min of oxygen for induction,
shifted to 2% isoflurane once in surgical plane). Prior to surgery, 0.03 mg/kg
buprenorphine diluted in 0.9% sterile sodium chloride (saline) was administered
subcutaneously. Anaesthetized rats were secured in a Kopf stereotaxic frame and a
single injection of ET1 (60 pmol dissolved in 3 µl sterile 0.9% saline) was injected
unilaterally over 5 min into the right dorsal striatum (AP: +0.5 mm, ML: 3.0 mm, DV: 5.0
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mm relative to Bregma) using a 32-guage Hamilton syringe (Hamilton Company, Reno,
NV). Rats injected with equal volume of sterile saline underwent identical procedures with
equivalent time under isoflurane anaesthesia, pre- and post-operative care. Following
ET1 or saline injection, rats were injected with 0.03 mL of antibiotic (intramuscular
enrofloxacin/Baytril, Bayer Inc., Toronto, Canada), monitored during recovery, single
housed, and observed for 3 months. Strategy set shifting tests began 3 months after
surgery at 16 months of age, followed by euthanasia at 17 months of age.

5.3.3 Thionine Histochemistry
Thionine staining was used to detect cellular Nissl substance and regions of glial scarring
and cell loss due to ischemic injury42. 4 months after saline or ET1 injection (following
behavioural testing), brain tissue was collected after transcardiac perfusion with freshly
depolymerized and buffered 4% paraformaldehyde solution (PFA). The tissue was postfixed in PFA for 24 h before transfer to 30% sucrose cryoprotectant. 30 µm coronal brain
sections were first washed in 0.01 M PBS to remove residual cryoprotectant. Sections
were mounted using 0.3% gelatin on SuperFrost Plus slides (VWR International, PA,
USA) and left to dry for 24 h prior to staining. Mounted sections were rehydrated from
100% ethanol to ddH20, followed by 30 s exposure to a solution of 0.25% thionine (0.25%
thionine acetate salt, 0.28% NaOH, 0.9% glacial acetic acid in ddH20). Slides were then
dehydrated from 50% ethanol to Xylene, followed by cover slipping with DePex mounting
medium (DePex, BDH Chemicals, Poole, UK).

5.3.4 Microscopy and Striatal Injury Analysis
Stained sections were analyzed using a Nikon Eclipse Ni-E upright microscope with a
Nikon DS Fi2 colour camera head (NIS Elements Imaging), stitched photomicrographs
using 2x and 10x objective lenses captured the region of injection, and anatomical
identification was verified with a rat brain atlas43. Infarct area was quantified by outlining
regions of glial scarring and cell loss; for each rat, infarct areas were averaged from two
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adjacent coronal sections at the injection site (AP: 1.92 mm relative to Bregma). Infarct
areas were observed in Wt-ET1 and Tg-ET1 rats, but not Wt and Tg rats (n = 6 for all
groups). During imaging and infarct area measurement, the experimenter was blinded to
rat ID and experimental group.

5.3.5 Set-Shifting
The set shifting protocol, which includes side bias determination, is detailed in 2.3.2 Set
Shift & Reversal on page 53. As the experiments in this chapter were performed prior the
experiments of Chapter 2 & 3, the response discrimination retrieval test and reversal
sessions were not yet implemented.
Briefly, rats were food restricted and maintained at 85-87% of free-feed mass to ensure
motivation for 45mg sucrose pellets (Dustless precision pellets, Bio-Serv; Burlington, ON)
during behavioural reinforcement in a sound-attenuated operant conditioning chamber
(Med Associates; St. Albans, VT). During all training and testing, lever presses were
reinforced with a sucrose pellet using a fixed-ratio 1 schedule. Habituation to the operantchamber was followed by initial lever-press training; rats were required to lever press on
at least 85 of 90 trials of lever presentations, pseudorandomly alternating sides, before
progressing to visual cue discrimination.
24 h after initial training, rats were given 100 trials to learn visual cue discrimination. In
each trial, both levers were extended but only the lever paired with the cue light, which
pseudorandomly alternated sides, would yield a sucrose pellet reward when pressed
(Figure 2-1 on page 58). The passing criterion for visual discrimination was 8 correct
consecutive responses. 24 h after meeting criterion, a retrieval session of 20 visual cue
discrimination trials was run to evaluate retention. Immediately after the retrieval session,
120 trials of response discrimination were initiated: only one lever would yield a sucrose
pellet on all trials, even though the cue light continued to alternate sides. For each rat, the
lever opposite a previously determined side bias was selected to be rewarding during
response discrimination44. This challenged the rats to ignore the previously learned visual
cue discrimination and to acquire a spatial strategy, constituting an extra-dimensional set
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shift. As described previously44, response discrimination trials were binned into 16 trials
of 8 congruent and 8 incongruent trials. Perseverative errors were scored when rats
reverted to visual cue discrimination on incongruent trials; once rats demonstrated
disengagement from visual cue discrimination (5 or fewer errors in a block of 8
incongruent trials), subsequent reversion to visual cue discrimination on incongruent trials
was scored as regressive errors. Incorrect lever presses on congruent trials were scored
as never-reinforced errors. Omissions (no lever press) were not treated as an error. The
passing criterion for response discrimination was 8 correct consecutive responses. We
departed from common approaches to operant conditioning chamber based set shifting45
in that we allowed rats to complete all 120 trials of response discrimination instead of
removing them from the chamber once they achieved criterion. This allowed us to quantify
the number of errors committed after criterion, offering a more complete measure of
regressive behaviour.
During all discrimination tests (visual cue, response), rats were granted a 10 s response
period during which the chamber was illuminated. If the correct lever was pressed, the
chamber remained illuminated for another 4 s so that rats could retrieve the sucrose pellet
reward. This was followed by a dark inter-trial period so that trials lasted a total of 30 s.
Cue lights were presented 3 s before lever extension and extinguished upon lever press
or the end of the 10 s response period.
In addition to profiling the types of errors committed, we also applied a logistic modelling
of group-wise error rates. This produced an exposure-response learning curve that could
be used to interpolate when 50% of a groups’ responses had transitioned to the new
strategy (equivalent to the IC50 of a logistic curve) and the efficiency of this transition (Hill
slope). Logistic modelling allowed for variable slopes and was bound by a 0% and 100%
error rate. If a group required more trials to reach 50% strategy change (greater IC50
value), then the group had a delayed strategy change. A shallower exposure-response
curve (lower Hill slope), indicated a reduced efficiency of strategy change. All set-shifting
behavioural indices are summarized in Appendix Table A-1 on page 209.
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5.3.4 Data Analyses
All statistical analyses were conducted using GraphPad Prism 7.0 software (GraphPad,
La Jolla, CA). Data are summarized in figures as means ± SEM. Two-way analysis of
variance (ANOVA) analyzed the effects of genotype (Wt/Tg) and injection (saline/ET1)
and the interaction between these two independent factors; Tukey post-hoc tests were
used to compare individual groups where main effects were found to be significant.
Significance was determined with α = 0.05.
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5.4

Results

5.4.1 Striatal Ischemic Injury
To quantify the extent of residual striatal ischemic injury 4 months after ET1 injection,
thionine staining of Nissl bodies was used to identify regions of glial scarring and cell loss.
While saline injected rats (Figure 5-1AC) displayed healthy neuronal cell populations
visualized using a 10x microscope objective (Figure 5-1EG), scarring in ET-1 treated rats
(Figure 5-1BD) was detected by a loss of neurons and the presence of dense populations
of glial cells (Figure 5-1FH). No significant differences were observed between the infarct
areas of Wt-ET1 (0.85 +/- 0.24 mm2) and Tg-ET1 (0.59 +/- 0.16 mm2) rats (Figure 5-1I;
unpaired t-test).

167

Figure 5-1: Wt-ET1 and Tg-ET1 have equal infarct areas in the ipsilateral striatum
Representative images of thionine stained coronal sections from Wt (A), Wt-ET1(B), Tg
(C) and Tg-ET1 (D), captured with a 2x object lens. The black rectangles outline
respective images captured with 10x objective lens magnification (E-H). Magnified
images of the dorsal striatum reveal typical striatal cellular morphology in saline injected
Wt and Tg rats (E,G) while Wt-ET1 and Tg-ET1 rats (F,H) have residual scars and cell
loss resulting from ischemic injury; these scars are outlined by red dashes (B,D). Scale
bar is 1 mm in 2x photomicrographs (A-D), and 200 μm in 10x photomicrographs (E-H).
Regions of residual scarring and cell loss in ET1 injured rats were used to quantify infarct
area in the ipsilateral striatum with n = 6 samples for both groups; mean infarct area did
not differ between Wt-ET1 and Tg-ET1 rats (I).
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5.4.2 Visual Cue Discrimination
The VCD task demonstrated equal capacity for associative learning across all four
experimental groups, as a two-way ANOVA revealed no differences in the number of trials
needed to achieve the performance criterion (i.e., 8 correct consecutive responses)
(Figure 5-2A). To determine whether genotype and/or injection affected memory retrieval
of the original VCD strategy, rats were tested on 20 VCD trials the following day, just prior
to the RD task (i.e., set-shifting). All groups accurately retrieved the original strategy,
selecting the visual-cue paired lever on ≥ 80% 20 VCD trials (Figure 5-2B); no differences
were found across groups on the 20 VCD retention trials (p>0.05, two-way ANOVA)
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Figure 5-2: Visual cue discrimination learning and memory retrieval
(A) The number of trials before criterion (8 correct consecutive responses) did not differ
across groups, indicating no differences in learning of visual cue discrimination (VCD).
(B) On the following day of testing, prior to response discrimination trials, a set of 20 VCD
trials were performed. No differences were observed across groups in the number of
correct responses, indicating a lack of effect of genotype or injection on the retention of
the VCD strategy.
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5.4.3 Set-shifting: Response Discrimination
Behavioral flexibility was assessed by comparing each group’s ability to set-shift following
the transition from the VCD task (i.e., “follow the light) to the RD task (i.e., only the lever
opposite the rat’s side bias was always correct; Figure 2-1 on page 58). A two-way
ANOVA found that ET1 injection caused a delay in the number of trials needed to achieve
the performance criterion (8 correct consecutive responses; F(1,36) = 7.575, p = 0.009),
such that Wt-ET1 and Tg-ET1 rats took longer to consistently engage the new strategy
(Figure 5-3A). However, in contrast to our prediction, there were no group differences
observed in either the number of errors to criterion (Figure 5-3B), errors made after
achieving the performance criterion (Figure 5-3C), or total errors committed over the 120
RD trials (Figure 5-3D).
To further investigate our prediction that the TgAPP21 would demonstrate a greater
increase in perseverance following striatal ischemic injury, we compared the error profiles
across the treatment groups. A two-way ANOVA revealed a main effect for genotype
whereby the transgenic rats actually performed fewer perseverative errors (F(1,36) =
4.373, p = 0.04), yet more never-reinforced errors (F(1,36) = 9.04, p = 0.005) and more
regressive errors (F(1,36) = 9.951, p = 0.003) compared to wildtype rats (Figure 5-4).
Moreover, this main effect of genotype to decrease the number of perseverative errors as
well as increase the number of regressive errors was driven by the Tg-ET1 group; these
rats demonstrated significantly fewer perseverative errors than the Wt-ET1 group (p =
0.04; Tukey’s post hoc test), and significantly more regressive errors than all the other
groups (Wt p<0.0001, Wt-ET1 p = 0.02, Tg p = 0.003; Tukey’s post hoc test). Finally,
striatal injection of ET1 also produced an overall increase in the number of regressive
errors committed (F(1,36) = 18.15, p = 0.0001). Collectively, these results suggest an
interactive effect of ET1 injection and pathogenic hAPP expression on the error profile;
however, instead of increased perseverance, these comorbid rats seemed to show a
difficulty in maintaining the new strategy as the task progressed (i.e., they continued to
regress to the original strategy).
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Figure 5-3: Response discrimination learning and number of errors committed
during set-shifting
(A) A two-way ANOVA revealed that injection of ET1 significantly increased the number
of trials to criterion (8 correct consecutive responses; p = 0.009), indicating a broad
impairment of cognitive flexibility in ET1 injected rats. No significant effects were observed
on the number of errors that were made prior to criterion (B), errors committed after the
rats had achieved the test criterion (C), or total errors made over the 120 trials (D).
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Figure 5-4: Set-shift error profile
The combination of transgene expression and ET1 injection drove the strongest change
in the error profile. Among ET1 injected rats, only the Tg-ET1 group demonstrated a
change in the number of perseverative errors (*p = 0.04, Tukey’s post hoc test). Tg-ET1
also showed the greatest increase in regressive errors; #Tg-ET1 committed more
regressive errors than Wt, Wt-ET1, and Tg (#p<0.0001, p = 0.02, and p = 0.003
respectively, Tukey’s post hoc tests). Genotype had a significant main effect on the
number of perseverative errors, never-reinforced errors, and regressive errors (p = 0.04,
p = 0.005, and p = 0.003 respectively), whereas injection type had a significant main effect
on regressive errors (p = 0.0001).
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5.4.4 Logistic Modelling: Exposure-Response Curve
The number of trials to criterion and error profiles do not capture the incremental changes
that occur in each trial of RD. In contrast, a logistic model of mean group-wise error rates
(Figure 5-5A) produced a behavioural exposure-response learning curve derived from all
incongruent trial data (including omission trials), and therefore the incremental effect of
each incongruent opportunity could be interpolated. The key indices of the exposureresponse learning curves could then characterize each experimental group: the number
of trials to 50% strategy change (equivalent to the IC50 of the logistic curve) is an index
of when the strategy occurred, and the Hill slope of the logistic curve is an index of how
efficiently that strategy change occurred.
The error rates were well modelled by a logistic curve (R2 = 0.74 - 0.92; Figure 5-5A), and
both the number of trials to 50% strategy change and Hill Slope were significantly different
across groups (F(6,232) = 14.98, p<0.0001). ET1 injection had a significant effect on the
number of trials to 50% strategy change (F(1,36) = 17.36, p = 0.0007; Figure 5-5B). This
reflects a delay in strategy change and coincides with the significant increase in the
number of trials to RD performance criterion in Wt-ET1 and Tg-ET1 rats. However, the
effect of injection on 50% strategy change was driven by a strong interaction with
genotype (F(1,36) = 17.36, p = 0.0002); although ET1 injection increased the number of
incongruent trials to 50% strategy change in wildtype rats (24.77 for Wt versus 34.46 for
Wt-ET1), it had no effect on transgenic rats. The 50% strategy change was significantly
greater in Wt-ET1 than all groups (Wt p<0.0001; Tg p = 0.01; Tg-ET1 p = 0.002; Tukey’s
post hoc test). The Hill slope was also significantly affected by ET1 injection (F(1,36) =
12.66, p = 0.0011; Figure 5-5C) and was also driven by a strong interaction between ET1
injection and genotype (F(1,36) = 11.45, p = 0.0017). In contrast to the genotypedependent effect on 50% strategy change, the Hill slope was reduced in transgenic rats
but not in wildtype rats. The Hill slope was significantly less in Tg-ET1 than all other
groups (Wt p = 0.002; Wt-ET1 p = 0.001; Tg p<0.0001; Tukey’s post hoc test). Thus, ET1
injection delayed strategy change in wildtype rats but not transgenic rats, and ET1
injection reduced the efficiency of strategy change in transgenic rats but not wildtype rats.

174

Figure 5-5: Logistic modelling of incongruent trial error rates
In wildtype rats, ET1 injection delayed strategy change, but did not impair the efficiency
of strategy change. In transgenic rats, ET1 injection did not delay strategy change but
slowed down the efficiency of strategy change.
(A) Logistic exposure-response regression effectively models mean group errors rates on
incongruent trials (R2 = 0.74 - 0.92).
(B) Number of incongruent trials to 50% strategy change estimates how many response
discrimination opportunities are needed for half of a group's responses to demonstrate a
strategy change (i.e., when the strategy change occurs). ET1 injection had a significant
effect on trials to 50% strategy change (p = 0.0007), which was driven by the significant
difference between Wt and Wt-ET1 (p<0.0001, Tukey’s post hoc test); transgenic rats
injected with ET1 showed no change in the mean number of trials to 50% strategy change,
reflecting a significant interaction between genotype and injection (p = 0.0002). The WtET1 group required significantly more incongruent trials to attain 50% strategy change
than Wt, Tg, and Tg-ET1 rats (*p<0.0001, p = 0.01, and p = 0.002 respectively, Tukey’s
post hoc tests).
(C) The Hill slope quantifies the steepness of an exposure-response curve, which reflects
the efficiency of strategy change (i.e., how fast the strategy change occurs). ET1 injection
had a significant effect on the Hill slope (p = 0.001), but there was a significant interaction
between genotype and injection (p = 0.002) such that only transgenic rats demonstrated
an effect of ET1 injection. Consequently, the Tg-ET1 group had a significantly lower Hill
slope parameter than Wt, Wt-ET1, and Tg rats (#p = 0.002, p = 0.001, and p<0.0001
respectively, Tukey’s post hoc tests).
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5.5

Discussion

In the present study, an operant conditioning-based set-shifting task was used to
investigate behavioral flexibility in a novel model of the combined stress of focal striatal
ischemic injury and mutant pathogenic hAPP (Swedish/Indiana) expression in aged
Fischer 344-APP21 rats (TgAPP21). Our Tg-ET1 rats demonstrated an unexpected
increase in regressive errors but not perseverative errors. Studies of other conditions,
including acute stress, autism spectrum disorders, mania, and schizophrenia, have also
found surprising results regarding behavioural flexibility46-48, including increases of
regressive errors49-56. To develop a better understanding of regressive errors, we
complemented traditional metrics (the number of trials/errors to criterion; scoring of error
types) with a logistic regression model to help quantify the timing and efficiency of strategy
change.

5.5.1 Comorbidity of AD and Stroke
Numerous preclinical rodent models have investigated the mechanisms underlying the
sensorimotor and cognitive deficits associated with dementia, including comorbidity
models which specifically examined the interaction between AD and stroke on the
performance of learning and memory-based tasks (for review, see Thiel et al., 2014)9,2427.

Consistent with previous clinical investigations, the collective findings of these rodent

comorbidity studies have shown that the nature and extent of the cognitive impairments
depends on the age of the animals at the time of insult and assessment, as well as the
location and severity of ischemic injury. It is important to note, however, that despite over
a decade of animal research devoted to examining the interaction of AD and stroke, to
our knowledge, the present study represents the first investigation into the performance
deficits associated with set-shifting ability.
Compared to age-matched control subjects, AD patients have been found to commit more
total errors in the WCST, largely due to an increase in perseverance29,31,32. Similarly,
patients who experienced a clinically-documented stroke in their basal ganglia also
showed an inability to flexibly shift attention from one set of rules to another during the
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WCST34,35. Based on these clinical studies, we predicted that unilateral striatal ischemic
injury would exacerbate the number of perseverative errors committed by the transgenic
rats. Surprisingly, traditional error type profiling instead revealed that pathogenic hAPP
expression decreased the number of perseverative errors made but increased neverreinforced errors and regressive errors, whereas ET1 injection increased the number of
regressive errors only. The combined effect of pathogenic hAPP expression and ET1
injection significantly altered the types of errors committed such that the Tg-ET1 rats
made the fewest perseverative errors and the greatest number of regressive errors.
Interestingly, this increase in regressive errors is consistent with the error profile observed
following bilateral disruption of the dorsal striatum in wildtype rats49,52, even though the
Tg-ET1 group had only unilateral ischemic injury.
It is important to note that although the comorbid rats in the present study showed the
greatest change in error profile (Figure 5-4), it was not clear from these traditional
analyses whether this shift from perseverative errors towards regressive errors truly
reflected impaired behavioral flexibility, as the number of errors to criterion as well as the
total number of errors committed were not significantly affected by genotype or ET1
injection (Figure 5-3). Thus, we applied a logistic model of group-wise error rates to help
characterize whether Tg-ET1 rats demonstrated a true functional impairment of
behavioural flexibility.

5.5.2 Logistic Modelling: Exposure-Response Curve
The number of trials or errors to criterion provides some quantification of the timing of
strategy change. On the other hand, scoring error types (perseverative, never-reinforced
and regressive) helps to profile the components of set-shifting behaviour, but this
approach does not offer a clear sense of the timing off these errors. Furthermore, using
fixed 16-trial bins to distinguish perseverative and regressive blocks limits the temporal
resolution that can capture behavioural change. By interpolating group-wise error rates
using a logistic exposure-response regression model derived from all incongruent trials,
we could capture trial-by-trial behavioural changes. To that end, the IC50 of the logistic
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curve corresponded with when 50% strategy change had been achieved, whereas the
Hill slope corresponded with the efficiency of strategy change. We found that Tg-ET1 rats
indeed had the most impaired in the efficiency of strategy change (Figure 5-5C); although
they appeared to disengage from the visual cue strategy earlier, the Tg-ET1 had a less
efficient acquisition of RD. This also raises the possibility that the timing and the efficiency
of strategy change may be differentially impaired. These findings demonstrate the added
value of analyzing the set-shifting test using logistic modelling (Figure 5-5).

5.5.3 Clinical Relevance of Comorbid Model
In contrast to our predictions, the combined stress of pathogenic hAPP expression and
striatal ischemic injury produced a decrease in perseverative errors and a synergistic
increase in regressive errors during the set-shifting task. Consequently, it may appear
that our model does not replicate the increase of perseverative errors observed in mild
cognitive impairment, AD, and striatal stroke29-35. However, it is important to acknowledge
the possibility that differences in the semantics and paradigms of rodent set-shift tasks
and the WCST may prohibit the ability to draw clear parallels for specific components of
behavioural flexibility. For example, the WCST literature often describes perseverative
errors in a manner that encompasses both the perseverative and regressive errors as
classified in the present study54,55. Furthermore, ‘non-perseverative’ WCST errors can
also be subcategorized as ‘efficient errors’ and ‘random errors’, each associated with
distinct cognitive impairments and neural correlates57 that do not have analogous
parameters in a two-dimension set-shift paradigm like that of the present study.
In support of the clinical relevance of our rat model, we elected to investigate the impact
of unilateral, not bilateral, ET1 injections given that stroke victims are less likely to suffer
infarcts of the same anatomy bilaterally. A bilateral injection would likely yield greater
impairment of behavioural flexibility, and future studies using bilateral injections could be
helpful in revealing the extent of contralateral compensation that may occur in our
unilateral injection model. In the present study, rats were tested 3 months after ET1
injection (at 16 months of age) in order to capture the permanent impairment incurred by
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striatal ischemia, but also to capture the impact of pathogenic hAPP on longer-term
recovery. AD-related pathology has been proposed to impair angiogenesis and repair of
vascular injury due to the vasculotoxic accumulation of β-amyloid, which may be an
important mechanism by which coincident AD-related pathology and vascular injury have
synergistic effects58,59. However, it is noteworthy that infarct sizes did not differ between
Wt-ET1 and Tg-ET1 rats 4 months after ET1 injury, thus differences in residual infarct
size cannot account for the observed behavioural differences. In future studies, the age
at injection and subsequent testing (and the delay period in between) will be additional
important variables to consider, as well as the impact of therapeutic intervention and
rehabilitation.
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Chapter 6: Discussion
6.1

Summary

The studies presented in this thesis set out to advance a better understanding of the
interactions between pathogenic APP, white matter inflammation, cerebrovascular
disease, and executive dysfunction. In particular, these studies test the hypotheses that
ageing and pathogenic APP induces white matter inflammation, resulting in
executive dysfunction and that vascular injury exacerbates white matter
inflammation and executive dysfunction induced by ageing and pathogenic APP.
The TgAPP21 rat model of AD was studied to test these hypotheses and address the
following research objectives
1) To determine the effect of pathogenic APP on white matter inflammation and
executive function (Chapter 2 and Chapter 3)
2) To characterize the temporal relationship between age, pathogenic APP
expression, white matter inflammation, and executive function (Chapter 3)
3) To evaluate the impact of comorbid pathogenic APP and cerebrovascular stress
(hypertension; Chapter 4) or injury (ischemia; Chapter 5) on executive function
The TgAPP21 rat was found to spontaneously demonstrate a regressive form of
behavioural inflexibility, reversal impairments, and increased white matter microglia
activation (Chapter 2). When further characterized across 4 age points, TgAPP21 rats
demonstrated precocious white matter microglia activation (Chapter 3). Regressive
behavioural inflexibility and reversal impairments were also observed at an earlier age in
TgAPP21 rats (8 months), but Wt rats also demonstrated increased white matter
microglial activation with age and a regressive target quadrant preference at 13 months
of age. These findings support the hypothesis that both age and pathogenic APP induces
white matter inflammation, resulting in executive dysfunction. However, behavioural
inflexibility did not continue to increase with age while white matter microglia activation
did. Thus, the relationship between white matter inflammation and executive dysfunction
may be dynamic and age-dependent.
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In studying the impact of cerebrovascular disease, Wt rats demonstrated increased white
matter astrocytosis in response to hypertension, while TgAPP21 rats had an elevated
baseline of white matter astrocytosis that did not increase further in response to
hypertension (Chapter 4). Hypertension impaired the working memory and behavioural
flexibility of both Wt and TgAPP21 rats, while striatal ischemic injury exacerbated
regressive behavioural inflexibility in the TgAPP21 rats (Chapter 5). Though astrocytosis
was correlated with blood pressure in Wt rats, microgliosis did not increased in response
to blood pressure elevation in either Wt or TgAPP21 rats, which makes it unclear that
hypertension had an effect on white matter inflammation. However, the hypothesis that
cerebrovascular disease can exacerbate executive dysfunction, namely behavioural
flexibility and working memory, was supported by the MWM delayed match-sample test
results. Overall, the results presented in this thesis both support and suggest specific
revisions to the initial hypotheses, which are explored in the following sections.

6.2

Regressive Behavioural Inflexibility

Several deviations from common protocols used in behavioural testing proved to be highly
insightful. In the MWM, TgAPP21 rats demonstrated a regressive-like preference for the
target quadrant. To our knowledge, this behavioural phenomenon in the MWM has not
been previously described. While most implementations of the probe tests are performed
for only 30 – 60 s in order to avoid extinction1,2, performing the probe test for 90 s was
crucial to capturing regressive behaviour in the MWM. This also presents important
implications for the interpretation of the MWM test; behavioural inflexibility can confound
evaluations of memory in the MWM probe. A conventional interpretation of increased
target quadrant preference would suggest that TgAPP21 rats had more robust or precise
memory of the learned platform location. The absence of genotype differences on
memory dependent tasks, except in 22M Wt and TgAPP21 rats, makes it less likely that
the TgAPP21 rats’ increased target quadrant preference could be attributed to better
memory. At the same time, the TgAPP21 rats’ concurrent regressive behaviour during
RD supports the interpretation that the TgAPP21 rats’ increased preference for the target
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quadrant, particularly in the last 30 s of the probe test, could be attributed to regressive
inflexibility. Similarly, observing behaviour for a full 120 trials during RD, regardless of
when shift criterion was observed, identified differences in the number of errors committed
after criterion. In contrast, testing is commonly ceased once criterion is achieved3,
although an increase of errors after criterion suggests a highly aberrant regressive
inflexibility.
Thus, behavioural testing paradigms may benefit from minor modifications that better
capture regressive forms of behavioural inflexibility. This extends to clinical research as
well, as current neuropsychological evaluations in human subjects do not distinguish
between perseverative and regressive forms of inflexibility4-6. This may be attributed to
the recency of the notion of a regressive subtype of behavioural inflexibility, which was
first explicitly proposed by Ragozzino et al in 2002 in a rat model of dorsomedial striatal
injury with unimpaired perseverative flexibility but increased regressive inflexibility7.
However, dissociated impairments analogous to regressive inflexibility have been
previously described in patients with Parkinson disease7. Similar to the WCST, the
computerized Penn Conditional Exclusion Test (PCET) offers evaluation of cognitive
flexibility but with added differentiation of perseverative and regressive inflexibility8. The
application of the PCET in studies of autism spectrum disorder5,9 and schizophrenia4,10
identified dissociated increases of regressive cognitive flexibility, which were attributed to
dysfunction in the striatum and frontostriatal systems. Accordingly, ET1 injury in the
TgAPP21 rats’ striatum, a region commonly afflicted by SBI, resulted in an exacerbated
increase of regressive inflexibility. Other conditions that disrupt the frontostriatal system,
which includes extensive reciprocal connections carried in the white matter between the
frontal cortex and the striatum, may also feature regressive forms of inflexibility that have
been overlooked. This includes major depressive disorder11, schizophrenia12, bulimia
nervosa13, attention-deficit/hyperactivity disorder14, obsessive-compulsive disorder14,15,
frontotemporal dementia16, Parkinson disease7,17, and AD18,19. Thus, evaluation of
regressive cognitive flexibility may have far-reaching clinical significance in psychiatry and
neurology. In particular, our findings support the evaluation of regressive inflexibility in
patients at risk of AD, patients with MCI, or patients with cerebrovascular disease of the
frontostriatal system, using methods such as the PCET.
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6.3

White Matter Inflammation

While the importance of white matter integrity for executive function is widely supported
in the current literature, very few studies have explored the impact of white matter
inflammation on executive function in the context of neurodegenerative conditions. This
is despite evidence of white matter inflammation as a common feature of both AD20,21 and
VCI22. As new biomarker technology specific to white matter inflammation emerges,
including both PET and MRI23, and neuropsychological evaluation of both AD and VCI
continues to be refined, validating the link between white matter inflammation and
cognitive function will be important for evaluating future anti-inflammatory therapeutics.
White matter microglial activation has been linked to executive dysfunction in a rodent in
a mouse model of carotid artery occlusion24 and in a mouse model of catatonic
schizophrenia25. In human post-mortem studies, executive dysfunction was link to white
matter microglia and astrocytic activation in both dementia pugilistica and alcohol-related
neuropathology26,27. Our parallel findings of increased and precocious white matter
microglia activation and regressive behavioural inflexibility in the TgAPP21 rat contributes
to this limited literature and suggest that this neuropathological-cognitive correlate may
also present in clinical cases of AD. Microglia activation was not observed in response to
blood pressure increase, and reactive astrocytosis was not observed in AngII infused
TgAPP21 rats which may have reached an upper limit of astrocyte reactivity independent
of blood pressure. However, Wt rats demonstrated a linear increase in white matter
reactive astrocytosis in response to MAP increase. At the same time, AngII infused Wt
rats failed to demonstrate significant improvement in sample trial swim time in the MWM
delayed match-sample test, indicating impaired working memory and behavioural
flexibility. While it was less clear that hypertension caused white matter inflammation, as
compared to the effect of pathogenic APP expression on microglia activation, chronic
astrocytosis due to hypertension could lead to dystrophic astrocytes and dysfunctional
inflammation20,28. This is also consistent with the central role of astrocytes in maintaining
and recruiting microglia to the NVU29-31. These findings support further investigation of
white matter inflammation as a substrate of cognitive inflexibility and other forms of
executive dysfunction in patients diagnosed with or at risk of AD or VCI.
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6.4

Mixed Pathology

Large post-mortem studies strongly suggest that AD and VCI are not only frequently coincidental32,33, but also have synergistic effects on cognitive impairment33-35 and
neuropathology33,36-39. The significance of a synergistic relationship, as opposed to a
merely additive effect of two coincidental categories of neuropathology, is particularly
relevant to the development of therapeutic strategies. If mechanisms that link
cerebrovascular and AD pathology can be targeted, the burden of comorbidity could be
greatly reduced. This is highlighted by the self-propagating pathological cycle of NVU
dysfunction, for which targeted therapies are emerging40,41. Further studies are needed
to evaluate whether the absence of a white matter astrocytic response to hypertension in
AngII-infused TgAPP21 increased the risk of neuropathology. Thus, our current findings
are inconclusive on whether hypertension and pathogenic APP expression have
synergistic delirious effects. our finding of greatly altered pattern of behavioural flexibility
in TgAPP21 rats with focal striatal injury, namely an impaired efficiency in set shifting
manifesting with decreased perseverative errors and increased regressive errors. The
comorbidity of striatal ischemic injury and pathogenic APP expression created a
disruption of behavioural flexibility that was distinct from and greater than the effect of
either pathology alone. This behavioural disruption in the comorbid group also would not
have been predicted from an additive combination of either pathology, suggesting a
synergistic effect on cognition.

6.5

Limitations

Although TgAPP21 rats demonstrated greater regressive inflexibility as well as increased
and precocious white matter microglia activation, statistical power was not adequate for
evaluating direct correlations between behaviour and histology. In 8-month-old rats,
reversal errors did correlate with microglia activation in the supraventricular corpus
callosum, but this was not observed across all ages. Similarly, group-wise analysis
identified significant correlations between forceps minor astrocytosis and the number of
regressive errors, but this was not observed within the different age cohorts, including the
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8-month-old rats. Furthermore, while white matter microglia activation showed a
precocious and greater age-dependent increase in TgAPP21 rats, regressive behaviour
peaked at 8 months of age. While this indicates that white matter activated microglia and
reactive astrocytes cannot entirely predict behavioural flexibility, it does not preclude a
dynamic relationship.
Though genotype differences in white matter astrocytosis was not observed in 8-monthold rats, 9-month-old TgAPP21 rats infused with saline had greater reactive astrocytosis
than Wt rats infused with saline. While this difference was not significant, it was still
unexpected based on the findings presented in Chapters 2 and 3. This may indicate that
the methods used in Chapter 4 (anesthesia, surgery, AngII, or the osmotic minipump) had
different and non-benign effects on Wt and TgAPP21 rats, including white matter
astrocyte reactivity. Anesthesia and surgery have been found to activate microglia, which
can affect astrocyte activity42. However, isoflurane has also been shown to reduce
expression of GFAP in astrocytes43. Additional control groups for the methods of Chapter
4 could have identified whether or not the increased astrocytosis observed in TgAPP21
was truly spontaneous or the result of the methods used. However, controlling for each
major methodological variable (anesthesia, surgery, AngII, or the osmotic minipump) in
addition genotype and infusate would not have been feasible. Moreover, while these
potential confounds may challenge some of the interpretations regarding the direct effects
of blood pressure elevations in Wt and TgAPP21 rats, it would still indicate that TgAPP21
rats are more prone to increased astrocyte reactivity. Thus, physiological stressors are
still more likely to induce a level of astrocytosis in TgAPP21 rats that results in a ceiling
of reactivity, so that further astrocyte reactivity appears not to respond to increased blood
pressure.
Quantification of GFAP+ astrocytes and OX6+ microglia relied on cross-sectional area
coverage by DAB staining. This approach was decided on the basis that DAB IHC does
not follow a linear relationship between antigen quantity and chromogen level44-46, so
instead of falsely quantifying the level of GFAP or MHC II (the target of the OX6 antibody),
a binary detection of antigen-positive cells was used. This was particularly appropriate
with GFAP and MHC II, which respectively differentiate reactive astrocytes and activated
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microglia from quiescent astrocytes and microglia with incomplete but informative
selectivity47,48. Thus, increased area coverage with these antibodies indicated increased
activation of these glial cells, not increased protein expression. However, the dynamic
morphology of both astrocytes and microglia presents a major limitation on this method,
as ramification or amoeboid phases would alter a single cells’ cross-sectional area
coverage. The cross-sectional area of a reactive astrocyte is greater than a quiescent
astrocyte49, while ramified quiescent microglia have a greater mean cross-sectional area
than amoeboid microglia50. Thus, increased GFAP+ area coverage should reflect either
a greater number of reactive astrocytes or more extensive reactivity within the average
astrocyte, while the relationship between OX6+ area coverage and microgliosis is less
certain. Increased OX6+ area coverage could be due to an increase of quiescent ramified
microglia or due to a greater number of activated microglia. Qualitative observation of
OX6+ microglia found hyper-ramified or reactive states of activation as the most common
phenotype, regardless of the number of cells that were OX6+ positive. Moreover, MHC II
expression is linked upregulation of a key pro-inflammatory cytokine (IFN-γ) and
downregulation of anti-inflammatory cytokine (IL-10)51. Thus, while area coverage is an
imperfect DAB IHC measure of microglia activation, increased area coverage is still most
likely to indicate a pro-inflammatory environment.
Lastly, the TgAPP21 rat expresses a pathogenic variant of APP that is known to cause
autosomal dominant-inherited EOAD, which may involve distinct disease mechanisms
from LOAD. However, while leukoaraiosis was previously associated more with LOAD,
which was attributed to the more multifactorial nature of LOAD52, the recent DIAN study
found leukoaraiosis to also be a core feature of EOAD53. While the etiology of
leukoaraiosis continues to be studied, the TgAPP21 rat model still offers evaluation of the
role of white matter microglial activation in white matter integrity, which is pertinent to ageassociated cognitive decline, VCI, EOAD, and also LOAD.
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6.6

Future Directions

The studies presented in this thesis offer a foundation for several future directions of
research. The TgAPP21 rat has demonstrated plaque-independent behavioural
inflexibility, increased white matter inflammation, and increased vulnerability to
cerebrovascular disease, two expressions of AD that corroborate clinical studies but are
considered to be hallmarks of the disease. However, cognitive flexibility is important for
maintaining functional independence and both inflammatory processes and vascular
disease are responsive to current pharmacological interventions. Moreover, the TgAPP21
rat models early stages of AD, prior to accumulation of senile plaque and NFT; earlier
identification and treatment of AD has greater potential to delay cognitive decline54. Thus,
TgAPP21 rat model offers an important opportunity to learn more of the early stages of
AD, for which current diagnostic methods have limited specificity54, and to evaluate the
potential of therapeutic interventions such as anti-inflammatory medications and antihypertensive medications. While the benefit of NSAIDs for preventing AD has been
controversial, the most recent meta-analysis of 236 000 participants in 16 cohort studies
concluded that NSAID use significant reduced AD diagnosis rate by 19%, despite
considerable heterogeneity in drug and dosing regimen55. A randomized-controlled trial
did find reduced incidence when NSAID therapy was initiated in asymptomatic
participants but increased incidence when treatment was initiated in participants with
cognitive impairment or dementia56. Thus, early intervention may be essential, for which
the TgAPP21 rat would be a good model. Other emerging anti-inflammatory interventions
for AD, targeting TNF-α and activation of microglia and astrocytes, would be informed by
evaluation in the TgAPP21 rat model: rapamycin, minocycline, pioglitazone, thalidomide,
etanercept, and celastrol57-59. Investigating the benefit of anti-hypertensive drugs on
working memory impairment and astrocyte activity in the comorbid hypertensive
TgAPP21 rat could also model whether and how anti-hypertensive medication may offer
cognitive protection which currently, continues to be inconclusive60-65. Similarly, studying
the effect of therapeutics that may the extent of stroke injury in the TgAPP21 rat may
reveal important mechanisms that lead to post-stroke cognitive impairment and dementia.
This includes 3K3A-APC, a modified activated protein C which has anticoagulant and
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cytoprotective properties that has been shown to protect neurons and endothelial cells
following ischemic injury66,67. The modelling and treatment of other comorbidities and risk
factors in the TgAPP21 rat that were not evaluated in this thesis, such as hearing loss,
obesity, and diabetes mellitus type II68, may also be highly informative. Several major
categories of existing therapeutics are being evaluated in preclinical and clinical studies
for their potential as disease modifying treatments of AD, including medications used to
treat hypertension, diabetes, rheumatological conditions, viral infections, and cancer
57,69,70;

the TgAPP21 rat may be an important preclinical model for this effort, particularly

for evaluating intervention in earlier stages of AD and the impact on executive dysfunction
and neuroinflammation. Therapeutic studies that show an impact, either directly or
indirectly, on white matter microglial activation in the TgAPP21 rat would also offer
stronger mechanistic evaluation of the role of white matter inflammation in cognitive
impairment.
Establishing priorities for therapeutic intervention should be guided by further
characterization of the TgAPP21 rat. While behavioural flexibility and working memory
were studied in this thesis, testing paradigms have also been established for evaluation
of inhibitory control, namely the stop signal task71. Astrocyte and microglia were identified
using antibodies for GFAP and MHC-Class II but identifying the cell populations activated
in the TgAPP21 rat or in response to vascular injury with greater specificity would require
more selective molecular targets. In particular, co-labelling astrocytes and blood vessels
may focus investigation on astrocytes directly involved in NVU homeostasis; co-labelling
astrocytes and Aβ or other APP products would test whether increased astrocytosis in
TgAPP21 rats infused with saline in Chapter 4 was in response to amyloid burden.
Identifying subpopulations of activated microglia may also clarify the pro-inflammatory
stimulus in TgAPP21 rats. Molecular targets may specify whether activated microglia are
responding to amyloid protein (TREM-2, LRP receptors) or degenerated myelin
(complement receptors, scavenger receptors, Galectin-3/Mac-2)72. Importantly, the
impact of white matter microgliosis and astrocytosis on oligodendrocytes and myelin
should also be evaluated in the TgAPP21 rat, as demyelination and dysfunctional
oligodendrocytes has been observed in rodent models of AD and in post-mortem
evaluation of AD cases, though mechanisms remain speculative73. Similarly, the
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functional effects of potential axonal injury by microglia and astrocytes could be evaluated
by studying synaptic integrity74,75 in cortical, subcortical, and hippocampal tissue using
IHC76,77, morphological and ultrastructural analysis of synaptic spines78,79, or in vivo with
PET80,81. Electrophysiological evaluation would also offer important functional evaluation
of axonal and synaptic function82. Plaque-independent disruption of synaptic transmission
has been observed in mouse models of AD82, and white matter microglial activation in the
TgAPP21 warrants similar investigation.
PET imaging continues to emerge as a potentially critical diagnostic tool in AD diagnosis.
However, the use of PET in clinical AD research is dominated by radiotracers for amyloid
and tau protein. To study the role of microglia activation in AD, especially in the context
of comorbid cerebrovascular disease, PET offers an important opportunity for in vivo
evaluation. Radioligands have been developed to bind the translocator protein (TSPO),
an outer-mitochondrial-membrane bound protein that is upregulated in activated microglia
and astrocyte83-87. Preliminary data of the application of this technology in a comorbid
TgAPP21 rat with striatal ischemic injury is presented in Appendix F.

6.7

Conclusion

The findings presented in this thesis support the hypothesis that age and pathogenic APP
induce behavioural inflexibility and white matter inflammation, as indicated by microglial
activation and reactive astrocytes. Pathogenic APP in the TgAPP21 rat both increased
the magnitude and accelerated the onset of behavioural inflexibility and white matter
inflammation. The additional impact of hypertension as a representative form of
cerebrovascular stress did not affect white matter microglia activation. However,
hypertension did impair the working memory and behavioural flexibility of both Wt and
TgAPP21 rats. While Wt rats demonstrated increased white matter astrocytosis in
response to hypertension, TgAPP21 rats appeared to have an elevated baseline level of
white matter astrocytosis and did not demonstrate a further astrocytic response to
hypertension. Thus, it cannot be concluded that hypertension, a form of cerebrovascular
stress, exacerbated white matter inflammation. However, the comorbidity of pathogenic
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APP expression and ischemic injury did result in a synergistic impairment of behavioural
flexibility; the TgAPP21 rats’ vulnerability to cerebrovascular injury was more apparent
following focal ischemic injury of the dorsal striatum, which resulted in greatly impaired
behavioural flexibility. Thus, the TgAPP21 rat is an important model for studying the
complex relationship between age, pathogenic APP, and cerebrovascular disease. The
TgAPP21 rat also presents important opportunities for future evaluation of novel
therapeutic interventions that target inflammatory processes and the links between AD
and cerebrovascular disease. These findings support the emerging significance of white
matter inflammation and executive dysfunction in the pathophysiology of ageing, AD, and
VCI.
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Appendix A: Set Shift Data Extraction
This appendix details the Excel (Microsoft) workbooks that were developed to extract
meaningful set shifting data from the raw data generated by MED-PC software (Med
Associates; St. Albans, VT). The supplemental file, Visual Cue Workbook.xlsm, extracts
visual cue discrimination data and relies on the import of raw data using the MED-PC to
Excel tool provided by Med Associates. The supplemental file, Response Discrimination
Workbook.xlsm, extracts response discrimination data and also relies on the import of
raw data using the MED-PC to Excel tool provided by Med Associates and includes VBA
macros. To ensure the stability of the workbooks, the files are designated as ‘read-only’;
do not save or overwrite the files and copy any extracted data into separate data files.
The workbooks were developed using Excel 2016; the instructions outlined below are
specific to Excel 2016.

204

A1

MED-PC to Excel Conversion
1. Open MPC2XL.EXE (MED-PC to Excel)
2. Under “Row Transfer” in the “Transfer Data” tab, press “Select”
3. Open “$Visual cue deminationnew.MRP” for visual cue discrimination files, open
“$Shift Response Discrimination.MRP” for response discrimination files.
4. Make sure both “Column Labels” and “Data” are select under the “Transfer” box
5. Select “Vertical (Column)” under the “Orientation” box
6. Open Excel workbook and ensure that the A1 cell on the first tab (Input) is selected;
this applies to both workbooks. Transferring data into any other cell can cause
irreversible malfunction of the workbooks.
7. Return to MED-PC to Excel, press “Transfer”, select raw data file

Appendix Figure A-1: MED-PC to Excel Setup

205

A2

Visual Cue Workbook

Once data is transferred into Visual Cue Workbook.xlsm, key measures will appear in
cells E3-5: Trials to Criterion, Errors to Criterion, Errors after Criterion. Criterion is set to
8 consecutive correct response. Omissions do not reset a series of correct responses.
Rows 27-426 show raw data with annotations: Trial number, whether criteria have been
met, running total counts of errors, and running counts of consecutive correct responses
(performance).

Appendix Figure A-2: Sample Visual Cue Discrimination Output
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A3

Response Discrimination Workbook

The Excel workbook Response Discrimination Workbook.xlsm requires the use of VBA
macros. To enable the use of VBA macros in excel, users must first enable the developer
tab (see “Show the Developer tab” in Microsoft Office Support documentation) and enable
macros (see “Enable or disable macros in Office files” in Microsoft Office Support
documentation).
Once Data is transferred into Response Discrimination Workbook.xlsm, go to the
‘Developer’ tab and select ‘Macros’. Run Compiled_Left2 (shortcut key: Ctrl + Shift + E)
or Compiled_Right2 (shortcut key: Ctrl + Shift + R) depending on whether the left or right
lever was selected to be rewarding, respectively. If uncertain which lever was selected to
be rewarding in a given experiment, the raw data file can be inspected using a text editor
such as Notepad or Word (Microsoft) and the experiment protocol can be found next to
‘MSN:’ as either $Shift Response Discrimination LEFT or $Shift Response Discrimination
RIGHT corresponding to left or right rewarding levers, respectively. Once the
Compiled_Left/Right2 macro is run, Excel should end on the Summary tab with error
profile data.
To reset the workbook, run the Clear All macro (shortcut key: Ctrl + Shift + C).
To produce a list of errors for each incongruent trial, as required for logistic regression
modelling, run Compiled_Left (shortcut key: Ctrl + E) or Compiled_Right (shortcut key:
Ctrl + R) on transferred data. Return to the Input tab and copy the data under Column D
which will indicate ‘1’ for incorrect lever presses or ‘0’ for correct lever presses or
omissions for all incongruent trials in order from the top of the column to the bottom.
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Appendix Figure A-3: Sample Response Discrimination Output for Error Profile

208

Appendix Figure A-4: Sample Response Discrimination Output for Logistic
Regression of Mean Group Error Rates

209

Appendix Table A-1: Set Shifting Indices
Trials &
Criterion

Errors

to 8 correct consecutive responses (irrespective of trial
congruency).

Perseverative Errors

Reflect a failure to disengage from the old VCD strategy
and occur on incongruent trials, early in set shifting. RD
trials were analyzed in blocks of 16; 8 of these trials were
incongruent trials. When rats showed adherence to the old
strategy by selecting the incorrect lever on 6 or more of a
block’s 8 incongruent trials (≥ 75%), all incongruent trial
errors in that block were characterized as perseverative.

Never-Reinforced
Errors

Incorrect lever responses on congruent trials. These errors
tend to occur as rats explore new strategies and reflects
the ability to filter out non-rewarding options.

Regressive Errors

Reflect a failure to learn or maintain the new RD strategy
due to regression towards the old VCD strategy. These
occur later in set-shifting on incongruent trials, after the rat
had already begun to disengage from VCD. RD trials were
analyzed in blocks of 16; 8 of these trials were incongruent
trials. If rats demonstrated disengagement from the old
VCD strategy (chose the incorrect lever) on 5 or fewer of a
block’s 8 incongruent trials (<75%), all incongruent trial
errors in that block were characterized as regressive. Once
a regressive block occurred, all subsequent blocks were
considered regressive as well.

Logistic model:

The interpolated number of incongruent trials needed for
Trials to 50% Strategy half of a group's responses to demonstrate a strategy
change during RD; when only 50% of a group’s responses
Change
follow the old strategy (commit errors). Equivalent to the
IC50 of a logistic exposure-response curve.
Logistic model:
Hill Slope

The Hill slope of a logistic exposure-response curve
quantifies the steepness of the curve, reflecting the
efficiency of strategy change.

Since omissions did not clearly indicate which strategy was followed, omissions were not
scored as errors in these indices. VCD = Visual Cue Discrimination, RD = Response
Discrimination
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Appendix B: MWM Regressive Preference for Target Quadrant
Representative recordings of probe test swimming behaviour. Both videos are run at 4x
speed and trace respective swim paths in the top left corner. The platform was previously
learned to be located in the top-right quadrant.
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Appendix C: Immunohistochemistry Protocols
C1

Solutions

Cryoprotectant (1 L)
10 g

PVP-40

500 mL

0.1M Phosphate Buffer (PB) solution (same as 0.1M PBS, but without NaCl)

300 g

Sucrose

300 ml

Ethylene glycol

Solution can take 0.5 – 2 h to dissolve. Recommended order: add PVP to PB, slowly
added sucrose and wait for both PVP & Sucrose to dissolve, add ethylene glycol, bring
volume up to 1L with PB.
Before use, put a test sample in freezer (falcon tube) ensure that the cryoprotectant does
not freeze
DAB Solution
0.05% diaminobenzidine tetrahydrochloride (Sigma-Aldrich #D5637) in 0.01M PBS
stir for 15 min and run through filter paper (Whatman Grade 2/8µm)
add 3% H2O2 15 s prior to use, stir.
Gelatin
1.5 g

Powdered Gelatin

500ml

Distilled water

Heat in microwave for ~30s (do not allow water to boil) and stir. Discard if there is any
indication that an old solution has spoiled.
Paraformaldehyde Solution (1 L)
40 g

paraformaldehyde

500 mL

distilled water

1 ml

NaOH (or ~15 drops)

100 mL

0.1M PBS

390 mL

distilled water; or enough to form 1 L solution

Adjust pH to 7.35 with HCl

212
Phosphate Buffered Saline (PBS)
1L 10X PBS Stock Solution (0.1M; 1 L)
90 g

NaCl

10.9 g

Na2HPO4 anhydrous or 20.6 g for Na2HPO4 heptahydrate

3.2 g

NaH2PO4 anhydrous or 3.7 g for NaH2PO4 monohydrate

Add distilled water to 1L once dissolved
Adjust pH to 7.35 using HCl and NaOH dropper
1x PBS Working Solution (0.01M)
Dilute 1 part 10X Stock solution with 9 parts distilled water; adjust pH
Phosphate Buffer Saline with 0.2% TritonX detergent (PBST)
add 1 mL TritonX to 500 mL 0.01M PBS
Sucrose 30% (500 ml)
150 g

sucrose

Add enough distilled water to make 500 ml solution once sucrose is fully dissolved
For long term storage (> 1 month), add pinch of isoniazid to solution (preservative;
caution! Highly toxic)
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C2

Immunohistochemistry Protocol

Primary:
OX6 mouse monoclonal (BD Pharmingen #554926); use 1:1000 in primary solution
GFAP mouse monoclonal (Sigma-Aldrich #G3893); use 1:2000 in primary solution
Secondary: Biotinylated Horse anti-mouse IgG (Thermo Fisher Scientific #31806)
Other reagents:
Normal Horse Serum (Abcam #7484)
ABC reagent kit (Thermo Fisher Scientific # 32020)
Day 1
Wash

Block endogenous peroxidase
Wash
Block nonspecific antigens
Incubate with Primary Antibody

0.01M PBS 10 min x 6 times
If weak DAB staining due to prolonged storage,
may need to wash 10 min x 10 times
1% H2O2 10 min
0.01M PBS 5 min x 3 times
2% horse serum in PBST
Primary in 2% horse serum in PBST
Overnight in 4°C
Day 2

Wash
Incubate with Secondary Antibody
Wash
Incubate with
Horseradish Peroxidase
Wash
Incubate with DAB Solution
Wash
Mount sections, airdry overnight
Dehydrate in sequential
concentrations
Coverslip

0.01M PBS 5 min x 3 times
1:500 biotinylated secondary in PBST
0.01M PBS 5 min x 3 times
2 drops of Avidin, 2 drops of Biotin
in 10 mL PBST
0.01M PBS 5 min x 3 times
OX6: 30 s
GFAP: 120 s
0.01M PBS 5 min x 3 times
Day 3
5 min in 50% 70% 95% and 100% Ethanol, then
5 min in 50/50% Ethanol/xylene solution, then
10 min in 100% Xylene; use new xylene if cloudy
DePex Mounting Medium; air dry for >48 h
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Appendix D: Microscopy and Image Analysis Protocols
This appendix outlines specific parameters used in acquiring micrographs (Nikon Eclipse
Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging; Mississauga, ON) and in
analysis using ImageJ v1.50b.

Appendix Figure D-1: Microscope Imaging Parameters
Using the 10x Objective, ensure that the following are set to:
-

Quality: 2560x1920 Fine
Exposure: 10 ms
Analogue gain: 1.0
Zoom: 1.0x
Light: 46
No filters on Turret1
Analyzer: Out

-

Aperture: 11.5
Field Stop: 10.5
Condenser: 7N1
Neutral Density Filter 8 & 32 only;
NCB32 filter should be out.

With every new section, perform white balance correction using a probe on off-tissue
direct light as reference
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Appendix Figure D-2: Focus Surface Setup
A focus surface allows the software to interpolate optimal focus depths, based on a
sampling of points by the user. This corrects for any slant in the stage or slide; this is
particularly useful when scanning a large stitched image, e.g. greater than 1 mm in any
dimension, with any greater magnification than the 2x objective. Ensure that the
interpolation method is selected.
Placing 4-6 focus points around the perimeter of the section and several focus points on
ROIs is recommended. A flat focus plane (i.e. colour gradient follows a straight line across
the plane) identifies a slide or stage slant; non-flat focus planes (i.e. colour gradient
follows a curved line, or a peak/valley is in the middle of the focus plane) may indicate
errors in the setting of focus points or in the program’s interpolation. If the focus plane
does not appear flat, continue to add focus points until the plane is flat – if this does not
resolve, use of the focus surface is not advised and automatic step-by-step focus is
recommended instead.
Note the range of the focus surface; the difference between the maximum and minimum
depth (measured in the z dimension) should not exceed ~50 µm across a coronal section
of ~15 mm width. This indicates a major stage or slide slope that will result in blurry
artifacts.
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Appendix Figure D-3: Micrograph Stitching
For consistent image sizes, pre-determined X & Y field dimensions are advised. Note that
the microscope software (and also ImageJ) does not reliably handle images greater than
28 000 pixels in any dimension.
Select “Focus manually at start”, “Focus Surface” or “Use step-by-step focus” as
appropriate.
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D1

Threshold Analysis: Detailed Walkthrough

Before starting, set & check the following settings:
Analyze > Set measurements.

Measure (Ctrl+M);
in the results window, Results>Options:
Make sure JPEG quality is set to 100.
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Step 1. Set/check scale for each new image

Step 2. Using the polygon tool, trace out the ROI of interest
(start with corpus callosum)
- Do not include edges (tend to be darker than rest of
white matter tract)
- Note that anchors can be dragged after selection is
complete – careful not to click outside of selection
before it is saved (will lose selection)
- When selection is complete, press [T]. ROI manager
window will appear
- Select new ROI, and Rename: ID_Section_Anatomy eg, 876_CCA_CC
- Recommended abbreviations:
- FM: Forceps minor
- Cing: Cingulum
- CC: Corpus callosum
- HPC: Hippocampus
- CCEnds: Supraventricular
- IC: Internal capsule
Corpus callosum
Measure [M]; paste area to “ROI area” column in appropriate data spreadsheet
- Ensure µm2, not pixels! Area value should have decimals.
Save! When all ROIs in the image are outlined and named, select all ROIs in the
Manager (click on the list of ROIs, Ctrl + A, or hold Ctrl/Shift as you select the ROIs >
More >> Save > Name as ID_Section in the image folder
- Avoid large tears, artifacts
- To remove artifacts or tears from selection:
- If large or extends beyond ROI, make multiple selections to construct ROI of
interest
- If smaller, use freehand too to outline artifact, save outline of artifact [T], select
ROI of interest and artifact outline, more>>XOR, save corrected ROI [T]
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Consult Paxinos’ & Watsons’ 6th edition The Rat Brain in Stereotaxic Coordinates to help
guide anatomical selection, especially for OX6 staining & IC.

Appendix Figure D-4: Forceps Minor
- Bregma +3.00 mm
- Yellow trace indicates ROI
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Appendix Figure D-5: Anterior Corpus Callosum
- Bregma +2.00 mm
- Extend selection to lateral ends of cingulum
- Lateral ends of selection should be roughly parallel to the dorsal/ventral axis
- On anterior corpus callosum, middle of selection should dip down to most ventral
reach of the CC

Appendix Figure D-6: Anterior Supraventricular Corpus Callosum
On anterior and middle corpus callosum, remove selection between medial borders of
ventricles
1.
2.
3.

Outline white matter tract to be deleted; lateral ends of this selection should be
roughly parallel with dorsal-ventral axis.
Edit > Selection > Make Inverse. Add to manager [T]
In ROI manager, select CC and Inverse middle sections,
More >> And, add to manager [T], rename as supraventricular corpus callosum
(CC Ends)
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Appendix Figure D-7: Anterior Cingulum
- Bregma +2.00 mm
- To combine bilateral Cingulum/HPC/IC selections, select both in the manager
(hold Ctrl while selecting), More >> OR (Combine), add selection to manager [T]

Appendix Figure D-8: Middle corpus callosum, supraventricular corpus callosum,
cingulum
- Bregma +0.00 mm
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Appendix Figure D-9: Posterior Corpus Callosum, Cingulum
- Bregma -3.00 mm

Appendix Figure D-10: Internal capsule
- Bregma -3.00 mm
- Exclude optic tract, ventral and often adjacent to IC.
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Appendix Figure D-11: Anterior Dorsal Hippocampus
- Bregma -3.00 mm
- Exclude fimbriae

Appendix Figure D-12: Posterior
Dorsal and Ventral Hippocampus
-

Bregma -5.50 mm

- Horizontal line extending to the
most latera reach of the hippocampus
delineated the dorsal and ventral
hippocampus.
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Step 3. Change to 8-bit grayscale (Image > Type > 8-bit)

Step 4. Subtract Background (Process > Subtract Background)
Make sure no ROIs are selected before this step!

Step 5. Threshold (Ctrl + Shift + T); set Max to 237. Do not apply!

Step 6. Measure Thresholded Area
-

Select ROI, press [M]
Ensure measurement is limited to threshold (Area should not be 100%).
Paste all measurements to data spreadsheet (do not paste over ROI area
column).

Step 7. Repeat for each ROI of interest
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D2

Threshold Analysis: Protocol Summary

Make sure correct measurements & options are set before following summary!
1. Set/Check scale for each new image
a. 2.942 “distance in pixels” pixels per 1.00 “Known distance” (µm); 2.942
pixels/unit
b. Select “Global”
2. Using the polygon tool, select ROIs.
a. Add selections to ROI manager (Shortcut: [T]), name accordingly.
b. Measure [M]; paste area to “ROI area” column in appropriate data
spreadsheet (ensure µm2, not pixels!)
c. Select all ROIs, save to image’s folder (ROI Manager>More>>Save)
3. Change to 8-bit grayscale (Image>Type>8-bit)
4. Subtract Background (Process>Subtract Background)
a. Make sure no ROIs are selected before this step!
5. Threshold (Ctrl+Shift+T); set Max to 237. Do not apply!
6. Measure Thresholded Area (Ensure measurement is limited to threshold).
a. Select ROI, press [M]
b. Paste measurements to data spreadsheet
7. Repeat step 6 for each ROI on the image
Clear ROI manager before starting on next section

Tips & Useful Keys
(File>Revert) to re-open current image
You can drag and drop Images and ROIs onto the ImageJ toolbar to open them
Custom

shortcut

keys

and

Macros

can

(Plugins>Shortcuts/Macros),
[Space] allows you to drag the picture with your cursor
[+]/[-] for zooming in/out
[Ctrl] + [ ] ] to view all ImageJ windows

speed

up

the

process
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Appendix E: Rat Tail Cuff Blood Pressure Measurement
Protocol
This appendix supplements the methods for blood pressure measurement outlined in
Chapter 4. This supplementary guide will include a summary of specific operating details
and suggestions for the CODA High Throughput Non-Invasive Blood Pressure system
(Kent Scientific; CODA-HT6) that are not found in the equipment user guide. The
parameters and suggestions outlined here were followed in generating data for Chapter
4.

Appendix Figure E-1: Cuff Positioning on Restrained Rat's Tail
Model rat in a restraining tube with an Occlusion cuff (O-Cuff) placed at the base of the
tail and a Volume Pressure Recording cuff (VPR-Cuff) distal to the base.

E1

Background

CODA allows non-invasive measurements of rodent blood pressure. This is accomplished
by occluding blood flow into and out of the tail using a cuff positioned near the base of
the tail, followed by controlled deflation of the occlusion cuff. As this cuff deflates, changes
in the volume of the tail are detected by a second cuff positioned distally on the tail. This
allows estimation of systolic and diastolic blood pressures. Rodents are held in a tightly
fitted tube that isolates the tail and confines the rodent to minimize movement. The
confined animals are held on warming platforms that help to increase tail surface
temperature, so that changes in tail volume can be more readily measured. The
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Whitehead lab’s high-throughput CODA equipment can measure 6 channels (i.e. rodents)
simultaneously.

Appendix Figure E-2: Sample channel output for one cycle
The horizontal axis denotes the time of the cycle. The red line represents the pressure of
the gradually deflating occlusion cuff. The blue line represents the volume recorded by
the VPR cuff.

When the O-Cuff (occlusion cuff) inflates to occlude blood flow to and from the tail, tail
volume remains constant or decreases, as measured by the VPR (Volume Pressure
Recording) cuff (Appendix Figure E-2). The VPR cuff acts as a differential pressure
transducer to estimate changes in tail volume. As the pressure of the O-cuff falls below
systolic blood pressure, blood begins to flow into the tail. The left (first) blue vertical line
indicates this point, which coincides with the minimum of the VPR curve: as flow returns,
tail volume increases (Appendix Figure E-2). This is exaggerated by reactive hyperemia.
When the O-cuff reaches diastolic pressure, blood flow into and out of the tail reaches a
maximum. This is indicated by the right (second) blue vertical line and coincides with the
inflection point of the VPR curve (maximum slope of the curve, indicating greatest rate of
volume change). Spikes at the right end of the VPR curve are artefacts. Only movement
artefacts between or near the systolic and diastolic pressures will interfere with successful
measurement. “Precipitous” decreases in O-Cuff pressure or VPR volume indicate a
broken/leaking cuff (see page 17-18 of User’s Guide and “Cuff Replacement”).
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The product manufacturers claim to measure heart rate, but these are inaccurate. Mean
pressure might also be inaccurate since the equipment does not record the length of
systolic or diastolic phases. This is necessary for the most correct estimate of mean
pressure. It appears that the program calculates mean pressure using the formula (mean
pressure) = 1/3*(systolic pressure) + 2/3*(diastolic pressure) which is not accurate at
increased heart rates.
Several published studies1-4 have validated the accuracy of VPR as a method for noninvasive estimation of blood pressure, using arterial catheterization & telemetry as the
gold standard for comparison. The systolic pressure estimate is more accurate than the
diastolic pressure estimate, and you can expect a slightly greater variance in inter-cycle
diastolic blood pressure recordings within individual channels & sessions

E2

Equipment Use & Maintenance

E2.1 Software Set-up
The user’s guide has thorough instructions on operating the software, starting on page 8.
Each Session consists of a user-set number (e.g. 25) of inflation/deflation cycles and
includes all the channels that were indicated for measurement. Sessions can be further
divided into sets of cycles. An experiment is the collection of all sessions that belong to
it; multiple sessions will be run as part of a project. Since sessions will likely be run on
multiple dates for multiple animal groups, it is recommended to name the sessions by
Date and Animal Group.
CODA Users guide instruction on pages 9-1 &, 19 are useful for first time use. Once an
experiment is set up using the Experiment Wizard, multiple sessions can be run as part
of the same experiment using the New Session Wizard. In the new session wizard, use
selected session as template allows you start a session quickly while keeping the same
session parameters as the selected session. Be sure to name new sessions appropriately
(e.g. Date and Animal Group) and to allocate the correct animals to their respective CODA
channels. It is useful to assign animals to animal groups for ease off initiating sessions.
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On the last window of either experiment or new session wizards, do not press “Start” until
the cuffs are in place on the animals.

E2.2 Recommended Session Parameters
Acclimation cycles: 0
Number of sets: 1
Time between sets: Default (does not matter if there is only one set)
Cycles per set: 25
Time between cycles: 5 seconds
Deflation time: 20 seconds for smaller rats, 15 second for larger rats (>400g)
Minimum volume: 15µL
Display style: Chart for each animal
10 successful cycles are recommended for an accurate mean measurement of blood
pressures. Running 25 cycles (without any designated “acclimation” cycles) should
produce a sufficient number of successful reads, though this may be reduced if the rats
consistently show low inter-cycle variance. Furthermore, the data is organized more
simply (fewer spreadsheets) when there are no designated “acclimation” cycles. The
program will automatically remove any cycles which are unsuccessful (see error codes in
user’s guide), though additional filtering will further reduce the number of successful
cycles; see E3 Data Quality & Analysis. With manual filtering of the data, it is not
recommended to discard any initial acclimation meet desired data quality.

E2.3 Warming Platform
The user’s guide has thorough instructions on operating the warming platforms, adapted
from page 5: begin warming platform by pressing the START/STOP button. Press it again
to stop warming. The controls of each warming platform apply to all four channels
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(channels cannot be controlled independently). By default, the platform will turn off
automatically after 1 hour– adjust the running time using the up and down buttons beside
the time display. Be sure that the warming platform will run for sufficient time, so that it
does not turn off mid-session. L1 warms up to 32°C, L2 to 35°C, and L3 to 38°C. There
are additional levels (L4-6) that can be activated by holding down the up button for 10
seconds (found below the heating level display). L4 is effective for keeping holding tubes
warm (i.e. while the rats are habituating to the room) but is often uncomfortable for the
animals. When warming is active, the green LED lights will flash when the set temperature
level is achieved. When the temperature of a channel falls below the set level, the light
will glow steadily. There is a tendency for animals to have lower surface temperature on
the leftmost channel (of the left platform) and rightmost channel (of the right platform).
For this reason, it is recommended to hold 3 rats on either warming platform on the
channels closest to the centre of the cart.

E2.4 Cuff Replacement
Cuffs will need to be replaced. At the time of writing this guide, only a total of four cuffs
were replaced over ~3000 cycles. Page 17-18 of the user’s guide has good information
on when and how to replace the cuff. Testing the cuffs using the device manager before
running a session will help prevent mid-session complications.

E2.5 Cleaning & Storage
Do not use alcohol or abrasive detergents on any equipment. Water should suffice for
regular cleaning of waste found on warming platforms. Following use, animal holders
should be soaked in Sparkleen solution, followed by warm water rinse and dry. Cuffs
should be disconnected and stored in a dry storage baggie/container to prevent damage
to bladder and tubing. If measurements are taken daily, it may be convenient to keep
cuffs connected to the CODA controller. When cuffs are not connected, the CODA
controller ports should be protected by the dust covers.
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E2.6 Animal Handling
For initial acclimation, the JOVE article recommends2: “To train and improve animal
acclimation, add additional cycles to your experiment and run the experiment for five
consecutive days. You also can assist with acclimation by placing the animal in the holder
for 15 minutes for 3 consecutive days prior to the actual study.”
Appendix Figure E-1 does not offer an accurate representation of the space that a rat
should be permitted during testing. Appropriate holding tubes should be selected
according to the width of the animals, and the nose cone should be positioned so as to
minimize animal movement. This means that the rat nares should be visible at the narrow
opening of the nose cone, and the posterior end of the animal should be pressed up
against the back cover of the holding tube. This will often require some pressure against
the animal when securing the back cover, with care not to pinch any tissue. Advance the
nose cone position as necessary if the rat still manages to move excessively or to draw
in its tail through the back cover; try not to reinforce this kind of behaviour (e.g. by
returning the animal to its cage). Blood pressure may be affected if the chest cavity does
not have enough room to expand, and as always, strive to minimize any animal
discomfort. Note that animals may also experience discomfort due to excess heating from
the warming platform; do not keep animals on L4 for a prolonged amount of time.
Movement and apparent stress should subside with repeated sessions. Placing a rat in
the same holding tube and warming platform channel for all sessions may reduce stress
and makes organization simpler for the experimenter. If randomization of holding tube
and placement is desired, take note of the holding tube numbers and platform channels.

E3

Data Quality & Analysis

The CODA software will automatically remove any cycles that do not meet its standards
for reliability; see error codes on page 16 of the user guide. Note that the program may
sometimes accept clearly inaccurate cycles and may occasionally reject seemingly
accurate measurements. It is worthwhile taking note of any cycles that were wrongfully
rejected/accepted for later filtering. Once the full report is exported to an excel file, data
should be transferred to spreadsheets that will organize sessions from multiple dates
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across multiple tabs. Data sheets should be organized such that excel functions can be
formulated to calculate: means, standard deviations, standard errors for systolic, diastolic,
and mean blood pressures, as well as tail volume (Appendix Figure E-3).
From consultation with the representative for the company that developed and distributes
the CODA equipment, it was recommended that any cycles with a volume reading of 15
or less should be discarded. The program is supposed to do this automatically (as per
session parameters), but it does not do so. Tail blood volume fluxes can readily reach
into the 100’s of µL, if enough time is granted during and before sessions (see operating
“operating summary”). The following are additional standards that can be met to help
ensure reliability of blood pressure measurements, though the values may need to be
adjusted with different groups of animals:
-

SD of pressure measurements for each channel should be less than 20

-

Total number of successful counts after automatic and manual filtering of cycles
should be greater than 15.

-

Mean volume across cycles should be greater than 50.

These values were based on subjective evaluation of data reliability. Another source
recommended deleting measurements if the standard deviation is greater than 302. When
data does not meet these standards despite filtering for cycles with volume
measurements <15, it may not be necessary to exclude the final pressure means of
individual channels/animals; it only suggests that more time and care should be given
during future sessions. Ultimately, the mean systolic, diastolic and mean pressure
measurement given for each channel should be used a single data point (not as a sample
with variance, since cycles are not independent of each other).
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Appendix Figure E-3: Suggested organization of data
Each spreadsheet tab includes CODA data from a different date, for all channels/animals.
Rows 27-30 show the outputs of automated formulas (X corresponds to respective
columns):
Row 27: =AVERAGE(X2:X26)
Row 28: =STDEV.S(X2:X26)
Row 29: =COUNT(X2:X26)
Row 30: =X28/SQRT(X29)
Additionally, automated cells can be added to notify when a column does not meet the
quality standards mentioned above. In this figure, B31-B33 indicate when the SD of
respective columns are too high (greater than 20) using the following code =IF(B28>20,
"!!!",""). B32 indicates when the total number of successful cycles (post manual filtering)
is too low (less than 15) using the following code =IF(B29<15, "!!!", ""). G31 indicates
when the mean volume reading is too low (less than 50) using the following code
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=IF(G27<50,"!!!",""). This template, including notification cells, can then be replicated
(copied and pasted) for each channel across multiple sessions.

E4

Operating Summary
1. Place rats in testing room to habituate to the room. Dim/red lighting is
recommended. Make sure that drinking water is accessible to the rats. Allow one
hour before placing rats into holding tubes.
2. Turn on warming platform to L4 with holding tubes and cuffs on the platform.
Warmer tubes will help the rats reach sufficient surface temperatures. (see E2.3
Warming Platform)
3. Test connected cuffs using the device manager. Replace cuffs as necessary (see
E2.4 Cuff Replacement).
4. After allowing the rats to habituate to the room for one hour, allow them to enter
the holding tubes. If removed from their cage, the rats will readily enter the
holding tubes. This should be accomplished with ease on a flat surface (such as
the top of a cart). Be sure not to pinch any fat, paws, or testicles when securing
back of tube. See E2.6 Animal Handling for more details.
5. Place cuffs onto rat tails. O-cuffs may reach the base of the tail and will work
well if they can be advanced to anywhere on the proximal third of the tail. Ensure
that O-cuffs stop at minimal resistance and are not too tight on the tail. The same
applies to VPR cuffs (placed distal to the O-cuff). The higher up the VPR cuff is
placed, the more blood volume will be measured; however, the two cuffs should
not be in contact with each other as this can affect inflation/deflation of the bladders
and produce measurement artefacts.
6. Turn warming platforms down to L3 or even lower if animals show distress from
heat (persistently vocalizing stress, moving tails off of the heated platform,
unusually active). Cover tails with the black blanket for efficiency of heating and to
provide some weight against tail movement. It is recommended to keep the blanket
over the tails during the course of all sessions, though it may be removed at the
user’s discretion.
7. Wait 10-15 minutes to allow tail surface temperatures to reach levels that facilitate
sufficient tail blood volume for BP measurements. Note that tail surface
temperatures (measured at base of tail) do not always correlate well with volumes
seen in BP measurement. The CODA user’s guide recommends 32-35°C. See
trade-off note in step 8. Waiting may not be necessary with larger tails (greater
blood volumes may be more readily measured), remove or reduce the wait time in
step 7 if it does not help with initial measurements.
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8. Run cycles.
o Pause as necessary to reposition cuffs or rats, though excessive handling
can increase fluctuations in blood pressure; handling of cuffs and animals
should be avoided unless necessary (cuffs fall off or shift to positions where
insufficient volume is measured, or a tail is withdrawn into the holding
tubes).
o You may also need to pause in between cycles to allow tail volumes to
increase gradually. Tail volume seems to increase with repeat
inflation/deflation cycles, so you can use the first several cycles to help
increase tail volume to satisfactory levels.
o If tail volumes are resistant to increase as cycles are being run, consider
increasing the heating level of the warming platform.
o Recognize the trade-off: as the rats are held on the warming platform for
longer, tail volume may increase, but the rats may also become agitated
and movement artifacts or cuff displacement can result.
o See E2.1 Software Setup for recommendations on number of cycles to run.

9. Remove cuffs, return rats to cage. Be mindful of any feces and urine and avoid
contact of rat waste with cuff material.

10. Save & Back Up data. Experiment Manager> navigate to session of interest>
produce a full report and export to excel. When the excel file opens, be sure to
save it. The CODA software keeps a copy of all data for later retrieval, including
measurement charts.
11. Consider rewarding rats with sunflower seeds.
12. Wash holding tubes with Sparkleen detergent and rinse with warm water, dry
with paper towel. A mouse shoebox cage is useful for soaking holding tubes in
detergent.
13. Wash warming platform. Water & paper towel usually suffices.
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Appendix F: PET/MRI Study
The following appendix outlines a pilot study of in vivo measurement of microglia
activation in the TgAPP21 rat following ET1 ischemic injury of the dorsal striatum. PET
imaging with a radioligand that localizes to activated microglia and reactive astrocytes
was complemented with MR and CT imaging to improve anatomical localization.

F1

Introduction

Subcortical infarcts indicate a greater risk for future strokes and cognitive impairment,
even when patients do not initially present with symptoms1,2. This sequela is thought to
be mediated in part by secondary chronic inflammation, particularly in the white matter,
which may also interact with other neurodegenerative conditions such AD3-5. White matter
pathology initiated by small vessel disease or infarcts is predictive for cognitive decline610

and involves inflammatory processes10-13. In vivo imaging of an animal model of

ischemic subcortical injury would be instrumental for characterizing secondary
inflammation and for testing therapeutic interventions.
18F-FEPPA

is a PET-ligand that binds to the translocator protein (TSPO), an outer-

mitochondrial-membrane bound protein that is upregulated in activated microglia and
astrocytes14-18. This radiotracer was injected into 8 – 12-month-old male Fischer 344 rats
following ischemic injury of the dorsal striatum. Following dynamic 90 min PET, the rats
also underwent 3T MRI and contrast-enhanced CT-perfusion imaging to help localize
radiotracer uptake and to explore additional in vivo imaging correlates of
neuroinflammation. To corroborate multimodal imaging findings, brain tissue was
analyzed using immunohistochemistry for microglia activation and reactive astrocytosis.
As integrity of prefrontal-subcortical circuits are particularly critical to cognitive status
following stroke,2,19 differences in 18F-FEPPA uptake were compared across white matter
segments anterior, proximal, or posterior to the site of injury. Blood sampling offers
important corrections to radiotracer input functions, but it is challenging in rodents; an
accurate population-derived input function would forego the need for future manual blood
sampling.
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F1.1 Objectives
-

Establish protocol for multimodal imaging (18F-FEPPA-PET/MR/CT) of a rodent
ischemic stroke model.

-

Determine spatial and temporal progression of white matter injury and
inflammation.

-

Evaluate the kinetics of

18F-FEPPA

and develop a population-derived input

function

F2

Methods

8 – 12-month-old TgAPP21 rats were imaged 7 – 10 days prior to focal ischemic injury of
the dorsal striatum (baseline imaging), 7 days following injury, and 30 days following
injury. To model focal ischemic injury, unilateral ET1 (60 pmol dissolved in 3 µl sterile
0.9% saline) was injected into the dorsal striatum of (n = 6), as described in 5.3.2
Endothelin-1 Focal Ischemic Injury. On each of the 3 imaging days,

18F-FEPPA

was

produced at an onsite cyclotron. Injected doses averaged 29.6 MBq, ranging from 22.4 –
37.6 MBq. Immediately following

18F-FEPPA

injection, a dynamic 90 min PET scan

(Siemens Inveon) was initiated, followed by a 40 min MR imaging sequence (Siemens
Biograph mMR), and then iopamidol (Isovue®)-enhanced CT (GE VCT). Dynamic PET
data was manually registered to subsequently acquired T2-weighted MR images. CT
analysis of cerebral circulation was focused on mean transit time (MTT), which estimates
the average time needed for blood to pass through tissue and corresponds to the ratio of
cerebral blood volume : flow. During baseline and 30-day post-injury imaging, arterial
blood samples were acquired from 5 subjects at 2, 8, 16, 64, and 90 min after 18F-FEPPA
injection. The ratio of unmetabolized 18F-FEPPA in plasma and blood was determined by
solid-phase extraction chromatography20,21. Following imaging 30 days after ET1
ischemic injury, rats were euthanized, and brain tissue was collected for IHC, as
described in 2.3.5 Immunohistochemistry & Image Processing.
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Appendix Figure F-1: Endothelin-1 injection into the dorsal striatum
Dashed outline identifies glial scar formed after ET1 injection, observed on DAB-IHC with
a primary antibody for GFAP (30µm coronal section).

Appendix Figure F-2: Brain Segmentation Model
Neuroanatomy and injury site identified by T2-weighted MRI; these segments were then
applied to co-registered PET data.
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Results

Appendix Figure F-3: Immunohistochemistry Corroborates 18F-FEPPA-PET/MR
Findings
High penumbral 18F-FEPPA uptake was observed 7 days after ET1-ischemic injury of the
dorsal striatum. Localization of increased uptake corresponded with OX6+ activated
microglia more consistently than GFAP+ reactive astrocytes. 30 days following injury,
continued uptake and microglial activation was observed distal to the injury site,
particularly in white matter tracts.
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Appendix Figure F-4: 18F-FEPPA Uptake Following Injury Persists in Anterior
White Matter Tracts
18F-FEPPA uptake was significantly increased around the injury site and proximal white
matter (WM) following injury. 30 days after injury, uptake in these regions reduced from
levels seen at day 7 but was still relatively increased throughout the brain, especially in
anterior white matter. *p<0.05, **p<0.01, ****p<0.0001 compared to baseline. n = 6, error
bars = SEM

Appendix Figure F-5: Mean Transit Time Prolonged by Ischemic Injury
These experiments were conducted following PET & MR imaging, thus anesthesia time
and quality was likely an important variable that affected cerebral circulation. Despite this
confound, MTT was found to be prolonged in the penumbral region 7 days after injury
and normalized by day 30. Axial resolution = 500 µm, scale = time (s)
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Appendix Figure F-6: 18F-FEPPA Kinetic Profile
The blood:plasma-bound ratio of the 18F-FEPPA radiotracer was well modelled by a biexponential function (R2 = 0.87), while the unmetabolized fraction of the radiotracer was
well modelled by a Hill function (R2 = 0.92). These population-derived kinetic models will
be applied to future arterial input functions in dynamic PET.
n = 5, error bars = SD.
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Conclusions

This study demonstrates the feasibility of

18F-FEPPA-PET

as an effective method for in

vivo imaging of microglia activity in a rat model of ischemic stroke. The localization of
microglia activity was further improved with MRI co-registration. Qualitative evaluation of
immunohistochemistry revealed that

18F-FEPPA

uptake corresponded better with

increased microglia activation than reactive astrocytosis (Appendix Figure F-3). PET
findings indicated sustained wide spread inflammation, especially in anterior white matter,
following ischemic injury of the dorsal striatum (Appendix Figure F-4).
Reduced MTT warrants further investigation of the impact of disrupted perfusion and
circulation on radiotracer uptake (Appendix Figure F-5). This also raises the question of
whether BBB disruption following ischemic injury may confound the distribution of

18F-

FEPPA in the brain22,23. Despite these limitations, the methods described here will enable
comparative investigation, such as the comparison of Wt and TgAPP21 rats’ response to
ischemic injury and the effect of anti-inflammatory interventions. Future studies can apply
the population-derived

18F-FEPPA

kinetics to arterial input functions (Appendix Figure

F-6), foregoing the need for further blood sampling.
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Appendix G: Animal Use Protocol

AUP Number: 2014-016
PI Name: Whitehead, Shawn N
AUP Title: Role of vascular risk factors in cognitive decline
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2014016 has been approved.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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